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“There is no part of my life, upon which I can look back without pain”. 
“I attribute my success to this – I never gave or took any excuse”. 
- Florence Nightingale. 
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Background and objectives: 
The overall objective of this thesis is to investigate readmissions in Australian hospitals in 
patients previously admitted with heart failure (HF) or an acute myocardial infarction (AMI). 
 
The specific aims of this thesis are: 
1. To conduct a scoping review of the contemporary Australian literature regarding 
readmissions with an index admission of any cardiovascular disease (CVD). 
2. To determine the rates of readmission and mortality in Australian and New Zealand 
HF patients between 2010-15. 
3. To determine the accuracy of the LACE index score (a prediction tool) for predicting 
30-day all-cause mortality and readmission rates (independently and combined) in 
South Australian AMI patients who had an angiogram between 2015-6. 
4. To conduct a pilot clinical study to determine whether an association exists between a) 
the quantity and b) the quality of sleep time in hospital and 30-day all-cause 
unplanned readmission in a South Australian cohort of cardiovascular inpatients. 
 
Methods: 
The thesis employs multiple methodological approaches including a scoping review (Chapter 
II), ‘big data’ techniques (Chapter III), registry data analysis (Chapter IV) and a prospective 
clinical observational cohort study (Chapter V). 
 
Summary of major findings: 
Chapter II: The scoping review of contemporary Australian literature found limited literature 
on the topic of readmissions following hospitalisation for a CVD or condition. Furthermore, it 
 xi 
found that the methods used in prior studies lacked uniformity and standardisation which was 
reflected in the large range of readmission rates observed (from 6.3% to 27%, median 13%). 
Chapter III: The hospital-level analysis of administrative data found that Australian and 
New Zealand HF inpatients had a 30-day all-cause mortality rate of 10.7% across 392 
hospitals and a 30-day all-cause readmission rate of 22.3% across 391 hospitals. Additionally, 
readmission rates remained stable whilst an overall improvement in the mortality rates were 
seen over the study period. 
Chapter IV: Analysis of registry patients found a 30-day unplanned readmission rate of 
11.8% and mortality rate of 0.7%. Moreover, the LACE index was a moderate predictor (C-
statistic=0.62) of readmissions in this cohort and a score ≥10 indicated moderate 
discriminatory capacity to predict 30-day readmissions. The two variables with the best 
predictive variables were length of stay and admissions to the emergency department in the 
prior six months. 
Chapter V: The clinical study found an association between the quality of sleep in hospital 
and 30-day all-cause unplanned readmissions as measured by the Pittsburgh Sleep Quality 
Index. This study also found trends but no statistically significant association between any 
objective measure of sleep quantity and 30-day all-cause unplanned readmissions. 
 
Conclusions 
This thesis has contributed to the literature by determining the rate of readmission in HF 
patients, incorporating predictive models into medicine and exploring a hypothesised variable 
(disrupted sleep) in clinical practice to help reduce the burden of readmissions. It supports the 
importance of measuring 30-day all-cause unplanned readmissions as an objective, broad, 





I certify that this work contains no material which has been accepted for the award of any 
other degree or diploma in my name, in any university or other tertiary institution and, to the 
best of my knowledge and belief, contains no material previously published or written by 
another person, except where due reference has been made in the text. In addition, I certify 
that no part of this work will, in the future, be used in a submission in my name, for any other 
degree or diploma in any university or other tertiary institution without the prior approval of 
the University of Adelaide and where applicable, any partner institution responsible for the 
joint-award of this degree. 
 
I acknowledge that copyright of published works contained within this thesis resides with the 
copyright holder(s) of those works. 
 
I also give permission for the digital version of my thesis to be made available on the web, via 
the University’s digital research repository, the Library Search and also through web search 
engines, unless permission has been granted by the University to restrict access for a period of 
time. 
 
I acknowledge the support I have received for my research through the provision of an 
Australian Government Research Training Program Scholarship. 
 





First and foremost, I would like to give my most sincere thanks and gratitude to my amazing 
supervisors Professor John Beltrame and Dr Rosanna Tavella, for their support, guidance and 
wisdom during my PhD journey. 
 
Dear John, thank you for being such an inspirational mentor and supervisor. You never gave 
up on me. I remember our first meeting when I asked you to supervise me on a vacation 
scholarship many years ago. You have always been honest and encouraged me to follow my 
dreams, you have my most sincere gratitude for this. Your wisdom and guidance have 
allowed me to develop professionally into the researcher that I am today. 
 
Rosanna, where do I begin? Thank you for being such a caring supervisor, your warm smile 
and advice helped me on both my good and bad days. I will always be grateful for sharing 
your wisdom with me. Rosanna, you have been a role model for me as a female clinical 
researcher, predominantly by leading the CADOSA Registry. You have taught me so many 
invaluable lessons both in research and life. John and Rosanna, I will always be indebted to 
both of you for teaching me how to conduct clinical research, to be leaders and collaborate as 
a team. 
 
A very special mention to Tracy, thank you for all of your support, advice (both in statistics 
and life) and friendship through this journey. We have had many laughs and I am glad that 
our paths crossed during our PhD journeys. 
 
To Linda Gallina, thank you for all the important work that you do to help run this team. 
Thank you for your friendship, support and words of wisdom, especially when things were 
not going the way I had planned. I hope you know how valuable your opinions and advice 
 xiv 
have been to me over the years and that I have learnt many life lessons from you. Grazie mille 
bella. 
 
To Professor Bob Adams and Dr Amy Reynolds thank you both for your guidance and 
expertise with the sleep study. You have both shown me how hard work and passion for 
research can make a difference to patient lives. 
 
To all the patients, nurses and other staff that I encountered during my clinical study in the 
Coronary Care Unit N1A and N1B at The Queen Elizabeth Hospital – thank you. The various 
life stories, the smiles and odd tear that I shared with each and every one of you on the wards 
reminded me that every patient’s journey is unique and that is exactly why our research is 
vital in improving patient’s quality of life. I learnt so much from all of you, my sleep study 
would not have been possible without your generosity and willingness to volunteer. 
 
Professor Christopher Zeitz and Associate Professor Matthew Worthley thank you for both 
being strong role models during the early stages of my career. I feel fortunate to have the 
support of such wise and inspirational leaders. 
 
A special thank you to my friend and mentor, Dr Nicky Thomas I will always be indebted to 
you for your graciousness and kindness, for listening and advising me when my PhD was 
getting me down. You have taught me many things about real science and research. Your 
advice was always exactly what I needed to hear. Thank you for inspiring me to continue 
when times were tough and for teaching me to never give up. 
 
To my family, I could not have completed this endeavour without your continuous support. 
Gracias Mamá, Papá, Juanita y Alicita. 
 
 xv 
Finally, to my dearest Tia Teresa, you began this journey with me and although you are no 
longer physically here with me at the end of it, I know you are smiling down on me. Thank 
you for all of your guidance and for always believing in and inspiring me and my sisters, you 
will live on eternally in our hearts. Tia Teresa Mascaro (07/06/1943 – 12/03/2017), to you I 





ACA = Affordable Care Act 
ACC = American College of Cardiology 
ACE = Angiotensin Converting Enzyme 
ACS = Acute Coronary Syndrome 
ABS = Australian Bureau of Statistics 
AICD = Automatic Implantable Cardiac Defibrillator 
AIHW = Australian Institute of Health and Welfare 
AHA = American Heart Association 
AHRQ = Agency for Health care Research and Quality 
AMI = Acute Myocardial Infarction 
AUC = Area Under the Curve 
BMS = Bare Metal Stent 
BP = Blood Pressure 
CABG = Coronary Artery Bypass Graft 
CAD = Coronary Artery Disease 
CADOSA = Coronary Angiogram Database Of South Australia 
CC = Condition Category 
CHD = Coronary Heart Disease 
CK-MB = Creatinine Kinase-Myoglobin Binding 
CMS = Centre for Medicare and Medicaid Services 
CRT = Cardiac Resynchronisation Therapy 
CVD = Cardiovascular Disease 
DES = Drug Eluding Stent 
ECG = Electrocardiogram 
ED = Emergency Department 
 xvii 
EF = Ejection Fraction 
EQ-5D-3L = Euro Quality of life questionnaire – 5 Dimensions – 3 Levels 
ESC = European Society of Cardiology 
ESS = Epworth Sleepiness Scale 
GRACE = Global Registry of Acute Coronary Events 
GTN = Glyceryl TriNitrate 
HF = Heart Failure  
HGLM = Hierarchical Generalised Linear Model 
HFmrEF = Heart Failure with midrange Ejection Fraction 
HFpEF = Heart Failure with preserved Ejection Fraction 
HFrEF = Heart Failure with reduced Ejection Fraction 
HR = Hazard Ratio 
HRRP = Hospital Readmissions Reduction Program 
ICC = Intraclass Correlation Coefficient 
ICD = International Classification of Diseases 
LVEF = Left Ventricular Ejection Fraction 
STEMI = ST-segment Elevated Myocardial Infarction 
STOP BANG = Snoring, Tiredness, Observed apnea, blood Pressure, Body mass index, Age, 
Neck circumference and Gender 
NREM = Non-Rapid Eye Movement 
NSTEACS = Non-ST-segment-elevation acute coronary syndrome 
NSTEMI = Non-ST segment Elevated Myocardial Infarction 
NYHA = New York Heart Association 
OSA = Obstructive Sleep Apnea 
PCI = Percutaneous Coronary Intervention 
PSG = Polysomnography 
PSQI = Pittsburgh Sleep Quality Index 
 xviii 
REM = Rapid Eye Movement 
ROC = Receiver Operating Characteristic 
RSMR = Risk Standardised Mortality Rate 
RSRR = Risk Standardised Readmission Rate 
TST = Total Sleep Time 
WHO = World Health Organization
 
Achievements and Recognition 
 
Published Manuscript from this Thesis 
Labrosciano C, Air T, Beltrame JF, Tavella R and Ranasinghe I. (2019) Readmissions 
following hospitalisations for cardiovascular disease: a scoping review of the Australian 
literature”. Australian Health Review. DOI:10.1071/AH18028. 
 
Other Published Manuscripts During the Candidature 
Smolderen KG, Gosch K, Patel M, Jones S, Hirsch AT, Beltrame JF, Fitridge R, Shishehbor 
M, Denollet J, Vriens P, Heyligers J, Stone N, Aronow H, Abbott D, Labrosciano C, Tutein-
Nolthenius R and Spertus J. (2018) Patient-centered Outcomes Related to Treatment practices 
in peripheral Arterial disease: Investigating Trajectories (PORTRAIT): Overview of Design 
and Rationale of an International Prospective Peripheral Arterial Disease Study. Circulation: 
Cardiovascular Quality and Outcomes. DOI: 10.1161/CIRCOUTCOMES.117.003860 
 
Moore K, Ganesan A, Labrosciano C, Heddle W, McGavigan A, Hossain S, Horton D, 
Hariharaputhiran S and Ranasinghe I. (2019) Sex Differences in Acute Complications of 
Cardiac Implantable Electronic Devices (CIED): Implications for Patient Safety. Journal of 
the American Heart Association. Volume 8, Issue 2. DOI: 10.1161/JAHA. 118.010869 
 
Ranasinghe I, Labrosciano C, Horton D, Ganesan A, Curtis JP, Krumholz HM, McGavigan 
A, Hossain S, Air T and Hariharaputhiran S. (2019) Institutional Variation in Quality of 
Cardiovascular Implantable Electronic Device Implantation: A Cohort Study. Annals of 




Thomas M, Patel KK, Gosch K, Labrosciano C, Spertus JA and Smolderen KG. (2019) 
Mental Health Concerns in Patients with Symptomatic Peripheral Artery Disease: Insights 
from the PORTRAIT Registry. Submitted to Journal of General Internal Medicine. 
 
Labrosciano C, Tavella R, Reynolds A, Air T, Beltrame JF, Ranasinghe I and Adams RJT. 
(2019) The Association between Sleep Quality and Quantity with Readmissions: An 
Exploratory Study among Cardiology Inpatients. Submitted to the Journal of Clinical Sleep 
Medicine. 
 
Labrosciano C, Horton D, Air T, Tavella R, Beltrame JF, Zeitz CJ, Krumholz HM, Adams 
RJT, Scott IA, Gallagher M, Hossain S, Hariharaputhiran S and Ranasinghe I. (2019) 
Frequency, Trends and Institutional Variation in 30-Day All-Cause Mortality and Unplanned 
Readmissions Following Hospitalization for Heart Failure in Australia and New Zealand. 




Published Abstracts from this Thesis  
* Denotes the presenter 
 
Labrosciano C*, Air T, Tavella R, Beltrame JF, Zeitz C, Horton D and Ranasinghe I. (2017) 
Rates of 30-Day Readmission and Mortality After Heart Failure Hospitalisation in Australia 
and New Zealand: A Population Study. Heart, Lung and Circulation, Volume 26, S145 - 
S146. 
 
Labrosciano C*, Air T, Tavella R, Beltrame JF and Ranasinghe I. (2017) Readmissions 
After Hospitalisation for Cardiovascular disease in Australia and New Zealand. Heart, Lung 
and Circulation, Volume 26, S300. 
 
Labrosciano C*, Air T, Tavella R, Beltrame JF, Zeitz C, Horton D and Ranasinghe I. (2017) 
Rates of 30-Day Readmission and Mortality After Heart Failure Hospitalisation in Australia 
and New Zealand: A Population Study. Heart, Lung and Circulation, Volume 26, S145 - 
S146.  
 
Labrosciano C*, Air T, Tavella R, Beltrame JF and Ranasinghe I. (2017) Readmissions 
After Hospitalisation for Cardiovascular disease in Australia and New Zealand. Heart, Lung 
and Circulation, Volume 26, S300. 
 
Labrosciano C*, Air T, Tavella R, Beltrame JF, Zeitz C, Horton D and Ranasinghe I. (2017) 
Post-Discharge Readmissions and Mortality Following Hospitalisation for Acute Myocardial 





Labrosciano C*, Tavella R, Air T, Zeitz C, Worthley M and Beltrame JF. (2019) Using the 
LACE Index to Predict 30-day All-cause unplanned Readmission and mortality in acute 
Myocardial Infarction patients: Insights from the CADOSA Registry. Heart, Lung and 




Other Published Abstracts During the Candidature 
*denotes the presenter 
 
Labrosciano, C*, Cowled P, Fitridge R and Beltrame J. (2016) Does a Relationship Between 
Ankle Brachial Index and Health Status in Patients With Peripheral Artery Disease Exist? A 
Pilot Study. Heart, Lung and Circulation, Volume 25, S318. Cardiac Society of Australia and 
New Zealand Annual Scientific Meeting 2017, poster. 
 
Ranasinghe I*, Horton D, Labrosciano C, Air T, Beltrame JF, Zeitz C and Tavella R. (2017) 
Early Mortality after Isolated Coronary Artery Bypass Graft (CABG) Surgery Among 
Hospitals in Australia and New Zealand. Heart, Lung and Circulation, Volume 26, S317. 
Cardiac Society of Australia and New Zealand Annual Scientific Meeting 2017, poster. 
 
Ranasinghe I*, Labrosciano C, Horton D, Air T, Beltrame JF, Zeitz C and Tavella R. (2017) 
Early Complications of Cardiac Pacemaker and Defibrillator Implantation Among Hospitals 
in Australia and New Zealand. Heart, Lung and Circulation, Volume 26, S179-S180. Cardiac 
Society of Australia and New Zealand Annual Scientific Meeting 2017, poster. 
 
Smolderen K*, Shore S, Wang J, Labrosciano C, Beltrame J and Spertus J. (2017) Abstract 
19317: Defining Clinically Meaningful 12-Month Health Status Changes in Patients With 
Peripheral Arterial Disease as Perceived by Patients. Circulation, 136:A19317. American 





Labrosciano C*, Air T, Tavella R, Beltrame JF, Zeitz C, Horton D and Ranasinghe I. (2017) 
Post-Discharge Readmissions and Mortality Following Hospitalisation for Acute Myocardial 
Infarction in Australia and New Zealand. Heart, Lung and Circulation, Volume 26, S89. 
Cardiac Society of Australia and New Zealand Annual Scientific Meeting 2017, poster. 
 
Labrosciano C*, Air T, Beltrame JF, Tavella R, Horton D, Zeitz C and Ranasinghe I. (2017) 
Variation in Early Death and Readmission Following an Acute Myocardial Infarction 
Hospitalization in Australia and New Zealand. Circulation, Volume 136, Supp 1, A18866. 
American Heart Association Annual Scientific Meeting 2017, poster.  
 
Smolderen K*, Wang J, Jones P, Labrosciano C and Spertus J. (2017) Developing a Clinical 
Predication Model for 1-Year Health Status Outcomes in Peripheral Arterial Disease: Insights 
From the PORTRAIT Registry. Circulation, 136:A19221. American Heart Association 
Annual Scientific Meeting 2017, poster. 
 
Ganesan A*, Hossain S, McGavigan A, Heddle W, Hortan D, Labrosciano C, 
Hariharaputhiran S, Air T and Ranasinghe I. (2018) Differences in Acute Complications of 
Cardiac Implantable Electronic Devices (CIED) in Public Versus Private Hospitals in New 
South Wales and Queensland. Heart, Lung and Circulation. 27:S160. Cardiac Society of 
Australia and New Zealand Annual Scientific Meeting 2018, poster.  
 
Nadlacki B*, Horton D, Labrosciano C, Hossain S, Hariharaputhiran S, Aliprandi-Costa B, 
Adams R, Visvanathan R and Ranasinghe I. (2018) Long-Term Mortality Following Acute 
Myocardial Infarction in Australia and New Zealand: a Population-Wide Study. Heart, Lung 
and Circulation. 27:S54-S55. Cardiac Society of Australia and New Zealand Annual 




Hariharaputhiran S*, Horton D, Hossain S, Labrosciano C, Nadlacki B, Adams R, 
Visvanathan R and Ranasinghe I. (2018) Long-Term Mortality Following Hospitalisation for 
Heart Failure in Australia and New Zealand: a Population-Wide Study. Heart, Lung and 
Circulation. 27:S55-S56. Cardiac Society of Australia and New Zealand Annual Scientific 
Meeting 2018, oral presentation. 
 
Ganesan A*, Hossain S, McGavigan A, Heddle W, Hortan D, Labrosciano C, 
Hariharaputhiran S, Air T and Ranasinghe I. (2018) Population-Level Gender Differences in 
Acute Complications of Cardiac Implantable Electronic Devices: Implications for Patient 
Safety. Heart, Lung and Circulation, 27:S182. Cardiac Society of Australia and New Zealand 
Annual Scientific Meeting 2018, poster. 
 
Decker C*, Gosch K, Thomas M, Labrosciano C and Smolderen K. (2018) Medication 
adherence profiles in peripheral arterial disease: insights from the international PORTRAIT 
Registry. European Journal of Cardiovascular Nursing, 17, 9-10. EuroHeart conference 
2018, oral presentation. 
 
Malik AO*, Peri-Okonny P, Provance J, Gosch K, Thomas M, Labrosciano C, Spertus JA 
and Smolderen K. (2019) The association of perceived stress with health status outcomes in 
patients with peripheral artery disease. Journal of the American College of Cardiology, 
73(9):2081. DOI:  10.1016/S0735-1097(19)32687-7. American College of Cardiology 





Smolderen K*, Safley D, Jones P, Patel M, Jones S, Shishehbor M, Aronow H, Labrosciano 
C, Fuss C, Scott K, Stone N and Spertus JA. One-year major adverse limb events and planned 
revascularizations following invasive versus optimal medical therapy for new or worsening of 
claudication symptoms: insights from the PORTRAIT Registry. Journal of the American 
College of Cardiology 73 (9) Supplement 1: 2115. DOI: 10.1016/S0735-1097(19)32721-4. 
American College of Cardiology conference 2019, poster. 
 
Stretton B, Tavella R, Zeitz C, Arstall M, Sinhal A, Worthley M, Beltrame J and 
Labrosciano C*. (2019) Antithrombotic Therapy and Bleeding Outcomes in Atrial 
Fibrillation Patients after PCI: Insights from the CADOSA Registry. Heart, Lung and 
Circulation 28, S284-S285. DOI: 10.1016/j.hlc.2019.06.350. Cardiac Society of Australia 




Presentations Arising from this Thesis 
*denotes the presenter 
 
Labrosciano C* Beltrame JF, Tavella R and Ranasinghe I. Readmissions following 
cardiovascular diagnosis in Australia: A Systematic Review. 10th Florey Postgraduate 
Research Conference 2016, poster. 
 
Labrosciano C*, Beltrame JF, Tavella R and Ranasinghe I. Readmissions following 
Cardiovascular Hospitalisations: A Systematic Review of the Contemporary Australian 
Literature.” Finalist in The Queen Elizabeth Hospital Research Day 2016, oral presentation. 
 
Labrosciano C*, Air T, Beltrame JF, Tavella R, Horton D and Ranasinghe I. Australian and 
New Zealand Rates of Readmissions and Mortality following Hospitalisation for Heart 
Failure. Australian Society of Medical Research Adelaide meeting 2017, oral presentation. 
 
Labrosciano C*, Air T, Beltrame JF, Tavella R, Horton D, Zeitz C and Ranasinghe I. 
Readmission and Mortality Rates following Heart Failure Hospitalisations across Australia 
and New Zealand. 10th Health Services & Policy Research of Australia and New Zealand 
Conference 2017, poster. 
 
Labrosciano C*, Air T, Beltrame JF, Tavella R, Horton D, Zeitz C and Ranasinghe I. Rates 
of 30-day Readmission and Mortality Following an Acute Myocardial Infarction across 
Australia and New Zealand. 10th Health Services & Policy Research of Australia and New 




Labrosciano C*, Tavella R, Reynolds A, Air T, Adams R, Beltrame JF and Ranasinghe I. 
Does poor sleep in hospital lead to cardiology patients returning? The Queen Elizabeth 
Hospital Research Day 2018, clinical oral session finalist. 
 
Labrosciano C*, Tavella R, Reynolds A, Air T, Adams R, Beltrame JF and Ranasinghe I. 
The Association between the Quality and Quantity of Sleep and 30-day Readmissions in 
Cardiology Patients: A Pilot Study. SAHMRI/ The Heart Foundation Cardiovascular 
Research Showcase 2018, poster. 
 
Labrosciano C*, Tavella R, Reynolds A, Air T, Adams R, Beltrame JF, Ranasinghe I. The 
Relationship between Sleep Characteristics and 30-day Readmission: A Pilot Study of 




Other Presentations During the Candidature 
* Denotes the presenter 
 
Ranasinghe I, Horton D, Labrosciano C*, Air T, Zeitz C, Beltrame JF and Tavella R. 
Variation in Risk Standardised Mortality following Isolated Coronary Artery Bypass Grafting 
Surgery Among Hospitals in Australia and New Zealand. 10th Health Services & Policy 
Research of Australia and New Zealand Conference 2017, oral presentation. 
 
Ranasinghe I, Labrosciano C*, Air T, Horton D and Hossain S for the ORION Study 
Investigators. The Observing Recurrent Incidence of Adverse Outcomes following 
HospitalisatioNs (ORION) Study: Towards Nationwide Reporting of Outcomes of Hospital-
Based Cardiovascular Care Using Existing National Data Infrastructure. 10th Health Services 
& Policy Research of Australia and New Zealand Conference 2017, poster.  
 
Ranasinghe I*, Horton D, Labrosciano C, Air T, Zeitz C, Beltrame JF and Tavella R. Early 
Mortality after Isolated Coronary Artery Bypass Grafting (CABG) Surgery Among Hospitals 
in Australia and New Zealand. Cardiac Society of Australia Annual Scientific Meeting 2017, 
poster. 
 
Ranasinghe I*, Labrosciano C, Air T, Horton D, Zeitz C, Beltrame JF and Tavella R. Early 
Complications of Cardiac Pacemaker and Defibrillator Implantation Among Hospitals in 
Australia and New Zealand. Cardiac Society of Australia and New Zealand Annual Scientific 




Smolderen K*, Shore S, Wang J, Labrosciano C, Beltrame JF and Spertus J. (2017) Defining 
Clinically Meaningful 12-Month Health Status Changes in Patients With Peripheral Arterial 
Disease as Perceived by Patients. American Heart Association Annual Scientific Meeting 
2017, poster. 
 
Smolderen KG*, Wang J, Jones P, Labrosciano C and Spertus J. (2017) Developing a 
Clinical Prediction Model for 1-Year Health Status Outcomes in Peripheral Arterial Disease: 
Insights From the PORTRAIT Registry. American Heart Association Annual Scientific 
Meeting 2017, poster. 
 
Ranasinghe I*, Labrosciano C, Horton D, Air T, Beltrame JF, Zeitz C and Tavella R. (2017) 
Early Complications of Cardiac Pacemaker and Defibrillator Implantation Among Hospitals 
in Australia and New Zealand. Cardiac Society of Australia and New Zealand Annual 
Scientific Meeting 2017, mini-oral presentation. 
 
Nadlacki B*, Horton D, Labrosciano C, Hossain S, Hariharaputhiran S, Aliprandi-Costa B, 
Adams R, Visvanathan R and Ranasinghe I. Long-term Mortality Following Acute 
Myocardial Infarction (AMI) in Australia and New Zealand (ANZ): A population-wide study. 




Awards and Recognition 
Faculty of Health Sciences Divisional Scholarship, University of Adelaide (2016-2019). 
 
Joanna Briggs Institute Certificate – Systematic Review Course (2016). 
 
Non-Award Study in the University of Adelaide Faculty of Health Sciences Introduction to 
Biostatistics and Biostatistics (2016). 
 
Australian Hotels Association (SA) Hotel Care Community Grant (CI B) - $7,774.80 Inc 
GST (2016). 
 
Science in Public Media & Communications Training Workshop, won competition supported 
by The Hospital Research Foundation (2017). 
 
The Hospital Research Foundation Travel Grant (2017). 
 
Cardiac Society of Australia and New Zealand Annual Scientific Meeting Travel Fellowship 
(2017). 
 
Adelaide Medical School Research Travel Awards - Round 2 (2017). 
 
Heart Failure work featured in the Cardiology Update of the Medical Observer: 
“https://www.medicalobserver.com.au/medical-news/cardiology/acs-treatment-differs-for-




The Hospital Research Foundation coordinated Community Awareness Program to U3A 
(University of the Third Age) Flinders. Talk titled “Returning to hospital after a heart attack” 
(4th May 2017). 
 
Nominated for the Channel 9 Young Achiever of the Year Award in 2018. 
 
Invitation from The Hospital Research Foundation to be interview on Coast FM 88.7 
(February 2018). 
 
Basil Hetzel Institute Management Committee member and student representative (2018-19).  
 
St. John’s First Aid, basic emergency life support and CPR course (26/07/2018). 
 
Peer reviewer for JBI Database of Systematic Reviews and Implementation Reports and 
Annals of Internal Medicine (2018-19). 
 
Judging Panel for the University of Adelaide First Florey Undergraduate Conference (2018). 
 
Ivan de la Lande Award (2018). 
 
Nominated for The University of Adelaide STEM Award in the 2019 Seven News Young 
Achiever of the Year Awards. 
 
CALHN Good Clinical Practice (GCP) Awareness Training on 4th December 2018. 
 
Community talk for The Hospital Research Foundation on 15th May 2019, titled “Returning to 




Women in STEMM Australia. Dr Jane Goodall’s Australian tour on 14th May 2019. 
 
 PRAXIS Monitoring Approved Research Workshop, Adelaide on 25th June 2019. 
 
Volunteer at Science Alive SA on 3rd August 2019. 
 











1.1.0 Cardiovascular Disease 
Cardiovascular disease (CVD) encompasses diseases and disorders of the blood vessels and 
heart, and is the greatest disease epidemic in the world. In 2012, the Australian Bureau of 
Statistics (ABS) estimated that 4.2 million Australians were living with CVD1. Acute CVD 
hospitalisations in Australia have increased by 20% over a 10 year period (2005-06 to 2015-
16)2. Moreover, admissions to hospital for any CVD accounted for 11% of all Australian 
hospitalisations between 2015 and 20162. In 2008, global figures found that CVD was the 
underlying cause of death in 17.3 million people3 and nationally, one Australian dies from 
CVD every 12 minutes4. In 2017, 43,000 Australian deaths were attributed to CVD5 costing 
11% of the Australia’s hospital expenditure6. 
 
1.1.1 Cardiovascular-related Mortality 
Over the last few centuries there have been drastic changes in the causes of mortality7.  
Prior to and during the World Wars, mortality was most commonly caused by famine, 
infectious diseases and pandemics. After the Great Wars ended, lifestyle factors such as 
obesity, sedentary routines, in addition to chronic/degenerative diseases and increases in 
stress have led to a greater proportion of cardiovascular-related deaths. The Australian 
Institute of Health and Welfare (AIHW) report that CVD is the underlying cause of death in 
approximately one third of all Australians (45,400 deaths in 2015), where 44% are due to 
coronary heart disease (CHD) and 10% are due to heart failure (HF) and cardiomyopathy2. 
Despite the significant mortality associated with CVD, both the number and rate of 
cardiovascular-related deaths have declined substantially over the last three decades. In 
Australia, the number of cardiovascular-related deaths has declined by 21% (from around 
57,500 to 45,400) between 1985 and 20152. However, there are a significant number of 




broader burden of CVD has critical significance, including the impact on functional capacity, 
quality of life, hospital resources and the economy. 
 
1.1.2 The Burden of Cardiovascular Diseases 
CVD has a detrimental effect on the Australian health care system, reflected as a financial 
burden to Australia’s economy9. Between 2008 and 2009 Australia spent $7,605 million on 
CVD, equating to 12% of the nation’s health-care expenditure10. 
 
Further to the financial damages, hospitalised patients with CVD are known to have poorer 
early health outcomes such as higher rates of 30-day mortality and readmission. The landmark 
New England Journal of Medicine paper by Jencks and colleagues reported that one in every 
five patients hospitalised for any reason is readmitted within 30 days of discharge11. Although 
readmission rates can vary dramatically between conditions and diseases, the two 
cardiovascular conditions that have consistently been reported as having the highest 
international rates of readmission are HF and acute myocardial infarction (AMI). 
Internationally, amongst patients admitted with a primary diagnosis of HF, approximately one 
in four (23.6%12, 24.56%13) patients are readmitted and just over one in ten (12.1%14, 
11.17%13) patients die within 30 days. Similarly, of the patients admitted with a primary 
diagnosis of AMI approximately one in every five (18.9%15, 19.94%13) are readmitted and 
16.60%13 die within 30 days. Moreover, both HF and AMI were diseases targeted by policy 
reforms in the United States and are further discussed in section 1.4.6. 
 
1.2.0 Angina Pectoris 
The classical symptom of chest pain or discomfort referred to as angina pectoris16 is a 




ankhone, meaning a strangling sensation and the Latin pectoris meaning chest17. This 
descriptive term is often simplified to ‘angina’ and refers the characteristic chest tightness 
attributable to myocardial ischaemia. Leonardo Da Vinci first detailed the coronary artery 
anatomy in his landmark diagrams, also documenting the presence of coronary artery disease 
(CAD) in 1511. This pioneering work was followed by William Harvey’s documentation of 
the definition of coronary circulation18. Subsequently, in 1772 William Heberden gave the 
first infamous elegant description of angina: 
“there is a disorder of the breast marked with strong and peculiar symptoms, 
considerable to the kind of danger belonging to it, and not extremely rate, which 
deserves to be mentioned more at length. The seat of it, and sense of strangling, and 
anxiety with which it is attended, may make it not improperly be called angina 
pectoris”19. 
This illustrative definition of the symptoms experienced by patients is still clinically 
applicable today in describing stable angina, where the symptoms occur from a predictable, 
reliable amount of exertion or stress. This constitutes the hallmark of ‘the chronic coronary 
syndromes’ as recently described in the European Society of Cardiology Guidelines20. When 
the usual pattern of angina changes in the duration, frequency or intensity, or occurs at rest, 
the symptoms are referred to as unstable angina, which indicates an acute coronary syndrome 
(ACS). The term ACS is applied to patients in whom there is a suspicion or confirmation of 
acute myocardial ischemia or infarction. 
 
1.2.1 Acute Myocardial Infarction 
An ACS results from acute obstruction of a coronary artery causing disruption of blood 
supply to the myocardium and resulting in myocardial ischaemia. Depending on the degree 
and location of obstruction, the clinical consequences range from unstable angina to AMI. 





In 2018, the Universal Definition of AMI was updated to clearly distinguish between 
myocardial infarction and myocardial injury21. The clinical diagnosis of AMI is based upon 
universally defined criteria21, unlike HF. The diagnosis of AMI is based upon changes on 
electrocardiogram (ECG), elevated cardiac markers along with supportive evidence of clinical 
symptoms or imaging evidence of new loss of viable myocardium or new regional wall 
motion abnormality. The evaluation of the ECG allows for the distinction to be made between 
the two types of AMI: ST-segment Elevation MI (STEMI) and ST-segment depression or 
Non-ST-segment Elevation MI (NSTEMI), their distinguishing features are described in 
Table 1.0. A STEMI is typically associated with a complete obstruction of the artery and 
leads to damage across the entire heart wall. In contrast, a NSTEMI involves the partial 
obstruction of the artery and the resulting ischaemia does not affect the entire heart wall. Non-
ST elevation acute coronary syndrome (NSTEACS) refers to patients presenting with 
NSTEMI or unstable angina22. The clinical presentation of these patients are similar, and the 






Table 1.0 Differences and similarities between STEMI and NSTEMI. 
 STEMI NSTEMI 
Electrocardiogram 
(ECG) 
ST-segment elevation, with or 
without T wave change 
Subsequent Q wave. 
*look for left bundle branch block as 
this can lead to rupture of the 
septum* 
Absence of ST–segment 
elevation but may include 
ST depression and/or T 
wave changes. 
Location of damage Transmural (across the heart wall). Subendocardial. 
 
1.2.2 Acute Myocardial Infarction Epidemiology 
Globally, over three million people suffer a STEMI and a further four million suffer a 
NSTEMI annually23. In 2008, the World Health Organization (WHO) attributed 7.3 million 
global deaths to AMIs3. The leading cause of Australian deaths in 2016 was CHD24,25, 
whereby AMI accounted for 40% of CHD mortality25. 
 
AMI incidence refers to the number of new cases that are identified every year and 
prevalence refers to the proportion of the population with AMI. The Australian incidence of 
AMI hospitalisations between 1993 and 2010 was found to be over 700,00026. Moreover, 
approximately 55,000 Australians suffer an AMI every year, equating to one infarct every ten 
minutes27. The cost of an Australian AMI hospitalisation is variable, though a prospective, 






1.2.3 Acute Myocardial Infarction Aetiology and Pathophysiology 
The aetiology of AMI is prolonged myocardial ischaemia causing obstructed coronary blood 
flow to the myocardium. Myocardial cell death does not begin immediately after the onset of 
myocardial ischaemia. An acute coronary artery occlusion lasting for at least 20 minutes 
initiates myocardial necrosis. Decreased coronary blood flow can occur for various reasons 
and thus the pathophysiology of AMI reflects the cause/s of the occluded coronary artery. 
Gould and colleagues demonstrated that a coronary artery obstruction must be at least 70% to 
impede on coronary flow reserve, but more severe lesions of at least 90% could result in 
myocardial ischaemia at rest29. Atherosclerotic plaques causing coronary artery occlusion 
from plaque rupture or erosion are the most common underlying cause of AMI, accounting 
for at least 70% of events30,31. Other aetiologies of decreased coronary blood flow and 
prolonged myocardial ischaemia include coronary spasm, coronary embolism, and thrombosis 
in non-atherosclerotic arteries. Thus, the pathophysiological mechanisms of AMI are defined 
by the triad of the ruptured atherosclerotic plaques30,31, or coronary spasm and/or thrombosis 
in non-atherosclerotic normal vessels32. 
 
1.2.4 Acute Myocardial Infarction Clinical Presentation and Diagnosis 
In patients presenting with chest pain suspicious of ACS, the key objective of clinical testing 
is to determine the presence or absence of AMI. Symptoms are similar in each of the ACSs 
and are characterised by angina, described by patients as a heavy weight on the chest which 
can radiate to the jaw, neck or back. Aside from angina, patients may present with an array of 
other symptoms that may include dyspnoea, nausea, cold sweat, feeling faint and fatigue. 
Angina lasting longer than 20 minutes may be considered characteristic of AMI.  
 
The ECG is the most common tool in the initial evaluation and triage of patients in whom 




myoglobin binding (CK-MB) is a biomarker which is released following damage to 
cardiomyocytes, however its use has been replaced by the troponin assay. The introduction of 
the biomarker troponin (both subtypes troponin I and troponin T) has provided improved 
sensitivity in determining myocardial damage. Levels of troponin continue to rise for 
approximately the first three hours following an AMI, and in some cases can remain elevated 
for 14 days33. The characteristic rise and fall of troponin is consistent with the acute injury to 
the myocardial cells21. 
 
Clinical cardiac societies have identified the importance of obtaining a 12-lead ECG in a 
timely fashion for the management of ACS and AMI. If the ECG specifies an ST-segment 
elevation in conjunction with elevated troponin levels, the final diagnosis is a STEMI – 
whereby a thrombus is causing complete occlusion of the artery. The ECG of some STEMI 
patients may also display a Q wave34. 
 
If the ECG shows an ST-segment depression or an T wave inversion the working diagnosis is 
a NSTEMI. Following the ECG, if the biomarker confirms a serially elevated troponin, the 
final diagnosis is NSTEMI – whereby a thrombus causes subtotal occlusion of the artery. If 
there are no abnormalities in biomarkers (specifically no troponin rise) the final diagnosis is 
unstable angina. 
 
1.2.5 Acute Myocardial Infarction Management 
The treatment of AMI aims to revascularise the heart and additionally reduce the oxygen 
consumption by the heart muscle. The introduction of percutaneous coronary intervention 
(PCI) has transformed the treatment of CAD. Thrombolysis and PCI are the principal 
treatments for STEMI35. Keeley and colleagues36 conducted a review of randomised trials in 




with primary PTCA had lower early mortality (7% vs. 9%, p=0.0002) and non-fatal 
reinfarction (3% vs. 7%, p=0.0003). More recently, the importance of patient health status 
(refer to section 1.4.4) has again shifted the focus of treatment in patients with CAD. 
 
Acute ST Elevation Myocardial Infarction Management 
A code STEMI is called and the patient urgently undergoes a primary PCI in order to re-
establish coronary artery patency; consistent with the ‘open artery hypothesis’37. It is vital that 
primary PCI is undertaken within 90 minutes of the STEMI being identified (known as door 
to balloon time). If a patient cannot be transferred to a catherisation laboratory for urgent PCI, 
thrombolytic therapy should be administered38-40. Thrombolytic therapy has been shown to be 
effective if administered within the first six hours of symptom onset and is most effective 
within the first hour41. If thrombolytic therapies fail to alleviate the occlusion, ‘rescue PCI’ 
may be undertaken when the patient arrives at a PCI-capable facility34. 
 
Acute Non-ST elevation Myocardial Infarction Management 
In relation to the management of NSTEMI, the Australian National Heart Foundation 
guidelines33 stratify patients into different risk categories according to their likelihood of 
mortality or recurrent events. Several risk assessment scores have been developed to help 
identify patients with NSTEACS, such as the Thrombolysis In Myocardial Infarction (TIMI) 
risk score. A patient is deemed to be at very high risk if they are hemodynamically unstable, 
have HF, cardiogenic shock or a mechanical complication arising from their AMI. For these 
patients the recommended treatment is angiography within two hours of symptom onset. 
Patients who are at high risk may present with the characteristic rise and fall in troponin that 
is consistent with AMI, dynamic ST-segment and or T wave changes with or without 
symptoms. It is recommended that these patients undergo angiography within 24 hours. 




insufficiency, left ventricular ejection fraction (LVEF) of ≦40%, prior PCI or CABG and a 
GRACE score between 109 and 140. It is recommended that these patients have a planned 
angiography within 72 hours. If a patient is low risk, they display none of the characteristics 
above, then angiography may be considered pending the results of non-invasive testing. 
 
Acute Coronary Syndrome Pharmacological Therapy 
Pharmacological treatment strategies include the administration of cardioprotective and 
antianginal medications. Cardioprotective drugs such as statins, aspirin and Angiotensin 
Converting Enzyme (ACE) inhibitors reduce the risk of major adverse events (such as stroke, 
a subsequent infarction or mortality). Anti-anginal medications such as nitroglycerin, aid in 
the managing the symptoms of angina. Following treatment of the acute incident, lifelong 
management to reduce the risk of adverse outcomes may include aspirin, ACE inhibitors, 
statins and possibly beta-blockers38. A comprehensive list of recommended medications is 





Table 1.1: Commonly used pharmacological therapy for AMI patients. 
Drug Reason for use 
Nitro-glycerine (also known as 
glyceryl trinitrate (GTN)) 
Dilate vessels. 
Opiates (predominantly morphine) Reduce chest pain. 
Oral antiplatelet agents (aspirin, 
clopidogrel and ticagrelor) and 
glycoprotein IIA/IIB inhibitors 
Inhibit the enzyme which causes platelet 
aggregation that leads to thrombus formation. 
Anti-coagulants (e.g. heparin, 
warfarin) 
Reduce clotting thereby reducing fibrin formation 
and prevents platelet aggregation that leads to 
thrombus formation. 
Beta-blockers Reduce oxygen demand of the heart. 
Statins Lower lipid levels and improve endothelial 
function. 
ACE inhibitors Cardioprotection. 






Acute Coronary Syndrome Procedures and Surgery 
Invasive coronary angiography involves a catheter being inserted (either via the femoral, 
brachial or radial artery) into the coronary arteries and is the gold standard method allowing 
the interventional cardiologist to image the coronary arteries by the injection of contrast42. 
Following on from the pioneering work of Sones, who performed the first angiogram in 
195943 there have been continuous improvements in the technique. 
 
PCI is a non-surgical procedure to unblock the obstructed coronary artery, during which a 
catheter with a small deflated balloon attached to its tip is advanced on a previously placed 
guide wire. When the balloon arrives at the site of the atherosclerotic obstruction, the balloon 
is inflated, and the plaque is crushed against the walls of the artery. A bare metal stent (BMS) 
or drug eluting stent (DES) may also be placed inside of the artery so that it remains open. A 
suspected STEMI is treated with urgent angiography and PCI44, within 12 hours of symptom 
onset34, followed by the continuation of aspirin and clopidogrel34. 
 
Acute Coronary Syndrome Lifestyle Changes 
Following AMI, patients are advised to make changes to their lifestyle to reduce the risk of a 
subsequent AMI or further CVD. It is recommended that the patient ceases smoking, reduces 
alcohol intake, eats a healthy diet, maintains a healthy weight and increases physical 
activity45. The attendance of cardiac rehabilitation is also highly recommended, as these 
programs encourage the patient to regain their strength, increase their physical activity and 





1.3.0 Heart Failure 
HF is a complex clinical syndrome that lacks a clear universal definition47,48, unlike AMI 
discussed in section 1.2.0 of this thesis. HF diagnosis is based on a clinical syndrome, 
dependent upon history, examination and the treating cardiologist’s judgement. Despite a lack 
of global concurrence, HF has been defined as the: 
“adequate ventricular filling, when the heart's output is decreased or 
in which the heart is unable to pump blood at an adequate rate to 
satisfy the requirements of the tissues with function parameters 
remaining within normal limits”47. 
 
In addition to the conceptual definition outlined above, clinical guidelines have been 
developed. HF can manifest clinically as right-sided HF or left-sided HF (which is subdivided 
into systolic and diastolic HF). Systolic HF or HF with reduced EF (HFrEF), refers to the 
reduced capacity for the heart to contract and is the more common form. Diastolic HF or HF 
with preserved EF (HFpEF), refers to impaired filling capacity of the left ventricle in the 
presence of normal contraction. 
 
As depicted in Table 1.3, the functional severity of HF can be classified in accordance with 
the patient’s ejection fraction (EF), which is measured by left ventricular function and 
reported as New York Heart Association (NYHA) classes I to IV49. As indicated in Table 1.4, 
HFpEF refers to patients with HF and an EF over 40%. In contrast, patients with an EF lower 
than 40% are referred to has having HFrEF. In addition to the European Society of 
Cardiology (ESC) guidelines50, the American College of Cardiology Foundation (ACCF)/ 
American Heart Association (AHA) Task Force guidelines51 have further subdivided HF to 
include a mid-range EF (HFmrEF) category which is defined as an EF as being between 41% 




Table 1.3: Classifications for HF, adapted from the American College of Cardiology (ACC)/ 
American Heart Association (AHA)52 and the New York Heart Association (NYHA)49. 
Stage52 Symptoms and Characteristics52 Class49 Functional classification49 
A Patient at risk of developing HF (i.e. 
patients with diabetes or coronary 
disease without prior infarct). 
I Normal physical activity 
without fatigue, palpitations or 
dyspnoea. 
B Structural heart disease without 
symptoms (i.e. reduced ejection 
fraction, left ventricular hypertrophy 
or chamber enlargement). 
II Slight limitation of physical 
activity. 
Ordinary physical activity 
causes fatigue, palpitations or 
dyspnoea.  
No symptoms at rest. 
C Clinically defined HF. III Limited physical activity. 
Reduced physical activity that 
results in fatigue, palpitations 
or dyspnoea.  
No symptoms at rest. 
D Refractory HF requiring advanced 
intervention (i.e. biventricular 
pacemakers or transplantation). 
IV Unable to conduct physical 
activity. 
If physical activity is 
performed, discomfort occurs. 






Table 1.4: Heart Failure classification via ejection fraction, adapted from the ESC 
guidelines50. 
Class Definition 
HFrEF Left Ventricular Ejection Fraction (LVEF) <40%. 
HFmrEF LVEF 40-49%. 
Elevated natriuretic peptide and at least one of the following additional: 
1. Structural heart disease. 
2. Diastolic dysfunction. 
HFpEF LVEF ≥50%. 
Elevated natriuretic peptide and at least one of the following additional: 
1. Structural heart disease. 
2. Diastolic dysfunction. 
 
1.3.2 Heart Failure Epidemiology 
Evidently, the ageing population in combination with the prolonged lifespan has led to 
increased prevalence and mortality in HF patients, which remain unacceptably high53. 
However, due to the lack of consensus on HF definition, the true prevalence of HF remains 
unknown. Understandably, there is ambiguity in the literature surrounding the incidence of 
HF, which is further alluded to in Chapter III of this thesis. 
 
Global figures estimate that there are currently 37.7 million patients suffering from HF54, with 
this figure rising due to increased survival following AMI55. Australian figures estimate that 
30,000 new cases of HF are diagnosed annually56. A systematic review57 reported the 
Australian prevalence of HF between 1990 and 2015 to be 1-2%, however this reported 




rising number of HF admissions are causing financial hardship, with the average HF 
admission to an Australian public hospital estimated to cost $990 per patient per day58. HF is 
a fatal condition, with mortality occurring in 50% of patients within five years of diagnosis58. 
The AIHW has reported a decline in Australian mortality due to HF from 1980 to 200159. 
 
1.3.3 Heart Failure Pathophysiology 
In the normally functioning heart, the left ventricular output is responsible for supplying the 
systemic circulation with its cardiac output and thus fundamental to life. The right ventricle 
operates at a lower pressure and ensures adequate preload to the left ventricle via maintenance 
of the pulmonary circulation. This thesis focuses on HF, which may involve either or both the 
right/left ventricle, however the discussion relates primarily to failure of the left ventricle 
unless otherwise specified. 
 
HF is a complex clinical syndrome manifesting as inadequate cardiac function to provide 
adequate tissue perfusion. The “typical” symptoms of patients with HF can manifest both 
upon exertion and at rest. Symptoms occur at rest due to inadequate cardiac function, that 
may be due to loss cardiac myocytes (for example myocardial infarction) but may equally 
arise from dysfunctional myocytes. Clinically, HF has been categorised on the basis of the left 
ventricular ejection fraction (LV-EF) and accordingly classified as HFrEF and HFpEF, using 
and LV-EF cut-off of 50%, these are discussed below. 
 
HFrEF is defined as HF with an LV-EF <50%, and is typically due to damage to the 
cardiomyocytes caused by AMI, hypertension and cardiomyopathy all contribute to the 




cardiac output9. There are both hemodynamic and remodelling aspects of the pathophysiology 
of HF. In HFrEF, global left ventricle systolic dysfunction predominates, usually with 
progressive chamber dilation and eccentric remodelling. Due to cardiomyocyte damage, 
haemodynamic and neurohormonal mechanisms (catecholamines, renin-angiotensin-
aldosterone system, and others) are activated to compensate for the reduced function. 
However, these ‘compensatory mechanisms’ are potentially deleterious as they may increase 
the workload of the heart and thus further aggravate the HF. 
 
Unlike the pathophysiology of patients with HFrEF, the underlying causes of HFpEF are 
multifactorial and less clearly understood60. By definition, the systolic contraction in HFpEF 
is not significantly impaired but there is inadequate functioning, resulting in increased left 
ventricular end-diastolic pressure at rest or during exertion. Although there is no major loss of 
cardiomyocytes, these cells may be enlarged and/or dysfunctional resulting in abnormal 
diastolic relaxation, filling or distention of the left ventricle and subsequently HF. 
 
1.3.4 Heart Failure Clinical Presentation 
Patients with HF have various symptoms which are dependent on the pathophysiology of the 
disease61. The most commonly associated symptom of HF is acute pulmonary oedema defined 
as the accumulation of fluid in the lungs, making it more difficult for oxygen to cross from the 
alveoli to the capillaries and resulting in hypoxia. HF manifests clinically as left-sided and 
right-sided HF, depending on the affected ventricle. Additionally, biventricular failure, or 
congestive heart failure, refers to both left and right HF. However, the term “congestive heart 
failure” is being used less frequently to describe these patients as congestion is not the sole 
cause of HF61. With the potential variation in the causes of HF, the symptoms are also quite 




low cardiac output. This alludes to the importance of cardiologists being meticulous when 
taking a patient’s history, to cover the broad range of potential causes of HF. The underlying 
aetiology of HF is in most cases due to pre-existing cardiovascular disease (hypertensive, 
ischaemic, valvular), cardiomyopathy, cor pulmonale (alternated structure and function of 
right ventricle) and pulmonary hypertension (association between lung and heart disease). HF 
can be aggravated by factors including anaemia, arrythmias, viral infections such as human 
immunodeficiency virus (HIV) or Chagas disease, history of substance abuse or exposure to 
other cardiotoxic substances (including chemotherapy drugs) and fever61. 
 
The clinical presentation of a HF patient lies on a broad clinical syndrome, making diagnosis 
challenging62. Moreover, it is important to distinguish the clinical presentation of patients 
with acute HF compared to those with chronic HF. A comprehensive history of the patient is 
evaluated and corroborated by physical examination63. Clinical diagnosis of HF is derived 
following careful patient history and physical examination. Physical examination of the 
patient involves meticulous assessment of the patient’s physical appearance, such as their 
posture, pallor, cyanosis or jaundice and emancipation, which can provide important clues for 
their diagnosis. Patients may present with fatigue which can be attributed to the decreased 
cardiac output. These symptoms may appear upon exertion, or at rest and despite the manner 
of presentation, all patients warrant further investigation63. Cardiac auscultations may also 
provide insight when diagnosing HF, the detection of the additional S3 sound, often referred to 
as a gallop may be indicative of left ventricular failure64. 
 
Left-sided Heart Failure 
Clinical presentation of pulmonary oedema is caused by failure of the left ventricle. This 
leads to increased left ventricular end diastolic pressure which increases pulmonary venous 




Law of Fluids, leading to fluid leaking from the pulmonary capillaries to the intra-alveolar 
tissues and then into the alveolar space. This accumulation of fluid, most commonly presents 
as increased dyspnoea (shortness of breath), which may be related to increased filling 
pressures or impeded cardiac output61 which are consistent with left-sided HF. Orthopnoea 
(dyspnoea when lying flat) at night, may be alleviated by sleeping in an upright position. 
 
Further physical examination may identify tachycardia, irregular cardiac rhythm or pulse and 
tachypnoea (abnormally rapid breathing), which can all be signs and symptoms of HF. The 
characteristic crackling sound heard, referred to as rales, is another common indicator of HF. 
As the disease progresses, an abnormal breathing pattern known as Cheyne-Stokes respiration 
may develop65,66, indicative of a poor prognosis67. 
 
Right-sided Heart Failure 
Similar to left ventricular failure described above, right-sided HF there is increased right 
ventricle end diastolic pressure. This increased pressure results in increased pressure of the 
superior vena cava and inferior vena cava, thus leading to increased pressure in the periphery. 
Swelling of the ankles and pitting oedema (in the ankles) are consistent with right-sided HF 
and may occur due to the fluid overload and increased hydrostatic pressure. Patients may also 
present with ascites (peritoneal fluid build-up) and hepatomegaly, observed upon physical 
examination. Jugular venous distention another symptom observed in patients with right sided 
HF and is observed via physical examination of the jugular venous pressure (JVP) indicates 
with good sensitivity and specificity (70% and 79% respectively)68 of the patients central 
venous pressure69. The jugular veins communicate directly with the superior vena cava and 
then the right atrium70. JVP is an estimation of right atrial pressure. If there is increased 
pressure in the right atrium, blood flows backward into the jugular vein, observed as pulsing 




related symptoms. Patient’s may also experience weight gain and loss of appetite or feeling 
full quickly (early satiety)61. 
 
1.3.5 Heart Failure Diagnosis 
Echocardiography is a non-invasive diagnostic imaging technique for patients suspected of 
having HF56. Echocardiography can measure important markers of cardiac function including 
haemodynamic status, EF, cardiac volume and mass72. Moreover, echocardiography assists in 
the distinction between HFrEF and HFpEF and may provide further insight to whether AMI 
or valvular disease precipitated the HF presentation. 
 
Chest x-rays provide a relatively safe, affordable and convenient initial investigation for 
patients presenting with suspected HF (or any cardiovascular condition)73. The chest x-ray 
provides the cardiologist with specific anatomical or physiological abnormalities of the heart, 
such as an enlarged left ventricle or atria (in the case of a HF patient)63, cardiomegaly 
(enlarged heart) and/or pulmonary oedema. 
 
An ECG is routinely conducted in all cardiovascular patients but help the cardiologist 
understand the cause of HF, which therefore aids in treatment61. An ECG may be helpful in 
identifying arrhythmias, the presence of conduction delay or abnormalities such as left bundle 
branch block amongst others. Biomarkers investigations may include analysis of plasma 
levels of B-type natriuretic peptide (BNP), a neurohormone that measures the overstretching 
of the cardiomyocytes, has shown to have good diagnostic accuracy for HF74,75 and has been 
recommended by the ESC HF guidelines76. In Australian clinical practice, BNP is more 
commonly requested in the emergency department, compared to than inpatient wards. 






1.3.6 Heart Failure Management 
The main goal of treatment and management of HF patients is to improve quality of life 
whilst reducing readmissions and mortality. As with AMI, there are various therapies and 
management options available to achieve these outcomes. Management of HF patients differs 
depending upon whether presentation is acute or chronic and have been described accordingly 
below. 
 
Management of Acute Heart Failure 
The goal of therapy for a patient presenting with acute HF is to stabilise the patient. For 
example, a patient who presents to the emergency department with shortness of breath will 
most commonly be treated with Continuous Positive Airway Pressure (CPAP) and frusemide. 
In the outpatients setting, a patient presenting with swelling of ankles may be prescribed 
frusemide. 
 
In some cases of HF, the intubation and mechanical ventilation of a patient may be required, 
which may be a traumatic experience for the patient. Fortunately, non-invasive ventilation 
approaches and avoid endotracheal intubation, by using a mask or similar device to provide 
ventilatory support and aids in the gas exchange occurring in the alveoli, CPAP and Bi-level 
Positive Airway Pressure (BiPAP) are the two methods utilised in patients. CPAP provides 
continuous positive pressure (usually between 5 and 12cm of water) and aids oxygenation. In 
1991, Bersten and colleagues77 conducted a study of 39 patients with respiratory failure and 
acute pulmonary oedema. Patients were randomised to receive either high flow oxygen 
therapy or CPAP, and the results concluded that the patients on CPAP had better outcomes. In 
comparison BiPAP provides and expiratory airway pressure and an inspiratory airway 




no significant difference in the period of non-invasive ventilation between patients given 
CPAP compared to BiPAP therapy78. Both CPAP and BiPAP are advantageous compared to 
other HF treatments79-81. 
 
Management of Chronic Heart Failure 
The majority of therapeutic recommendations for patients presenting with HF have been 
conducted through randomised controlled trials in patients with HFrEF. Medications are 
prescribed with the intention of alleviating the most common symptom of HF such as 
exertional dyspnoea and orthopnoea. Different pharmacological agents have been shown to 
benefit patients with HF, by improving survival and reducing morbidity in the form of 
readmissions (refer to Table 1.5). Patients presenting with chronic HFrEF may be treated with 
beta-blockers and ACE inhibitors, with the more recent addition of aldosterone antagonists 
such as spironolactone. These pharmacological agents antagonise the detrimental 
neurohormonal systems that are activated in HF, as described in section 1.3.3. Furthermore, 
the guidelines recommend that a patient with stabilised systolic HF that is still symptomatic 
be administered beta blockers. A trial of over 15,000 patients who were prescribed a beta 
blocker in addition to an ACE inhibitor improved all-cause mortality by 30-65% and reduced 
the number of deaths and hospitalisations by 35-40%82. Beta blockers prevent the detrimental 
tachycardia that is aggravated by the sympathetic systems response which results in a surge of 
catecholamines. ACE inhibitors and spironolactone antagonise the activated renin-aldosterone 
system, thereby reducing the detrimental effects of fluid retention and increased afterload. 
Loop diuretics, digoxin and nitrates may also be considered to improve patient symptoms. 
The addition of Ivabradine may be considered, although it has been shown to have no effect 
on mortality, but significantly decreases morbidity83. Devices such as cardiac 
resynchronisation therapy (CRT), permanent pacemakers and automatic implantable cardiac 




shown to be to be of particular benefit to patients with an EF <35% with left and right 
ventricle dys-synchronisation, which is reported as a broad QRS84. HF is a fatal disease thus, 





Table 1.5: Pharmacological Medical Therapy for Heart Failure. 
Agent Survival Morbidity 
ACE inhibitors e.g. Enalapril86,87. Improved. Decreased. 
Angiotensin II receptor blockers88-92 e.g. 
losartan, valsartan and candesartan. 
Improved. Decreased. 
Beta blockers93-101 e.g. bisoprolol, 
metoprolol and carvedilol. 
Improved. Decreased. 
Loop diuretics e.g. furosemide. Improved. Decreased. 
Digoxin102. No effect. Decreased. 
Nitrates. Improved. Decreased. 
RAAS inhibitors e.g. spironolactone. Improved. Decreased. 
Ivabradine83. No effect. Decreased. 
Eplerenone103. Improved. No effect. 
 
Non-pharmacological Management 
Lifestyle modifications such physical activity programs, fluid management and weight loss 
are all essential in the management of HF. HF specific programs, either clinic or home-based 
interventions provide the patient with psychosocial support, education and support to modify 
risk factors, including ceasing smoking and reducing alcohol intake. Moreover, by designing 
HF programs that specifically focus on the individual patient, the programs result in 






Finally, as HF is a chronic and terminal illness, the objective of care may shift from 
prolongation of life to improving the patient’s quality of life. At this point, hospice care may 
be an appropriate option for patients. Although hospice care has long been thought of as a 
facility for terminal cancer patients, the second most common (18.7%) admitting diagnosis 
was cardiovascular or circulatory diseases104. Moreover, as HF progresses, the associated 
symptoms have been reported to be a greater burden than the symptoms of advanced cancer 
patients105. Palliative care exemplifies the principles of shared decision making by providing 
the patient with evidence based information and working with the patient (and their 
family/relatives) to deliver holistic care106. For example, a patient in advanced or final stages 
of HF may wish to have their implantable cardioverter defibrillator deactivated107. 
 
1.4.0 Evaluation of Health Care and Health Outcomes 
Health care quality is defined by the Institute of Medicine as: 
“the degree to which health services for individuals and populations increase 
the likelihood of desired health outcomes and are consistent with current 
professional knowledge108”. 
The quality of health care refers to how well the care provided coincides with the predefined 
benchmarks108 and the extent to which the clinician portrays this109. Six domains have been 
suggested by the Institute of Medicine (IOM) to define the quality of health care, they are: 
effectiveness, safety, equity, timeliness, efficiency, and patient-centeredness108. These six 
domains have been promoted by the IOM as a core focus when measuring health outcomes 
and health care quality. The quality of health care should be measured and defined by how 
care effects the health of individual patients and not by health care efficacy110. It is imperative 




assessed by measuring the health care structures, processes and outcomes114. As health cannot 
be directly measured, it is quantified by a single indicator, surrogate marker115. Readmission 
rates are an example of a surrogate marker for avoidable adverse events. Moreover, the 
validity and reliability of readmission rates as a measure of health care quality have also been 
recently debated in the literature116. 
 
The Donabedian model offers a conceptual framework allowing the measurement of health 
care quality by measuring structure, process and outcomes117. An example of measuring 
structure is assessed by the number of procedures or admissions that an institution may 
perform. An example of measuring process is by evaluating how and which medications are 
prescribed. Furthermore, performance can be specifically measured in a disease or condition, 
for example the rate readmissions and/or mortality that occurs in a cohort of HF patients. 
 
1.4.1 The Evolution of Health Outcomes 
Health can be measured in two distinct approaches: quantity and quality118, which are each 
measured using diverse methods. Health outcomes have been measured and reported since the 
mid to late nineteenth century, as seen in the novel research conducted by Florence 
Nightingale119,120, where she improved the health outcomes of British soldiers fighting in the 
Crimean War. Nightingale investigated the potential causes of the rising number of deaths in 
military hospitals despite her best efforts to make the environment safe and clean121. She 
published her findings that infections were the major cause of these deaths and reduced 
mortality rates from 42.7% to 2.2%122. Today, health evaluation continues to be increasingly 
important. Policymakers, health care providers and health researchers have become more 
concerned with the rigorous assessment of health care policies, health interventions and health 






1.4.2 Health Data Sources 
Review and abstraction of medical records for the purposes of medical research have well 
documented methods. With the introduction of electronic health records in clinical practice, 
the use of administrative data for the purposes of research has also evolved. Additionally, the 
notion of big data is ill-defined123. Administrative data, a type of big data, that is not collected 
for research purposes and most commonly originates from government or large agency 
records for financial purposes and thus can be thought of as transaction data124. Due to the 
ambiguity in the aims of this data collection, the data is usually complex and requires 
“cleaning” and organisation before it can be used for research purposes125. The involvement 
of administrative data in health care and outcomes research is continuously evolving. The 
introduction of administrative data into health care research began in 1970, when 
administrative data was used to examine the patterns and variation of health care practice 
between different areas in Vermont in the United States126. In 1990, administrative data was 
used to analyse the potential issues surrounding the safety and quality of health care provided 
to patients, with the proposal of using administrative data as a screening tool127. The 
progression of uses of screening continued when the United Health care Corporation 
developed a screening tool to determine outcomes rates, adverse events and other outcome 
measures128. The assistance of administrative data in screening for potential complications 
following hospital procedures and the potentially preventable readmissions began in to early 
1990s129-131. The identification of readmissions for complications following medical 
procedures using Medicare claims data (using the International Classification of Diseases 
(ICD)-9-CM coding) was first utilised by Riley and colleagues in 1993132. In 1994, further 
analysis of administrative data found that patients who suffered complications were older, had 
more comorbidities, endured a longer length of stay and experienced poorer outcomes131. In 




data in the development of screening tools for the reduction of medical error and consequently 
improvement of patient’s safety133. 
 
The source and type of health care data used for monitoring and research depends on the 
question which is being investigated134. Australia uses a universal health care system, making 
these services accessible to all Australians135 and is comprised of both public and private 
sectors funded at both state and federal levels136. Medical data is collected in various ways. 
Administrative records are routinely collected by hospitals to keep track of patients, 
admissions and costs. With the analogy of administrative data being much like bank 
transactions, this data source contains key information such as date, time, primary and up to 
50 subsequent diagnoses and procedures that a patient has during that encounter. In 
comparison, clinical registry data is collected for a specific reason to improve the outcomes of 
patients, using observational study methods137. Registry data that is collected for the purpose 
of improving quality of health care collect data used to benchmark, analyse and improve 
specific health outcomes138. In Australia, the Australian Commission for Safety and Quality in 
Health Care developed principles139 and a framework140 for the operation of clinical registries. 
Although clinical registries are useful and credible tools in measuring and monitoring 
improvements in health care, in recent years, registries have facilitated clinical research and 
even randomised clinical trials141. 
 
1.4.3 Administrative Data Coding 
The WHO classifies diagnoses into the universally accepted coding structure known as the 
International Classification of Diseases (ICD). Several editions of the ICD coding exist, the 
eleventh edition was announced by the WHO in 2018. However, the ninth edition is used in 




practice. The ICD system has been adapted and refined for different countries or health care 
systems142,143. In Australia, the coding standards were developed by the Australian National 
Centre for Classification in health. Similarly, procedure codes have been developed by the 
institute known as Australian Classification of Health Interventions (ACHI) codes. For 
international studies where different editions or coding versions exist, mapping codes are 
available which enable the cross referencing of these codes. A comparison of the quality of 
ICD-10-AM to the original ICD-10 coding found 85% accuracy144. Comorbidities are 
grouped into clinically meaningful groups known as Condition Categories (CC)145,146, further 
explored in Chapter III of this thesis. 
 
Data linkage refers to the linkage of data from different sources/datasets via a unique 
common identifier147,148. For example, Chapter III of this thesis links hospital administrative 
records to mortality registry records, for the reporting of mortality rates using a statistical 
technique known as probabilistic matching149. Probabilistic matching is a technique which has 
been shown to have over 99% accuracy in this context150. Gaining access to administrative 
data and the subsequent data linkage can be complex and tedious for the purposes of 
research125,151. 
 
1.4.4 Health Status 
Health status is a holistic concept taken from the patient’s perspective incorporating their 
symptoms, functional limitation and quality of life (discrepancy between actual and desired 
function)152. To put this into context, a patient with CHD may present with angina. This 
patient suffers from functional limitations in daily life which may impede their physical 
function such as taking daily walks. The physical symptoms of angina may also impact the 




patient’s ability to function socially. All these limitations impact the patient’s quality of life. 
Health status aims to determine the impact of disease on a patient’s life153, thus it is a 
subjective measure unique to every individual patient154-156. Health status is conceptualised in 











Figure 1.0 An overview of Health Status adapted from Spertus, 2008157. 
 
Health status is most commonly measured using self-administered questionnaires, which can 
either be generic or disease-specific and the combination of both instruments is most 
appropriate to measure changes in health status158. The measurement of health status has 
permitted the clinician to work with the patient to make shared decisions for their 
treatment159. The importance of understanding what the patient values most (such as treatment 
of symptoms) results in improving health status and has been reinforced by a scientific 
statement from the American Heart Association160. The advances in shared decision making 
in clinical practice are increasingly important, following concerning evidence that clinicians 
do not accurately estimate patients’ health status161. 
 
Disease Symptoms Functional  Limitation 









1.4.5 Measuring Health Outcomes 
Health outcomes can be assessed using both objective and subjective methods. Objective 
outcomes are important clinical markers such as readmissions or mortality. Subjective 
endpoints allow for the assessment of patient’s health status and can be measured using 
patient reported outcome measures to determine quality of life, social health, pain and patient 
satisfaction162. The effectiveness of outcome measures is optimal when a combination of 
objective and subjective measures are used. Surrogate outcomes are not the direct measure 
but are useful in reflecting values that are difficult to measure directly109. For example, 
readmissions are a surrogate marker of hospital performance and quality116,163-172 and 
indicative of health care costs173,174. In contrast, a meta-analysis of 16 studies of inpatients 
found no relationship between quality of care and readmissions that occurred within 31 days 
of discharge173. Furthermore, Butala et al175 has stated that the use of hospital-wide 
readmission measures are not good surrogates for hospital quality. This was further supported 
by a recent editorial that referred to the complexity of hospitals and that readmissions cannot 
possibly reflect hospital performance176.There are various health outcomes that can be 
measured, this thesis focuses on readmissions and mortality. 
 
A readmission is defined as a return to hospital following an index admission within a certain 
timeframe173,177,178. Readmissions can be measured at various time points, including seven 
days, 15 days, and 30 days after discharge of an index admission. The 30-day time frame is 
commonly assessed and has clinical relevance13 as it is believed that if optimal care is 
provided during the index admission, a poor outcome should not ensue within a month. 
Moreover, the methods used to measure readmission rates differ between studies, a topic 
which is further explored in Chapter II of this thesis. Readmissions can either be measured as 
all-cause or same-cause (for readmissions that have the same diagnosis as that of the index 




same hospital or to any hospital. Readmission can be further considered as planned or 
unplanned, defined as related or unrelated to the index hospitalisation. Unplanned 
readmissions are more commonly reported in the literature because they are thought to reflect 
the safety and quality of the index hospitalisation179. Determining whether a readmission 
relates to the index hospitalisation is not clearly defined. The distinction between planned or 
unplanned readmission has been made evident through the Planned Readmissions Algorithm 
(PRA)180 created by the Centres for Medicare and Medicaid Services. The algorithm removes 
planned readmissions as they are not believed to reflect quality of care180. Chapter III of this 
thesis utilises a modified PRA, to accommodate for the Australian modification of the ICD 
coding. 
 
Additionally, patients who returns to the emergency department without being admitted into 
the hospital (“treat and release”) form a separate outcome. There is debate in the literature as 
to whether this outcome should form separate outcome to readmissions or whether they 
should be categorised into the same group as readmissions. 
 
The outcome of mortality is an objective measure which can also be a surrogate marker of 
hospital safety and quality. For this purpose, mortality can be measured either in-hospital or at 
30 days from the date of admission (unlike readmissions which are measured from the date of 
discharge). Although the fact of death is a hard outcome, the cause of death is not always 
accurate, due to the decreased number of autopsies performed. 
 
Composite outcomes combine more than one measure of safety and quality and may be 




such measures is complicated because although they provide a broader perspective, they can 
take away from the impact of specific areas182. 
 
Avoidable or preventable readmissions are poorly defined in the literature and the 
classification is usually left to the physician’s discretion. A meta-analysis reported that 23.1% 
of readmissions were preventable, however the definition of preventable readmissions were 
non-existent in the studies reported183. 
 
1.4.5.2 Health Outcomes in Acute Myocardial Infarction 
Readmission following an index hospitalisation for AMI occurs for approximately one in four 
patients at one month. Additionally, approximately one in every ten patients will die within 
one month. These rates are quite variable depending on the study cohort and the methodology 





Table 1.6: Reported rates of readmission and mortality following an index hospitalisation for acute myocardial infarction (AMI). 










Tuscany, Italy retrospective cohort study. 2011-14 30-day mortality. 7.0 
Dodson et al.187 SILVER-AMI prospective cohort study from the United States. 2013-16 30-day readmission. 18.2 
Kim et al.188 United States STEMI national readmission database analysis. 2010-14 30-day readmission. 12.3 





Krumholz et al.15 United States Medicare patients. 2006 30-day readmission. 12.3 



























1-year readmission. 20.2 
Saczynski et al.193 New England population-based sample. 2003-05 12-month 
readmission. 
46 




1-year mortality. 5.4 
Tran et al.195 Canada  
AMI + PCI 




AMI + CABG 11 
STEMI + PCI 9.2 





1.4.5.3 Health Outcomes in Heart Failure Patients 
Compared to AMI readmissions, the readmission of HF patients is well-known to be quite 
high, particularly within the 30 days following discharge163,196-202. Akin to the outcomes of 
AMI patients, there is variability in the rates of readmission and mortality of HF patients. 
Table 1.7 outlines the range of readmission and mortality rates of patients hospitalised with 
HF, although roughly one in every five patients is readmitted to hospital and approximately 





Table 1.7: Reported rates of readmission and mortality following an index hospitalisation for heart failure. 
Publication Cohort/ data source Year Outcome definition Rate (%) 




Aranda et al.197 United States Medicare data in patients hospitalised for HF for the first time. 2002-2004 6-9 months all-cause readmission. 
6-9 months all-cause mortality. 
24 
8 




Eapen et al.205 Acute Study of Clinical Effectiveness of Nesiritide in 
Decompensated Heart Failure (ASCEND-HF) multinational, double-blind, 
placebo-controlled trial. 
2007-2010 30-day all cause readmission. 
30-day all-cause mortality. 
11.4 
1.2 
Krumholz et al.13 United States Medicare administrative claims data. 2005-2008 30-day all-cause mortality. 11.17 
Krumholz et al.14 United States Medicare administrative claims data. 1999-2001 30-day all-cause mortality. 12.1 
Santos et al.206 Spanish National Health System retrospective analysis. 2012 Mortality in hospital and up to 1-year 
post-discharge. 







Publication Cohort/ data source Year Outcome definition Rate (%) 
Schaufelberger et al.207 Swedish Hospital Discharge Registry. 1988-2000 30-day mortality. 20 to 20 in 
men. 
0 to 17 in 
women. 
Robertson et al.208 New South Wales linked data. 2000-2007 28-day all-cause readmission. 
1-year all-cause readmission. 
28-day all-cause mortality. 





Vader et al.209 Post hoc analysis of three acute HF trials.  30-day all-cause readmission/death. 







1.4.6 Readmissions as a Marker of Health Care Safety and Quality 
The relevance of readmission rates as a surrogate marker for hospital quality is a 
contemporary and controversial topic in the literature has been heavily influenced by the 
pioneering work undertaken in the United States. Standardised mortality rates for individual 
hospitals became the first outcome measure to be made publicly available in 2007 by the 
Centre for Medicare and Medicaid Services (CMS)210. In 2010, the Affordable Care Act 
(ACA) implemented the Hospital Readmissions Reduction Program (HRRP) aiming to reduce 
readmissions and thus health care costs for three targeted conditions: HF, AMI and 
pneumonia211. Following its implementation, the HRRP issued hospitals with higher than 
expected readmission rates with financial penalties212. Between 2007 and 2015, the risk 
standardised 30-day readmission rates declined from 21.5% to 17.8% among targeted 
conditions and from 15.3% to 13.1% in non-targeted conditions213. 
 
Despite the reduction in readmission rates following the introduction of the HRRP, post-
discharge mortality rates appear to have risen214. This topic is further explored in the 
Australian and New Zealand context in Chapter III of this thesis. It has been suggested that 
the observed reduction in readmission rates could be attributed to changes in diagnosis coding 
resulting in the drastic overestimation of readmission, due to the lack of control groups and 
standardisation of rates214. Additionally, gravely ill patients contribute only to the mortality 
and not the readmission rate215, once again contributing to the observed surge of mortality 
rates. 
 
Patient factors, as opposed to hospital factors, have also been argued to drive readmission 
rates. One article suggests that focusing purely on readmission reduction due to hospital 
factors would result in neglecting quality improvement216. Moreover, the lack of concordance 




conditions following the introduction of the HRRP217. Accounting for both the combination of 
hospital and patient factors allows for optimal hospital quality and performance. Following 
case-mix adjustment of AMI and HF Medicare patients, the variation remained consistent 
implying the observed variation may be due to hospital quality in addition to other factors218. 
Moreover, analysis of Medicare data between 2014 and 2015 suggested that hospital quality 
formed a component of the readmission measure, in addition to patient factors219. 
 
1.4.8 Readmission Risk Prediction Models 
Risk prediction models in health aim to predict which patients are most at risk for a certain 
outcome. By prospectively applying risk prediction models, patients at high risk for adverse 
outcomes could be identified and targeted for prevention of events. Different tools can be 
implemented to help predict which patients are at higher risk, as it been acknowledged that 
clinical providers are unable to accurately predict which patients will require readmission220. 
There are various proposed and potential risk factors for readmission such as demographic, 
socioeconomic and disease severity factors. Although there have been several prediction tools 
devised to help clinicians determine which patients are most at risk of readmission, they have 
been found to be poor predictors in general medical patients221. Two commonly used 
screening tools are the LACE index222 and HOSPITAL score223. Although both have been 
validated in general and surgical patients, the LACE index uses more readily available 
variables and was developed in a Canadian setting (whose health care system is universal and 
more comparable with an Australian setting). The development of risk models and risk 
stratification allow for the identification of patients at higher risk of a certain outcome. There 
are multiple models available to predict readmission and mortality risk which have shown 




Table 1.8: Different models for predicting readmission and/or mortality. The C statistic is a measure of model discrimination, it measures the function (both 
the sensitivity and specificity) of the model. The C statistic values lie on a range of 0.0 to 1.0 (perfect prediction). A C-statistic scores of 0.5 is a random 
chance, C statistic scores of <0.7 are inadequate, C statistic scores of 0.7-0.8 are acceptable and C statistic scores of 0.8-0.9 are excellent224. 
 
Risk Model Original Validation 
Population 
What does it measure? Or 
Outcome measure? 
Model discrimination / performance 
Amarasingham et al.203 United States single centre HF 
patients 2007-2008 using 
electronic health records. 
30-day readmission. 
30-day mortality. 
C statistic = 0.72 
C statistic = 0.86 
Bottle et al.225 English general medical 
inpatients (2000-2001) derived 
using administrative data. 
Future emergency admissions. ROC score = 0.72 
Centres for Medicare and 
Medicaid Services AMI model226 
United States Medicare patients 
(aged ≥65 years) 2005-2006 
derived using administrative 
data. 
30-day all-cause unplanned 
readmission. 




Centres for Medicare and 
Medicaid Services HF model227 
United States Medicare patients 
(aged ≥65 years) 2005-2006 
derived using administrative 
data. 
30-day all-cause unplanned 
readmission. 
C statistic = 0.60 
Risk Model Original Validation 
Population 
What does it measure? Or 
Outcome measure? 
Model discrimination / performance 
Global Registry if Acute Coronary 
Events (GRACE)228 
Europe, Australia, New Zealand, 
North and South America 
registry of ACS patients between 
1999-2005. 
6-month mortality. 
6-month mortality or myocardial 
infarction. 
C statistic = 0.81 
C statistic = 0.73 
Hammill et al.134 United States linked data from 
the Get With The Guidelines–
Heart Failure Registry with 







Administrative data only AUC=0.718 
Administrative + registry AUC =0.761 
Administrative data only AUC = 0.587 




HOSPITAL223 United States general medical 
patients using administrative and 
clinical data between 2009-2010. 
Potentially avoidable 30-day 
readmission. 
C statistic = 0.71 
Risk Model Original Validation 
Population 
What does it measure? Or 
Outcome measure? 
Model discrimination / performance 
LACE index222 Canadian general medical and 
surgical patients using 
administrative data between 
2004-2008. 
30-day readmission and/or 
mortality. 
C statistic = 0.684. 
LACE+ index229 Canadian medical and surgical 
patients using administrative 
data between 2003-2009. 
30-day readmission and/or 
mortality. 
C statistic = 0.771. 
QRISK230 United Kingdom aged 35-74 
who did not have diabetes and 
existing cardiovascular disease 
at time of recruitment between 
1995-2007. 
10-year risk of a cardiovascular 
event. 
Women ROC = 0.7879. 






England and Wales using 
QResearch database between 
1994-2010.  
10-year risk of developing 
cardiovascular disease. 
Women ROC = 0.842. 
Men ROC = 0.828. 
Systematic COronary Risk 
Evaluation (SCORE)232 
Model was derived from 12 
European countries using 




ROC reported for individual countries = 0.71 to 0.84. 
The Reynolds Risk Score233 United States women aged over 
45 years using 35 risk factors 
between 1992-2004. 
10-year cardiovascular event. Best fitting model C statistic = 0.809. 
 79 
1.4.8.1 LACE Index 
The LACE index was developed in Canada as a simple, easy to use tool to predict a patient’s 
risk of readmission or mortality in the 30 days post discharge222. The LACE index is 
comprised of four sections (length of stay, acuity of admission, comorbidity as per the 
Charlson comorbidity index234 and emergency department visits in the prior six months) that 
can be answered retrospectively from case notes222. Internal validation of the LACE index in 
a cohort of medical and surgical patients found good accuracy (C statistic of 0.684)222. 
 
The LACE index has been further validated in various international disease cohorts resulting 
in varying degrees of accuracy. Among cardiovascular cohorts, patients with HF have been 
the most widely assessed cohort and have reported mixed accuracy of this tool. Two separate 
studies in different Canadian provinces reported a C statistic of 0.59 in patients with HF235,236. 
In contrast, a study of HF patients in the United States found that the LACE index was not a 
reliable measure to predict readmission237. Additionally, an abstract presented at the 2016 
Cardiac Society of Australia and New Zealand reported that the LACE index was a strong 
predictor (C statistic = 0.82) of 30-day readmissions in 246 patients with ACS238. The use of 
the LACE index as a predictor of readmissions and mortality in a local cohort of patients 
hospitalised with an AMI and undergoing angiography is explored in chapter IV of this thesis. 
Despite best efforts, risk prediction models are still evolving and have poor performance, this 
may be due to the theory of post hospital syndrome. 
 
1.4.9 Post Hospital Syndrome 
As described in section 1.4.8.1, the risk prediction models are poor and thus this is an 
evolving field due to the uncertainty surrounding the potential causes of readmission. A 
hypothesised cause of readmission is post hospital syndrome, proposed by Professor 




index hospitalisation239. Professor Krumholz suggests that a readmission that occurs within 30 
days of discharge and is rarely related to the index diagnosis239. During the inpatient 
admission patients suffer from a range of psychological and physiological stressors, which are 
beginning to be explored in the literature. Physiological stressors include the loss of muscle 
mass and strength due to the decreased mobility in hospital stay240, which can manifest as 
newly developed disability which continues when the patient returns home and has impaired 
functioning in performing daily activities241-243. In addition, inpatients may experience 
decreased appetite or dietary restriction, such as sodium restriction for HF patients, which 
may lead to malnutrition of patients244. The index hospitalisation may also cause patients to 
experience delirium or altered cognition due to administration of medications, which has been 
shown to continue post discharge245. Psychological stressors may be exacerbated due to the 
pain and discomfort experienced by the patient. More recently, the concept of sleep disruption 
during the index hospitalisation has been hypothesised as a potential contributor to the 
observed patient readmission, a concept further explored in Chapter V of this thesis. 
 
1.5.0 Sleep 
Sleep has been defined throughout the ages in various ways. Scientifically, sleep is described 
as an altered state with an impaired level of consciousness to the external world246. Sleep is 
divided into two alternating stages, Non-Rapid Eye Movement (NREM) and Rapid Eye 
Movement (REM), where REM sleep is composed of four stages. Table 1.9 compares the 




Table 1.9: Physiological components of normal sleep, comparing REM to NREM sleep.  
 REM NREM 
Heart rate and BP Increased, makes myocardial 
infarction more likely in the 
morning247. 
Reduced BP248. 
Respiratory rate Increased249,250 and increased 
airway resistance251. 
Reduced respiratory rate248. 
Cardiac   Decreased cardiac output252,253 
and reduced heart rate248. 
Body Temperature  Decreased248,254. 
Muscle tone Atonia with rapid eye 
movements248. 
Reduced vasomotor tone and 
motor activity248. 
Metabolism Reduced255. Reduced248. 
Cognition Promotes emotional healing, 
brain restoration and growth254. 
Emotional contents of 
dreams248. 
 
Others  Decreased/concentrated urine 
and sympathetic nerve 
activity, increased endocrine, 
promotes healing and 






Sleep is beneficial for restoration256, particularly of the heart257. Poor sleep has been 
associated as a risk factor for CVD258. Sleep also restores energy and well-being, 259 
encourages memory consolidation 260 and strengthens immunity261. 
 
1.5.1 Fragmented Sleep 
Sleep fragmentation is defined as the interruption of an entire 90 minute sleep cycle or the 
lack of normal order of sleep stages254. Logically, it is anticipated that the unfamiliar hospital 
environment may cause disrupted sleep in addition to pain, noise, other patients, emergencies 
and being woken to take medication262. As expected, a British study comparing sources of 
sleep disturbance in hospital from the perception of nurses and patients262 found that 65% of 
patients had good sleep at home and 22% of these patients felt they had poorer sleep in 
hospital262. Similarly, other studies262,263 have reported poorer sleep during the index 
hospitalisation compared to sleep at home. Moreover, various studies have shown that sleep 
disruption in hospital is associated with negative patient outcomes264-269. 
 
As opposed to the ‘normal’ physiology of REM and NREM sleep described in Table 1.7, 
deprivation of either stage of sleep results in pathophysiology with different symptoms. 
Deprivation of NREM sleep has been associated with fatigue, restlessness, decreased pain 
tolerance, anxiety, increased illness, increased secretions of cortisol, increased 
immunosuppression, delayed healing, nausea, diarrhea, constipation, headache, vertigo, 
discoordination and neck muscle weakness254. Deprivation of REM sleep has been associated 
with alertness, apathy, irritably, confusion, disorientation, combative, delusions, hallucination 
and decreased steroid secretions254. 
 
Sleep deprivation and fragmentation of sleep has been shown to negatively interfere with the 




sleep time (TST) after one night of sleep deprivation (0.74±1.39 hours vs. 7.33±0.52 hours, 
p<0.001) and that increased arterial stiffness was associated with the sleep deprivation271. 
CVD resulting from either short duration or poor sleep has been associated with 
inflammation272, immunosuppression, disorientation254, hypertension273 and rapid heart 
rate274. 
 
1.5.2 Sleep and Mortality 
Overall sleep duration is associated with mortality in a U-shaped curve with the highest risk 
found for short and long sleepers and the lowest risk in individuals who reported sleeping for 
an average of seven to eight hours275-278. A 12-year prospective study in the Netherlands of 
patients without a history of CVD was conducted to investigate the association between sleep 
duration and CVD incidence279. Compared to participants who had seven to eight hours of 
sleep, those with less than six hours of sleep had a 15% higher risk of CVD incidence. 
However, no association was found between those who slept for more than nine hours and 
CVD incidence. 
 
1.5.3 Measuring Sleep 
Similar to health outcomes, sleep can be measured both quantitatively and qualitatively. TST 
is defined as the duration (usually reported in minutes) of sleep within a 24-hour period280,281. 
The amount of sleep varies depending on several factors (including age and amount of 
daytime activity) and is unique to every individual, however there is general consensus that an 
average adult requires between seven and nine hours of sleep248,282. TST has been shown to be 
associated with health outcomes in CHD patients279,283-285. Both long and short279,284-289 TST 





Poor sleep quality can lead to mood disturbance, cognitive inefficiency, motor impairment, 
social discomfort, nonspecific physical ailments, reduced productivity, health related quality 
of life291-295 and has been related to CVD279,287-289,296,297. Moreover, resulting difficulties in 
cognition have been shown to impair patient’s self-care260,298. 
 
1.5.3.1 Polysomnography 
Polysomnography (PSG) was introduced in 1974299 and is the gold standard measure for 
examining sleep patterns. PSG can detect and measure the different stages of sleep by using 
electrodes that measure brainwaves muscles and eye movement. Although it is the gold 
standard measure, PSG is expensive and is an intrusive method, hence it can be difficult to 
use in clinical research. 
 
1.5.3.2 Actigraphy 
Actigraphy uses a piezoelectric transducer, worn on a wristband to measure sleep300 and has 
been validated against PSG301. Actigraphy was first used to measure activity in the 1950’s to 
evaluate for psychological disorders in children302. Although the use of actigraphy was 
deemed useful as a research instrument by the American Academy of Sleep Medicine, in 
1995, its use clinically remained uncertain303. 
 
A Danish study validated the Phillips ActiGraph against PSG in 37 schizophrenic and five 
bipolar patients and found good agreement for TST (intraclass correlation coefficient 
(ICC)=0.78) but low for wake after sleep onset (WASO) (ICC at, or close to zero)304. The 
same model of ActiGraph used in an 8.5 hour sleep study in a laboratory found high 
sensitivity (0.9565), low specificity (0.329) and high accuracy (86%) between the two 




and PSG had a sensitivity of 90% and accuracy of 84%, but had low specificity (46%)306. The 
method of actigraphy will be utilised in chapter V of this thesis. 
 
1.5.3.2.1 Total Sleep Time 
As referred to in section 1.5.3, TST is defined as the amount of sleep within a 24-hour 
period280. Studies have shown that TST may be underestimated depending on the method 
used, for example wrist actigraphy may underestimate TST when compared to PSG306,307. 
However, a review reported that TST measured by actigraphy compared to PSG found good 
to very good correlation (between 0.7 and 0.98)308. Interestingly, some studies have found that 
TST is related to health outcomes309. 
 
1.5.3.2.2 Wake After Sleep Onset 
WASO is defined as the number of minutes that the patient stays awake beginning from the 
time the patient falls asleep until they wake up280. A validation study compared WASO 
measured by actigraphy as opposed to PSG and found that actigraphy overestimated WASO 
by 32% on average 306. 
 
1.5.4 Sleep Quality 
In addition to measuring the objective quality of sleep as described above, subjective 
measures of sleep quality can also be analysed using validated questionnaires.  
 
1.5.4.1 Pittsburgh Sleep Quality Index 
The Pittsburgh Sleep Quality Index (PSQI) was first introduced in 1988 and aims to 




is comprised of seven components: sleep quality, sleep latency, sleep disturbance, sleep 
duration, sleep efficiency, sleep medication use and daytime dysfunction, which provide an 
overall global score from zero to 21. Higher scores indicate poorer sleep and scores greater 
than five are used to distinguish between good and poor sleep with 89.6% sensitivity and 
86.5% specificity310,311. Validation of the seven components of the PSQI have found high 
overall internal consistency (Cronbach’s alpha coefficient = 0.83)310. Test-retest correlation 
coefficients for each component ranged from 0.65 (medication use) to 0.84 (sleep latency)310. 
The PSQI correctly distinguished between 88.5% of good and poor sleepers (kappa = 0.75, 
p<0.001) with sensitivity of 89.6% and specificity of 86.5%310. 
 
A study of 152 thoracic surgery patients in the intensive care unit were asked the PSQI and 
46.1% reported poor sleep quality in hospital (pain was a major factor significantly related to 
their poor sleep quality)312. A systematic review of 22 studies that used the PSQI found 
disturbed sleep for up to one-year post-discharge313. 
 
1.5.4.2 Epworth Sleepiness Scale 
The Epworth Sleepiness Scale (ESS) was first introduced in 1991 to measure the patients 
likelihood of falling asleep during the day314. The ESS is scored from zero to 24, with higher 
values indicating greater excessive daytime sleepiness. The ESS has been validated in 
populations with both sleep and neurological disorders311,314,315. 
 
1.5.4.3 STOP BANG Questionnaire 
The Snoring, Tiredness, Observed apnea, blood Pressure, Body mass index, Age, Neck 
circumference and Gender (STOP BANG) questionnaire is an eight-item questionnaire that 




been shown to have high (93% for moderate OSA and 100% for severe OSA) sensitivity in 
the detection of OSA316. Moreover, two independent studies317,318 of patients in sleep clinics 
have validated the STOP-BANG questionnaire. A study of 6369 patients screened for OSA 
using the STOP-BANG questionnaire found that a score lower than three do not have OSA 
and scores between five and eight can identify patients with a greater probability of moderate 
to severe OSA319. The STOP BANG questionnaire has been successfully used clinically, to 
screen for OSA in preoperative patients320,321. 
 
Summary 
This summary of the literature identifies explicit gaps regarding Australian readmissions. For 
example, the Australian rates of readmission for cardiovascular disease are unknown and thus 
their impact on the Australian health care system is also unknown. This thesis aims to address 
these gaps in the literature by conducting a thorough review of all Australian literature 
followed by an evaluation of the readmission and mortality rates following admission to 
hospital for heart failure in Australia and New Zealand. Moreover, as indicated above, 
although readmission prediction models have been derived, their accuracy in Australian 
cardiovascular cohorts have not been reported. This thesis assesses the accuracy of the LACE 
index to predict readmissions and mortality in a cohort of patients undergoing angiography. 
There is also a need to determine which factors may play a role in readmissions, thus sleep 
quality and quantity will be explored as a potential cause of readmissions. To evaluate the 
proposed aims, the integration of various methods will be applied including a scoping review, 
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Cardiovascular disorders are among the most common cause of hospitalisation in the 
Australian Health System with more than 500,000 hospitalisations occurring annually9. This 
care is expensive, consuming 40% of the total national health care expenditure on 
cardiovascular disease (CVD)322. International studies have suggested that many of these 
hospitalisations are due to readmissions. Selected populations in the United States have found 
that one in four patients with heart failure (HF) are readmitted within 30 days12, rising to one 
in two at six months323. Similarly, 15% of stroke patients are readmitted by 30 days324, rising 
to 20-40% by one year325. High rates of readmission are also reported in selected populations 
in the United States for common conditions and procedure such as acute myocardial 
infarction (AMI) (19% by 30 days), percutaneous coronary intervention (PCI) (15% by 30 
days)326 and peripheral artery revascularisation (17.6% by 30 days)327. A proportion of these 
readmissions are inevitably due to the underlying condition. Nevertheless, a large proportion 
may be avoidable. Readmissions occurring due to preventable reasons such as hospital 
acquired infection, thromboembolism and medication errors are frequent, with a systematic 
review suggesting that at least a quarter of all readmissions are preventable183. Thus, reducing 
hospital readmissions is highly desirable to improve patient care and minimise avoidable 
health care expenditure. 
 
Driven by the international findings, clinicians and policymakers in Australia are also 
increasingly focusing on reducing readmissions with cardiovascular conditions frequently 
touted as a priority condition. For example, the New South Wales (NSW) government plans 
to reduce the rates of unplanned readmissions by the year 2021328. However, readmission may 
be driven by contextual factors and international data may have limited relevance to the 
Australian setting. For example, Australia’s universal health care system allows equal access 




as the United States. More affordable and accessible health care in Australia may result in 
lower rates of readmission. Thus, efforts to reduce readmissions through clinical or policy 
intervention requires an understanding of readmissions in the Australia setting including the 
frequency of readmissions, potential contributing factors and the impact of readmissions on 
the health system. 
 
Accordingly, we conducted a scoping review of the Australian literature to identify and 
synthesise available evidence regarding readmissions following a hospitalisation for 
cardiovascular conditions. Our primary objective was to systematically evaluate the 
Australian literature with the intention of determining the frequency of readmission. 
Secondary objectives included (a) identifying the patient, hospital and social factors that 
contribute to the risk of readmissions, (b) detailing the potential impact of readmissions on the 
health care system, and (c) describing interventions that have been assessed in the Australian 
setting to reduce readmissions. 
 
2.1 Material and Methods 
2.1.1 Search Strategy 
We searched Medline (Medical Literature Analysis and Retrieval System Online), EMBASE 
and CINAHL (Cumulative Index to Nursing and Allied Health Literature) bibliographic 
databases, restricting the search to English-language human clinical research articles 
published between 1 January 2000 and 11 March 2016 to review contemporary cardiovascular 
practice. We conducted the search using Medical Subject Heading [MeSH] terms including 
patient readmission, cardiovascular disease, coronary disease, cardiac surgical procedures and 





We also searched the grey (non-academically peer-reviewed) literature by examining the 
reference lists of retrieved papers and conducting a Google search to identify any additional 
articles and other policy documents. This included an exhaustive search of Australian 
government and non-government stakeholder websites for publications on the topic of 
readmission following cardiovascular hospitalisations. A complete list of the grey literature 
search is available in Appendix B (S4). 
 
2.1.2 Study Selection 
We included observational studies of cardiovascular readmissions and studies reporting 
outcomes of interventions to reduce cardiovascular readmissions. Cardiovascular 
readmissions were defined as (1) articles where the primary or secondary objective related to 
readmissions; or (2) where hospital readmission was the primary outcome or a substantive 
secondary outcome. Included studies were required to recruit at least 100 adult (aged over 18 
years) cardiovascular patients from Australia and measure readmissions following an 
inpatient admission for a cardiovascular condition. We excluded (1) review articles without 
original data; (2) studies that included readmissions as a composite endpoint but failed to 
report readmission data separately; (3) multi-national studies that included data from 
Australia, without reporting Australian data separately; and (4) studies that reported more 
than 50% of the data collected prior to the year 2000. 
 
2.1.3 Assessment of Methodological Quality 
Abstracts were independently screened by two investigators (CL, IR). All potentially relevant 




validity prior to inclusion in the review using standardised critical appraisal instruments from 
the Joanna Briggs Institute Meta-Analysis of Statistics Assessment and Review Instrument 
(JBI-MAStARI) Appendix B (S5). Disagreement on article selection was resolved by 
discussion between reviewers. 
 
2.1.4 Data Extraction and Synthesis 
Relevant data were extracted from each article and entered into a standardised database. Data 
extracted from all articles included sample size, study design, study period (years), number of 
centres, state(s), study aim, study hypothesis, primary outcome, time of readmission 
measurement, type of rehospitalisation (inpatient readmissions, emergency, or both), factors 
affecting readmission, findings, strengths and weakness. We assessed for data heterogeneity 
by evaluating study design, methodology and reporting. We performed a statistical test of 
heterogeneity, where appropriate, using the I2 test329. We reported our findings using the 




The search yielded 794 articles and two government reports of which 729 remained following 
exclusion of duplicates. Based on abstracts, 657 articles were removed, with 72 full texts 
articles remaining. We identified 25 observational studies that reported readmissions as an 
outcome (Table 2.1). Furthermore, we identified 10 studies that described the outcomes of 





Table 2.1: Characteristics of Observational Studies. 




Setting All cause vs. Disease 
specific readmissions 
counted 
Readmitted to same 
vs any hospital 
Method to measure 
readmission 
Rate (%) unless indicated otherwise 
≤30 days 1-6 months 6 months 12 months ≥12 months 
Saito et al (2015)331 HF 2 468 Tas All Any Linked 17     
Huynh et al (2015)332 HF State-wide 1537 Tas All Any Linked 21     
Robertson et al 
(2012)208 




Linked 27     
HF 11     
All    73  
HF    32  
Paul et al (2008)333 HF 1 133 SA All Same Phone call 25  43   
Islam et al (2013)334 HF Multicentre 6252 VIC HF Any Not reported 10     
Betihavas et al 
(2015)335 
HF 3 280 NSW, 
QLD, SA 
Cardiac condition Same Not reported 13    66 

























135 VIC All Same Not reported    56  
Lefkovits et al 
(2015)338 
HF 13 289 VIC All Any Linked 26     
PCI 23 9166 13     
Bureau of Health 
Information (2015)339 
AMI 53 27325 NSW All Any Linked 17     
Stroke 47 12776 11     
HF 72 29961 23     
Kilkenny et al 
(2013)340 
Stroke 1 788 VIC All Any Linked 15 
 
 36 42  
Kilkenny et al 
(2013)341 
Stroke 35 3328 NSW All Same Hospital records 7     
Cadilhac et al 
(2016)342 
Stroke 40 3007 VIC All Any Phone call  22 treated 
in stroke 
unit, 24 in 
other unit 
(p=NS) 
   
He et al (2015)343 Stroke 5 (state-
wide) 











Yu et al (2016)344 Stroke 1 182 NSW Stroke Same Hospital records and 
phone call 
  5   
Nguyen et al (2015)345 AF 1 302 NSW All Same Hospital records and 
phone call 
  41   
Rana et al (2014)346 AMI 1 1660 VIC IHD Same Hospital records 6 9 12 15  
     All   13 19 25 31  














    
Parker et al (2008)348 ACS 1 489 NSW Cardiac-related Same Hospital records and 
phone call 
 13 (2-12 
months) 
   
Worrall-Carter et al 
(2016)349 
ACS State-wide 28985 VIC All Any Linked     10 female, 
11 males 




1 180 NSW All Same Hospital record and 
face to face 
assessment 
   7 NOCAD, 
39 CAD 
 




Murphy et al 
(2008)351 
CABG 1 181 VIC Not reported Any Phone call 14     







Hospital record and 
phone call 




Slamowicz et al 
(2008)353 
CABG State-wide 6627 VIC All Any Linked 7 = 7 
days 
15 = 30 
days 
 32   
Atkins et al (2014)354 ATD 1 6172 WA ATD Any Linked     32 
 
Abbreviations: ACS = acute coronary syndrome; AF atrial fibrillation; ATD = atherothrombotic disease; CABG = coronary artery bypass surgery; HF = heart failure; AMI = acute 
myocardial infarction; NOCAD = non-obstructive coronary artery disease; PCI = percutaneous coronary intervention; NOCAD = non-obstructive coronary artery disease; CAD = 





Table 2.2: Characteristics of studies reporting interventions to reduce readmissions. 













Intervention Control Group 
Rate of readmission (%) 
Intervention Group 
Rate of readmission (%) 
p value 
≤ 30 days 6 M 12 M >12M ≤30 
days 
































HF 280 RCT QLD, 
SA, 
NSW 







   69.3    67.1 0.887 
Roughea





































QLD 9 Same Same Hospital 
records 
Policy 7.2    2.4    0.02* 
















HF 280 RCT Not 
reporte
d 
3 All Not 
reporte
d 
































MI 470 Before 
and 
After 
VIC 1 Cardiac Same Hospital 
records 
Strategy to 
reduce door to 
balloon time 
  12.8   11.1   0.68 NS 
Note: ^ reported as median (IQR). # result was significant but favoured the control. * statistically significant. 





Refer to Figure 2.1 for the PRISMA flow chart of article selection. As studies of interventions 
typically included highly selected populations, we report our findings for observational and 




Records identified through 
database searching (n =794) 
Additional records identified 








Readmissions not core 
focus (n=17) Studies included in 
review 
(n = 35) 
Records excluded based 
on abstract 
(n = 657) 
Full-text articles 
assessed for eligibility 
(n = 72) 
Duplicates removed 
(n = 67) 
Figure 2.1: PRISMA flow chart of article search and selection for inclusion in the 
systematic review. 
 




2.2.1 Characteristics of Observational Studies of Readmissions 
Of the 25 included articles and reports, most (n=11) were single centre333,336,340,344-346,348,350-
352. Less frequently, they were multicentre (n=7)331,334,335,338,339,341,342 or state-wide (n=5) 
studies208,332,343,349,353 with two337,347 failing to report the number of centres. The sample sizes 
of these studies varied from 133 to 29,961 participants, with a median value of 1,660. 
Fourteen study designs involved retrospective cohorts208,331,332,338-341,343,346,347,349,350,353,354 with 
the majority limited to Victoria (n=9)334,337,338,340,342,346,349,351,353 and NSW 
(n=8)208,335,339,341,344,345,348,350. 
 
Most studies reported readmissions following a hospitalisation for HF (n=10), acute coronary 
syndrome (ACS) (n=7) and stroke (n=6) with some studies reporting readmission rates for 
more than one condition. In addition, four publications reported readmission rates following 
procedures: PCI (n=1) and coronary artery bypass graft (CABG) surgery (n=3). Readmission 
rates following hospitalisation for other cardiovascular conditions and procedures were 
infrequently reported. 
 
When the primary objective of studies was considered, most (n=14) focused on determining 
the frequency of readmission331,333,336-340,342,343,345,349,350,365, while several  (n=8) studies 
evaluated one or more factors associated with readmissions including the development of a 
readmission risk model332,335,344,346,348,351-353. Two studies evaluated the burden (defined as bed 
days and costs) of readmissions on the health care system208,354 and a single study compared 





2.2.2 Definition of Readmissions and Methods for Data Collection 
The definition of readmission was highly variable between publications. All-cause 
readmission was reported in 16 studies331-334,337-342,345,347,349,353, eight studies334-
336,343,344,348,352,354 chose to report only patients returning to hospital for the same 
cardiovascular diagnosis as their index hospitalisation and one study351 did not report the type 
of readmission measured. About half of the studies (n=13) fully captured readmissions by 
counting readmissions to any hospital in the same state208,325,331,332,334,338-340,342,349,351-354,  while 
the remainder (n=12) only counted readmissions to the same hospital333,335,337-339,341,343-347,350. 
The time interval following discharge ranging from seven days to five years with most 
reporting readmission rates at 30 days post-discharge. 
 
Methods used to collect readmission data varied greatly. Telephone follow-up (n=3) 333,342,351, 
hospital medical records (n=3) 341,343,346, linked hospital administrative data (n=10) 
208,331,332,336,338-340,349,353,354, or a combination of more than one of these methods344,345,348,350,352 
were used to determine readmissions status of patients and four studies334,335,337,347 did not 
report a method. The completeness of follow-up was not reported for most studies208,332,334-
336,340,341,343,345-347,349,350,352-354,366. Among those that did report complete follow-up of all 
participants enrolled in the study, only three331,333,337 reported complete follow-up, with the 






2.2.3 Frequency of Readmissions 
All studies reported the frequency of readmissions at various time points (Table 2.1), with 
readmission rates generally (and expectedly) increasing with time. Eleven studies331,333,337-
342,345,349,350 reported all-cause readmissions and as expected, these studies reported higher 
rates of readmission compared to studies reporting readmissions for the same diagnosis as the 






Figure 2.2: All-cause rates of readmissions by disease or procedure. 
 
 
Figure 2.3: Same cause readmission studies by disease or procedure. 
  




Of the studies that reported readmissions as a proportion of all patients discharged, 
readmissions were most commonly reported at, or within 30 days of the index hospitalisation 
(n=14) 208,331,332,334-336,338-341,346,347,351,353. The all-cause readmission rate among these studies 
was highly variable, ranging from 6.3% to 27%, with a median value of 13%. When 
individual conditions for the initial hospitalisation were assessed, 30-day all-cause 
readmission following HF (n=8 studies) ranged from 10.1% to 27% (median 18.9%), stroke 
(n=3 studies) ranged from 6.5% to 11% (median 11%), AMI (n=3 studies) ranged from 12.7% 
to 17% (median 12.9%). 
 
Extractable 30-day data were available in 11 studies (n= 123,874, Figure 2.3). However, we 
could not pool the results of the individual studies to provide a summary frequency of 
readmissions due to high heterogeneity among studies (Q-test: c2 = 2395.9, p<0.001; I2 = 
99.5). Significant heterogeneity persisted when individual conditions were evaluated 
prohibiting pooling of results by condition: HF (n=6 studies)208,331-333,338,339 c2 = 177.27, 
p<0.001, I2 = 97.2%; AMI (n=3 studies)339,346,347 c2 = 21.65, p<0.001, I2 = 90.8%; stroke (n=3 







Figure 2.3: Forest plot of 30-day all-cause readmissions. Note that some studies reported data 
for more than one cohort. Abbreviations: AMI = acute myocardial infarction, CABG = coronary 
artery bypass graft surgery, PCI = percutaneous coronary intervention. 
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Of the studies that reported 30-day readmission rates, one study assessed variation in 
readmission rates among hospitals for AMI, HF and stroke with the results indicating marked 
institutional variation in the risk standardised readmission ratio at 30 days although the range 
among hospitals was not reported339. Of the studies that reported readmission rates beyond 30 
days, the highest number of readmissions were reported among patients with HF (76.9% of 
patients were readmitted for a cardiovascular-related diagnosis, during a median follow-up 
time of 5.3 years)336. 
 
2.2.4 Risk Factors Associated with Readmissions 
A risk model to predict readmission or evaluate specific patient factors associated with an 
increased risk of readmission was developed in eight studies332,335,344,346,348,351-353. These used 
data from single332,344,346,348,351,352 and multiple335,353 centres and evaluated readmissions 
following an index hospitalisation for HF332,335, ACS346,348, CABG surgery351-353 and 
ischaemic stroke344. Appendix B (S6) provides a list of all patient factors tested in risk 
prediction models. 
 
Patient factors that were significant in models were varied but included length of stay332 and 
living alone332,351, prior emergency department attendance346,353, prior cardiac diagnosis and 
procedures346, renal impairment346, electrolyte disturbance346, sedentary lifestyle339, older 
age339  and a higher score on the Charlson comorbidity index335,353. Two studies348,352 
evaluated whether psychiatric comorbidities increased the risk of readmission. A study of 
ACS patients found readmissions to be more prominent in patients with pre-existing 
depression or developed depression after their ACS, compared to patients without a history of 




depression prior to CABG surgery had increased rates of six-month readmission352. Finally, 
only one study343 from the Northern Territory evaluated whether Indigenous status increased 
the risk of readmissions following a stroke. The study concluded the risk of readmission for 
stroke was almost doubled in Indigenous patients compared to the Caucasian population (HR 
1.82, 1.32-2.51). 
 
2.2.5 Studies that Reported the Burden of Readmissions 
The burden of readmissions can be measured in various ways including cost, bed days and 
from the perspective of the patient or health care system. Two studies estimated the burden of 
readmissions in Australia208,354. A single centre study from Western Australia found patients 
who were readmitted following an index hospitalisation for atherothrombotic disease cost the 
health care system $101 million over two years, representing approximately 42% of the total 
cost of care over this period354. A study of 29,161 HF patients followed for five years using 
linked data from NSW measured the burden placed on the health care system by counting the 
number of bed days208 showing that there were 954,888 hospital bed-days utilised over the 
study period as a result of all-cause readmissions. 
 
2.2.6 Studies of Interventions to Reduce Readmissions 
Interventions testing the reduction of readmissions as a key outcome were reported in ten 
studies355-364, including five randomised control trials355,357,359,362,363 (Table 2.2). Almost all 
interventions (8/10) targeted HF355-362 and consisted of a health professional conducting a 




pharmacist or other health care professional) or at a medical facility usually within a few 
weeks after discharge (refer to Appendix B (S7) for a description of all interventions). 
 
Similar to the observational studies, the definition of a readmission varied. Readmissions 
were measured at <30 days360, 6 months356,359, 12 months355,358,364 and over 12 months357,361-
363. Readmissions were counted using linked data by one study358, another study used a phone 
call to the patient362 and the remaining studies used hospital records. 
 
A statistically significant decline in readmissions in favour of the intervention was observed 
in four studies, although only one was a randomised trial. Davidson et al355 evaluated an 
individualised 12-week nurse-coordinated multidisciplinary rehabilitation program for 
patients with HF in a randomised trial. Patients in the intervention group had a lower 12-
month all-cause readmission rate compared to the control group (44% vs 69%, p=0.01). 
Driscoll et al356 examined the effect of chronic HF management programs across 27 centres (a 
mixture of hospital and home-based programs). This study did not evaluate the outcome of 
the HF management programs against a control group. Instead, each program was ranked 
using a quality improvement tool (intervention score) based on their level of evidence. Results 
indicated that those with a high intervention score had a lower readmission rate (14% vs 25%, 
p=0.005). Roughead et al358 evaluated whether a home medication review by both a general 
practitioner and pharmacist among veterans diagnosed with HF reduced readmissions in an 
observational cohort. A 45% reduction in readmissions was observed for patients who 
received home medication review. Finally, Scott et al360 tested hospital performance feedback 
and a multifaceted quality improvement intervention using a before and after study design. A 
significant reduction in same-cause readmission was observed with the intervention in 






We performed this scoping review to summarise the contemporary Australian literature on 
readmissions following hospitalisation for CVD. We found 25 studies evaluating hospital 
readmissions over the past 16 years. We observed a median 30-day readmission rate of 13% 
(range 6.3% to 27%) with reported readmission rates of 10.1%-27% for HF, 6.5% to 11% for 
stroke and 12.7% to 17% for AMI. These findings parallel the high readmission rates 
observed in the international literature. However, these figures should be interpreted with 
caution as we could not pool readmissions data due to the substantial heterogeneity among 
studies. Notably, the time point at which readmissions were measured, whether disease-
specific or all-cause readmissions were counted, and the method and accuracy of ascertaining 
the readmissions status varied considerably. Furthermore, we found only few interventions 
that successfully reduced readmissions highlighting the need for clinical trials to find more 
effective strategies to reduce readmissions. 
 
Our review also identified several knowledge gaps in the Australian literature. While 
readmission after HF, stroke and AMI were reported, other common and important conditions 
such as atrial fibrillation and peripheral arterial disease were rarely studied and readmission 
rates for these common conditions are unknown. Similarly, the risk of readmission among 
disadvantaged populations relevant to the Australian setting such as those in regional and 
remote areas and Indigenous populations are uncertain. Moreover, only one Australian study 
evaluated hospital variation in early readmission rates despite early readmissions being 
correlated with quality of hospital care367. The substantial variation in the readmission rates 




whether such variation extends to other Australian regions is uncertain. Finally, we found a 
paucity of studies assessing the impact of hospital readmissions on the health care system. 
This information is crucial for developing effective clinical and policy strategies to reduce 
readmissions because costs and resource considerations are a major driver of decision making 
for health. Taken as a whole, our research indicates the need for Australia-wide studies of 
readmissions for common cardiovascular conditions to determine the frequency, the extent of 
variation among Australian hospitals and regions. 
 
Our review also highlights the need to develop and test clinical interventions to reduce 
readmissions. Interventions to reduce readmissions that have been trialled in Australia have 
focused almost exclusively on home or hospital-based management of HF. These long-term 
disease management programmes focus on reducing disease-specific (HF) readmissions, even 
though most readmitted patients return to hospital with diagnoses that differ from their index 
hospitalisation368,369. Thus, interventions that solely target the initial condition may be 
inadequate to reduce all-cause readmissions, which may partially explain the limited 
effectiveness of interventions observed in our review. While some readmissions inevitably 
occur due to disease progression the quality of care transition from hospital to community 
also contribute to early readmission370,371. While none of the existing interventions reviewed 
specifically targeted care transition practices, comprehensive care transition interventions 
have been shown to be effective in the international literature. For example, Re-Engineered 
Discharge consisting of seven strategies to improve the transition from hospital to the 
community, reported a 30% reduction in 30-day readmissions and lowered hospital costs by 
$416 per patient372. However, discharge and follow-up care processes are highly contextual 
and due to differences in health systems, interventions tested internationally may not be 
effective in the Australian setting. Thus, it is essential that such interventions are customised 





Our review also highlights the need for standardised methods to measure and report 
readmissions in Australia. Standardised methods are necessary for sustained quality 
improvement efforts. For example, the United States Government’s Centre for Medicare and 
Medicaid Services and the American College of Cardiology (ACC) publicly report 
readmission rates for AMI14, stroke373, HF12 and PCI374 among hospitals in the United States 
using nationally standardised methods. These efforts have stimulated clinical and policy 
interventions such as the American Heart Association’s Target HF program and the ACC’s 
Hospital to Home initiative as well as policy initiatives by the United States government such 
as the Hospital Readmission Reduction Program (HRRP)375 and is thought to contribute to the 
declining readmission rates in the United States Medicare population376. Developing 
standardised methods to report and compare readmission rates in Australia may act as a 
catalyst for similar large-scale clinical and policy efforts to reduce readmissions. 
 
Our review has important limitations. We chose to focus solely on readmissions following 
hospitalisation for CVD and our findings may not be generalisable to other conditions. We 
included grey literature, although they have not been academically peer-reviewed they are an 
important contribution to our study because we present a more in-depth evaluation of 
readmissions in the Australian setting. 
 
2.4 Conclusions 
Relatively high rates of readmissions are reported for cardiovascular conditions in Australia, 
paralleling the high rates of readmissions reported in the international literature although the 
Australian literature should be interpreted with caution due to the substantial methodological 
heterogeneity among studies. Furthermore, several knowledge gaps exist, most notably a 




Moreover, only a few interventions have been shown to successfully reduce readmissions. 
Further research is required to fully determine the burden of readmissions, develop 
standardised measure to report readmissions, and to test interventions to reduce readmissions 
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Heart failure (HF) is a common and costly cause of hospitalisations. All-cause mortality and 
unplanned readmission within 30-days of a hospitalisation are widely accepted measures of 
HF care quality and outcomes. In the United States, where these outcomes are widely reported 
high rates of 30-day all-cause mortality and unplanned readmission following HF 
hospitalisations have been observed among hospitals, suggesting considerable variation in HF 
practice12,377. Moreover, improving these outcomes is the focus of policy innovation including 
public reporting of institutional rates and penalties for hospitals with high outcome rates. The 
Hospital Readmissions Reduction Program (HRRP)378 introduced in 2012 has been credited 
with a rapid decline in risk standardised 30-day readmission rates from 21.5% to 17.8%379. 
Although considerable debate has centred on whether the HRRP has contributed to an 
increase in 30-day all-cause mortality214 with previous studies showing conflicting results. 
 
Health care systems are known to differ in patient characteristics and factors such as access to 
care and funding models, which may impact the observed frequency of HF outcomes and the 
extent of institutional variation380. However, national studies of outcomes following 
hospitalisations for HF outside of the United States are rare381,382. Moreover, no national study 
has systematically evaluated institutional variation in HF 30-day mortality or readmission 
rates beyond the United States Medicare population. Thus, whether the outcomes observed in 
the United States are generalisable to other health care systems is uncertain. This information 
is critical for health services and policymakers globally who are seeking to implement similar 
policy measures to improve HF outcomes. Examining the pattern of 30-day HF outcomes in 
different health care systems may also be useful to United States health services and 
policymakers who are seeking to understand the impact of current United States policies to 





This study assesses 30-day all-cause mortality and unplanned readmissions following a HF 
hospitalisation using national data from Australia and New Zealand, countries with advanced 
health care systems but without coordinated national policy framework to improve HF 
outcomes. This chapter specifically sought to determine the extent of institutional variation in 
these outcomes that may suggest variation in care quality among hospitals. This chapter also 
evaluated trends in these outcomes over a period that corresponded with the implementation 




3.1.1 Data Source 
Administrative hospitalisation data was collected from each Australian state and territory’s 
Admitted Patient Data Collection and the equivalent New Zealand National Minimum Dataset 
(Hospital Events). This data included all inpatient and day-only admission records from all 
public hospitals and most (~80%) private hospitals irrespective of age and payer. Hospitals 
routinely collect standardised sets of variables for every encounter including patient 
demographic characteristics, primary and secondary diagnoses, procedures performed and 
patient status at discharge. Both Australia and New Zealand use the coding standards 
developed by the Australian National Centre for Classification in Health coded as per the 
International Classification of Diseases, tenth revision, Australian Modification (ICD-10-AM) 
and Australian Classification of Health Interventions (ACHI), for diagnoses and procedures 
respectively. Prior studies have shown cardiovascular diagnoses and procedures are well 
coded with >85% accuracy144. In this chapter, hospitalisation data were available from New 
Zealand (100% of the population) and seven of the eight Australian states and territories 





Within each Australian state and territory, each patient’s hospitalisation encounter was linked 
to subsequent hospitalisation records to track all-cause readmissions to any hospital. To 
capture deaths occurring in the community, hospitalisation records were also linked to each 
state and territory’s Registry of Deaths which records all deaths including out of hospital 
deaths. Health records were linked using probabilistic matching techniques based on multiple 
patient identifiers by designated data-linkage units within each region with linkage accuracy 
reported to be >99%150. In New Zealand hospital encounters are linked nationally using a 
unique patient identifier and all deaths are recorded in the National Minimum Dataset 
(Hospital Events).  
 
3.1.2 Study Cohorts 
Patients aged >18 years hospitalised between 2010 and 2015, who were a resident of 
Australia or New Zealand with a primary diagnosis of HF were included in the cohort. HF 
was defined as ICD-10-AM codes I11.0 (hypertensive heart disease with congestive HF), 
I13.0 (hypertensive heart and kidney disease with congestive HF), I13.2 (hypertensive heart 
and kidney disease with both congestive HF and kidney failure), and I50.0-9 (HF). Consistent 
with methods used to publicly report these outcomes in the United States12,377, separate 
cohorts were created to assess mortality and readmission. The mortality cohort included all 
patients with a primary diagnosis of HF at the first admitting hospital. For hospitalisations 
involving subsequent transfers to another hospital, a primary HF diagnosis was required at 
every hospital for the patient to be retained in the cohort. Patients transferred in from another 
hospital were excluded. The cohort for evaluating 30-day readmissions included all patients 
discharged alive with a primary diagnosis of HF at the final discharging hospital. Patients 
transferred in from other hospitals were included while patients transferred out to another 





Patients in both cohorts were required to have at least one year of prior data to assess 
comorbidities and at least 30 days of follow-up data available to assess 30-day outcomes. 
Both cohorts excluded patients that (1) had been admitted to hospital with a primary diagnosis 
of HF in the preceding 30 days as this is an outcome of the prior hospitalisation; (2) patients 
with a length of stay that was less than one day, unless death or a transfer to another hospital 
occurred, as this may not indicate a true episode of acute HF; and (3) patients who self-
discharged against medical advice as their outcomes may not reflect quality of hospital care. 
 
3.1.3 Study Outcomes 
30-Day All-Cause Mortality 
All-cause mortality within 30 days of the admission date, irrespective of whether the death 
occurred in hospital or in the community. 
 
30-Day All-Cause Unplanned Readmissions 
All-cause unplanned readmissions were measured within 30 days of the discharge date. 
Consistent with prior methods, we did not count planned readmissions in the outcome as these 
do not reflect differences in quality of care. Planned readmissions were removed using an 
algorithm as outlined in Figure 3.1. The ‘Care Type’ variable removed most scheduled 
hospital readmissions for rehabilitation, palliative care, maintenance care and other non-acute 
care types and day-only admissions for routinely scheduled treatments such as dialysis. The 
adapted Medicare Planned Readmission Algorithm180 (Figure 3.1) removed admissions for 
diagnoses and procedures always considered as planned (such as maintenance chemotherapy 













































Figure 3.1: Algorithm for identifying Planned Readmissions. Note that this algorithm was 
only applied to the first readmission. 
 
Non-acute care  
e.g. rehabilitation, chronic mental health 
and palliative care and routine 
haemodialysis. 
(n = 17,433) 
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3.1.4 Hospital-Level Risk Standardised Mortality and Readmission Rates 
Hospital-level outcomes rates were estimated by calculating each hospitals’ risk standardised 
mortality and readmission rates using a hierarchical generalised linear model (HGLM) to 
account for differences in the hospital case-mix, sample-size, and clustering of patients within 
hospitals. 
 
To develop the risk-adjustment models, patient factors were independently identified and 
associated with each outcome by fitting a logistic regression model using a randomly selected 
50% sample of each cohort (derivation sample). Candidate variables included age, sex and 
patient comorbidities. Patient comorbidities were derived using the administrative data using 
the Condition Category (CC) classification383 that grouped ICD codes into 180 clinically 
meaningful conditions using diagnosis codes from the index admission and hospitalisations in 
the preceding 12 months. Variables that may impact quality such as length of stay or race 
were purposely excluded from the model. All candidate variables were included in the model 
and non-significant variables were iteratively removed from the initial model using a stepwise 
purposeful selection approach224 and evaluated for interaction terms. The final model 
contained all variables significant at p<0.05 and interactions at p<0.01. The model 
discrimination was assessed by calculating the area under the receiver operating characteristic 
curve as expressed by the C-statistic. The model calibration was assessed by comparing 
observed outcome rates with predicted outcome rates in deciles of patient risk. The model 
performance was then reassessed in the remaining 50% sample of each cohort (validation 
sample). 
 
We then used the HGLM to estimate a random-intercept term that reflects each hospital’s 




other hospitals with similar case-mix and sample size. The hospital specific risk standardised 
mortality rate (RSMR) was calculated as the ratio of predicted hospital deaths over expected 
hospital deaths, multiplied by the crude national average mortality rate. Likewise, the risk 
standardised readmission rate (RSRR) was calculated as the ratio of predicted hospital visits 
over the expected hospital visits, multiplied by the crude national average rate. The predicted 
number of outcomes was calculated based on the hospitals case-mix and the estimated 
hospital-specific intercept term. The expected number of outcomes was calculated based on 
the hospital’s case-mix and national average intercept. The ratio was then multiplied for each 
hospital by the overall crude rate of mortality or unplanned readmissions, respectively for 
ease of interpretation. Bootstrapping with 1000 replications was used to empirically construct 
a 95% confidence interval estimate for each hospital’s RSMR or RSRR using the percentile 
method. A hospital was deemed a statistical outlier if the hospital’s entire 95% interval 
estimate was above or below the national average. This approach for estimation of the RSMR 
and RSRR ensured that the observed variation among hospitals was not due to underlying 
differences in case- or procedure-mix and is consistent with best-practice guidelines for 
profiling variation in outcomes among hospitals384. All hospital-level analyses were limited to 
unique hospitals with at least 25 HF hospitalisations during the study period to enable a robust 
estimate of the hospital rate. 
 
3.1.5 Trend in Risk-Adjusted 30-day Mortality and Readmission Rates 
Patient-level trends in outcomes from 2010 to 2015 were analysed by evaluating monthly 
change in risk-adjusted 30-day mortality and readmission rates using generalised linear 






3.1.6 Ethical Approval 
Human Research Ethics Committees of the University of Adelaide and respective Australian 
States and Territories provided ethical approval with a waiver of informed consent to use de-
identified patient data. De-identified data from New Zealand was obtained under a data user 
agreement with the New Zealand Ministry of Health. All ethical approvals with associated 
reference numbers are summarised in Table 3.2. 
 
Table 3.2: State and territories Human Research Ethics Committee approvals. 
Ethics Committee Reference Number 
New South Wales Population & Health Services Research Ethics Committee. 2015/06/591 
Australian Capital Territory Health Department Human Research Ethics 
Committee. 
ETH.7.15.143 
Australian Capital Territory Calvary (Bruce) Hospital Human Research 
Ethics Committee. 
Dated 07/10/2015 
South Australian Depart of Health and Aging Human Research Ethics 
Committee. 
HREC/15/SAH/102 
West Australian Department of Health Human Research Ethics Committee. 2016/47 
Tasmanian Department of Health Human Research Ethics Committee. H0016011 
Queensland Human Research Ethics Committee. Public Health Act Approval  
Victorian Human Research Ethics Committee. Mutual Acceptance of NSW 
HREC approval 






3.1.7 Statistical Analysis 
Data were summarised as frequencies and percentages for categorical variables. Continuous 
variables were presented as mean ± standard deviation or median and interquartile range. All 
significance levels were two-sided with a p<0.05. The Technical Appendix outlines the 
RSMR calculation. Statistical analyses were performed using SAS version 9.4 (SAS Institute 
Inc., Cary, NC). The hierarchical generalised linear model was estimated using the 
GLIMMIX procedure in SAS. 
 
3.2 Results 
3.2.1 Study Cohort Characteristics 
Mortality Cohort 
The mortality cohort comprised of 153,592 patients with a primary diagnosis of HF that met 




















Figure 3.3: Patient Selection for the Heart Failure Mortality Cohort. 
Exclusions (not mutually exclusive) 
Eligible Population 
 
536,214 hospitalisations from 
2010-2015 with ICD-10-AM codes 
I11.0, I13.0, I13.2, I50.0 and I50.9. 
Study Population 
 
153,592 patients with heart failure 
meeting inclusion/exclusion 
criteria. 
Exclusions (not mutually exclusive) 
• Lack of at least 30 days follow-up 
(n=3,468). 
• Heart failure admission within 
prior 30 days (n=24,277). 
• Length of stay less than one day 
(n=13,998). 
• Discharged against medical advice 
(n=1,615). 





Patients had a mean age 78.9±11.8 years, 51.5% were male with hypertension (43.0%), prior 
history of HF (36.6%) and arrhythmias (20.1%) being the most common cardiovascular 
comorbidities, while chronic lung disease (20.4%), renal failure (21.6%), and protein-calorie 





Table 3.2: Selected Baseline Patient Characteristics. 
















Age (years) 78.9±11.8 83.0±10.02 78.4±12.0 <0.01 78.6±11.9 78.67±11.69 78.57±12.02 0.17 
Male (n, %) 79,158 (51.5) 8,351 (50.8) 70,807 (51.6) 0.04 76,842 (51.7) 17,409 (53.0) 59,433 (51.3) <0.01 
Length of Stay (days) 5.0 (3.0-9.0) 5 (2-10) 5 (3-9) 0.86 5.0 (3.0-9.0) 6 (3-9) 5 (3-9) <0.01 
Cardiac Comorbidities (n, %) 
 
Congestive Heart Failure (CC 80) 56,163 (36.6) 7,330 (44.6) 48,833 (35.6) <0.01 57,572 (38.7) 14,870 (44.8) 42,402 (36.7) <0.01 
AMI and Unstable Angina (CC 81-82) 16886 (11.0) 2142 (13.0) 14744 (10.8) <0.01 17,026 (11.5) 4,827 (14.7) 12,199 (10.5) <0.01 
Chronic Atherosclerosis (CC 83-84) 30357 (19.8) 3464 (21.1) 26893 (19.6) <0.01 29,756 (20.0) 7,321 (22.3) 22,435 (19.4) <0.01 
Valvular and Rheumatic Heart Disease 
(CC 86) 




Hypertension (CC 89-91) 66,043 (43.0) 7,106 (43.2) 58,937 (43.0) <0.01 64,700 (43.5) 15,442 (47.0) 49,258 (42.5) <0.01 
Specified Heart Arrhythmias (CC 92) 30,866 (20.1) 3,515 (21.4) 27,351(19.9) <0.01 33,259 (22.4) 8,677 (26.4) 24,582 (21.2) <0.01 
Percutaneous Coronary Intervention 3,448 (2.2) 230 (1.4) 3,218 (2.4) <0.01 3,524 (2.4) 928 (2.8) 2,596 (2.2) <0.01 
Coronary Artery Bypass Graft 1,679 (1.1) 56 (0.3) 1,623 (1.2) <0.01 1,729 (1.2) 377 (1.2) 1,352 (1.2) 0.78 
Non-cardiovascular Comorbidities (n, %)        
Major and Metastatic Cancer (CC 7-9) 5,471 (3.6) 1,217 (7.4) 4,254 (3.1) <0.01 5,015 (3.4) 1,489 (4.5) 3,526 (3.0) <0.01 
Diabetes with Renal or PAD 
Complications (CC 15) 
26,516 (17.3) 3,173 (19.3) 23,343 (17.0) <0.01 25,360 (17.1) 6,836 (20.8) 18,524 (16.0) <0.01 
Disorders of Fluid/Electrolyte/Acid-
Base (CC 23) 
31,114 (20.3) 4,390 (26.7) 26,724 (19.5) <0.01 30,288 (20.4) 8,645 (26.3) 21,643 (18.7) <0.01 
Renal Failure (CC 130-131) 33,192 (21.6) 4,657 (28.3) 28,535 (20.8) <0.01 32,364 (21.8) 9,461 (28.8) 22,903 (19.8) <0.01 
Cirrhosis and other Liver Disease (CC 
25-29) 
5,157 (3.4) 897 (5.5) 4,260 (3.1) <0.01 4,782 (3.2) 1,383 (4.2) 3,399 (2.9) <0.01 




Chronic Lung Disease (CC 108,109, 
114) 
31,284 (20.4) 4,274 (13.7) 27,010 (19.7) <0.01 30,376 (20.4) 8,043 (24.5) 22,333 (19.3) <0.01 
Dementia (CC 49) 8,659 (5.6) 1,819(11.1) 6,840 (5.0) <0.01 7,923 (5.3) 1,723 (5.2) 6,200 (5.4) 0.47 
Protein-calorie malnutrition (CC 21) 13,977 (9.1) 2,477 (15.1) 11,500 (8.4) <0.01 13,142 (8.8) 3,456 (10.5) 9,686 (8.4) <0.01 
Hemiplegia, Paraplegia, Paralysis, 
Functional Disability (CC 67-69, 100-
102, 177-178) 
8,114 (5.3) 1,226 (7.5) 6,888 (5.0) <0.01 7,223 (4.9) 1,990 (6.1) 5,233 (4.5) <0.01 
Chronic Skin Ulcers (CC 148-149) 7,569 (4.9) 1,432 (8.7) 6,137 (4.5) <0.01 7,117 (4.8) 1,962 (6.0) 5,155 (4.5) <0.01 
Cellulitis (CC 152) 8,949 (5.8) 1,334 (8.1) 7,615 (5.6) <0.01 8,642 (5.8) 2,510 (7.7) 6,132 (5.3) <0.01 
Psychiatric Disorders (CC 54-60) 10,702 (7.0) 1,558 (9.5) 9,144 (6.7) <0.01 8,816 (5.9) 2,468 (7.5) 6,348 (5.5) <0.01 
# Refers to revascularisation in the preceding year 





The readmission cohort was comprised of 148,704 patients who met the selection criteria 
(Figure 3.4). Patients were of similar age (mean age 78.6±11.9 years) and sex (51.7% males) 
to the cohort evaluating mortality and had a similar distribution of cardiac and non-cardiac 















Figure 3.4: Patient Selection for the Heart Failure Readmission Cohort. 
Eligible Population 
 
536,214 hospitalisations from 
2010-2015 with ICD-10-AM codes 
I11.0, I13.0, I13.2, I50.0 and I50.9. 
Study Population 
 
148,704 patients with heart failure 
meeting inclusion/exclusion 
criteria. 
Exclusions (not mutually exclusive) 
• Lack of at least 30 days follow-up 
(n=4,458). 
• Heart failure admission within prior 
30 days (n=25,386). 
• Length of stay less than one day 
(n=11,252). 
• Discharged against medical advice 
(n=1,658). 
• In hospital mortality (n=17,221). 






3.2.2 Study Outcomes 
30-Day All-cause Mortality 
Overall, 16,442 (10.7%) patients died within 30 days of admission with 10,086 (6.6% of the 
cohort, 61.0%) of all deaths occurring in hospital and 6,356 (4.1% of the cohort, 39.0%) of all 
deaths occurring post discharge. 
 
30-day All-cause Unplanned Readmissions 
Overall, 65,551 readmissions occurred within 30 days of hospital discharge, including 
multiple readmissions for the same patient. Of these, 17,433 readmissions occurred for 
planned non-acute care and were excluded from the outcome. A further 4,218 readmissions 
were identified as planned by the planned readmission algorithm (refer to Figure 3.1) and 
were excluded. Thus, 33,158 (22.3%) patients had at least one unplanned readmission within 
30 days of discharge. 
 
The most common primary diagnosis associated with unplanned readmission was HF 
(33.9%). The remaining 66.1% of patients were readmitted with an array of diagnoses 
including exacerbation of chronic obstructive pulmonary disease (4.1%), pneumonia (3.2%) 
and atrial fibrillation and flutter (2.9%). 
 
3.2.3 Patient-level Risk-adjustment Model 
Mortality 
Age and 23 comorbidities were independently associated with the outcome of 30-day 
mortality (Table 3.3). The model performance showed good discrimination (C-statistic 0.70) 
and was well calibrated across deciles of patient risk, with predicted mortality of 2.5% in the 




mortality (Figure 3.5). When re-tested in the validation sample, the model showed similar 





Table 3.3: Mortality Risk Adjustment Model with Development and Validation Samples. 
  
Development Split Sample (50%) Validation Split Sample (50%) 
 
Estimate SE P Value OR 95% CI Estimate SE P Value OR 95% CI 
Intercept -5.96 0.12 <0.01 
  
-5.81 0.11 <0.01 
  
Age (per year increase) 0.04 <0.01 <0.01 1.04 1.04 – 1.05 0.04 <0.01 <0.01 1.04 1.04 – 1.043 
Metastatic Cancer (CC 7-9) 0.92 0.05 <0.01 2.51 2.27 – 2.77 0.95 0.05 <0.01 2.596 2.36 – 2.86 
Diabetes with Renal or PVD Complications (CC 15) 0.30 0.04 <0.01 1.44 1.33 – 1.56 0.28 0.04 <0.01 1.33 1.23 – 1.44 
Diabetes with Other Manifestations or No Complications (CC 16-
20, 119-120) 
-0.28 0.04 <0.01 0.76 0.71 – 0.81 -0.24 0.04 <0.01 0.79 0.73 – 0.84 
Protein-Calorie Malnutrition (CC 21) 0.33 0.04 <0.01 1.39 1.30 – 1.49 0.27 0.04 <0.01 1.31 1.22 – 1.41 
Cirrhosis and Other Liver Diseases (CC 25-29) 0.76 0.06 <0.01 2.15 1.92 – 2.40 0.71 0.06 <0.01 2.04 1.82 – 2.28 
Infectious and Inflammatory Joint Disease (CC 37-38) 0.20 0.08 0.01 1.22 1.05 – 1.42 0.17 0.08 0.03 1.19 1.02 – 1.38 
Osteoarthritis and Other Degenerative Joint Disease (CC 39-43) -0.22 0.03 <0.01 0.81 0.75 – 0.86 -0.22 0.03 <0.01 0.80 0.75 – 0.86 
Dementia (CC 49) 0.63 0.04 <0.01 1.87 1.72 – 2.03 0.47 0.04 <0.01 1.59 1.47 – 1.73 
Seizure Disorders and Convulsions (CC 74) 0.27 0.13 0.03 1.32 1.03 – 1.68 0.59 0.11 <0.01 1.81 1.45 – 2.26 
Congestive Heart Failure (CC 80) 0.20 0.03 <0.01 1.22 1.16 – 1.29 0.31 0.03 <0.01 1.36 1.29 – 1.43 




Valvular Heart Disease including Endocarditis (CC 86) 0.19 0.03 <0.01 1.20 1.13 – 1.29 0.17 0.03 <0.01 1.19 1.11 – 1.27 
Hypertension (CC 89-91) -0.13 0.03 <0.01 0.88 0.83 – 0.92 -0.10 0.03 <0.01 0.90 0.86 – 0.95 




<0.01 0.82 0.77 – 0.87 -0.2145 0.03 <0.01 0.81 0.76 – 0.86 
Chronic Lung Disease (CC 108-109, 114) 0.20 0.03 <0.01 1.22 1.16 – 1.29 0.2301 0.03 <0.01 1.26 1.19 - 1.33 
Pneumonia (CC 111-113) 0.38 0.03 <0.01 1.46 1.38 – 1.55 0.43 0.03 <0.01 1.53 1.45 – 1.62 
Renal Failure (CC 130 & 131) 0.13 0.03 <0.01 1.14 1.07 – 1.22 0.11 0.03 <0.01 1.11 1.05 – 1.19 
Incontinence (CC 134) 0.30 0.04 <0.01 1.35 1.24 – 1.47 0.38 0.04 <0.01 1.47 1.35 – 1.59 
Cellulitis and Chronic Skin Ulcer (CC 148-149, 152) 0.46 0.05 <0.01 1.58 1.44 – 1.73 0.30 0.05 <0.01 1.35 1.23 – 1.49 
Significant Endocrine and Metabolic Disorders (CC 22) 0.12 0.05 0.02 1.13 1.02 – 1.25 0.32 0.05 <0.01 1.37 1.25 – 1.51 
Revascularisation with PCI or CABG (CC 203-204) -0.62 0.09 <0.01 0.54 0.45 – 0.65 -0.75 0.09 <0.01 0.47 0.39 – 0.56 
Fracture or Dislocation of Hip (CC 158)  0.13 0.07 0.06 1.14 0.99 – 1.31 0.15 0.07 0.04 1.16 1.01 – 1.33 
Psychiatric Disorders (CC 54-60) 0.19 0.05 <0.01 1.21 1.11 – 1.32 0.26 0.05 <0.01 1.3 1.19 – 1.42 
 
Abbreviations: CABG = Coronary Artery Bypass Grafting, CC = Condition Category, PCI = Percutaneous Coronary Intervention, PVD = Peripheral 











Age, sex and 22 comorbidities were independently associated with the outcome of unplanned 
readmissions (Table 3.4). The model showed moderately good discrimination (C-statistic 
0.60) and calibration, with predicted readmission rates of 15.8% in the lowest decile to 35.3% 
in the highest decile of risk closely matching the observed readmission risk (Figure 3.6). 
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Table 3.4: Readmission Risk-Adjustment Model with Development and Validation Samples. 
 Development Sample (50%) Validation Sample (50%) 
 
Estimate SE P OR 95% CI Estimate SE P OR 95% CI 
Intercept -1.90 0.07 <0.01 
  
-1.94 0.07 <0.01 
  
Age (per year increase) <0.01 <0.01 <0.01 1.00 1.00 – 1.00 <0.01 <0.01 <0.01 1.00 1.00 – 1.01 
Male Sex 0.07 0.02 <0.01 1.07 1.03 – 1.11 0.04 0.02 0.05 1.04 1.00 - 1.07 
Infection (CC 1-6) 0.07 0.03 0.01 1.07 1.02 – 1.12 0.07 0.03 0.01 1.07 1.02 – 1.12 
Major and Metastatic Cancer (CC 7-9) 0.36 0.05 <0.01 1.44 1.32 – 1.57 0.23 0.05 <0.01 1.26 1.15 – 1.38 
Diabetes with Renal or PVD Complications (CC 15) 0.11 0.03 <0.01 1.12 1.06 – 1.17 0.15 0.03 <0.01 1.17 1.11 – 1.23 
Disorders of Fluid/Electrolyte/Acid-Base (CC 23) 0.09 0.02 <0.01 1.09 1.04 – 1.15 0.10 0.02 <0.01 1.10 1.05 – 1.16 
Cirrhosis and other liver Disease (CC 25-29) 0.16 0.05 <0.01 1.18 1.07 – 1.30 0.19 0.05 <0.01 1.20 1.10 – 1.32 
Rheumatoid Arthritis and Other Musculoskeletal and Connective 
Tissue Disorders (CC 38, 43) 
0.18 0.02 <0.01 1.20 1.14 – 1.26 0.10 0.02 <.0001 1.11 1.06 – 1.16 
Psychiatric Disorders (CC 54-60) 0.10 0.04 <0.01 1.11 1.03 – 1.19 0.15 0.04 <0.01 1.16 1.09 – 1.25 
Acute Myocardial Infarction and Unstable Angina (CC 81-82) 0.17 0.03 <0.01 1.18 1.12 – 1.25 0.17 0.03 <0.01 1.19 1.12 – 1.25 
Vascular Disease (CC 104-106) 0.09 0.02 <0.01 1.09 1.04 – 1.15 0.07 0.02 <0.01 1.07 1.02 – 1.13 
Chronic Lung Disease (CC 108, 109 & 114) 0.15 0.02 <0.01 1.17 1.12 – 1.22 0.18 0.02 <0.01 1.20 1.15 – 1.25 
Renal Failure and Dialysis (CC 130-131) 0.18 0.03 <0.01 1.20 1.14 – 1.26 0.15 0.03 <0.01 1.16 1.10 – 1.22 
Neuropathy and Other Neurological Disorders (CC 71, 76) 0.16 0.04 <0.01 1.18 1.08 – 1.28 0.09 0.04 0.04 1.09 1.00 – 1.19 
Peptic Ulcer, Haemorrhage and Other Specified Gastrointestinal 
Disorders (CC 34) 
0.08 0.04 0.04 1.08 1.00 – 1.16 0.08 0.04 0.03 1.09 1.01 – 1.17 
Iron Deficiency and Other/Unspecified Anaemias and Blood Disease 
(CC 47) 





Abbreviations: CABG = Coronary Artery Bypass Grafting, CC = Condition Category, PVD = Peripheral Vascular Disease. 
 
Heart Failure (CC 80) 0.13 0.02 <0.01 1.14 1.10 -1.18 0.15 0.02 <0.01 1.17 1.12 – 1.21 
Cellulitis, Local Skin Infection (CC 152) 0.10 0.04 0.01 1.11 1.03 - 1.19 0.11 0.04 <0.01 1.12 1.04 – 1.20 
Prior CABG (CC 204) -0.39 0.09 <0.01 0.68 0.57 – 0.80 -0.29 0.08 <0.01 0.75 0.63 – 0.88 
Other Gastrointestinal Disorders (CC 36) 0.11 0.02 <0.01 1.11 1.07 – 1.16 0.10 0.02 <0.01 1.10 1.06 – 1.15 
Angina Pectoris/Old Myocardial Infarction (CC 83) 0.12 0.04 <0.01 1.13 1.06 – 1.21 0.12 0.03 <0.01 1.13 1.06 – 1.21 






Figure 3.6: Calibration Plot of Predicted vs Observed of 30-day all-cause  
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3.2.4 Hospital Level Risk Standardised Outcome Rates 
Risk standardised 30-day mortality rate (RSMR) 
During the study period, 392 hospitals were identified as having at least 25 HF 
hospitalisations. Among these hospitals, the crude 30-day mortality rate ranged from 0 to 
26.9%. Following risk standardisation, the median RSMR was 10.7% and ranged from 6.1% 
to 17.3% (IQR 9.5%-12.0%, Figure 3.7). Of these hospitals, 59 (15.1%) were statistical 
outliers with nine (4.8%) having an entire 95% confidence interval estimates below the 


















































Risk Standardised Readmission Rate (%)
Risk standardised 30-day readmission rate (RSRR) 
There were 391 hospitals identified as having a minimum of 25 HF hospitalisations. Among 
these hospitals, the crude hospital 30-day readmission rate ranged from 4.9% to 45.6%. 
Following risk standardisation, the median RSRR was 22.3% and ranged from 17.7% to 
27.1% (IQR 21.4% to 23.4%, Figure 3.8). Of the 391 hospitals, 24 (6.2%) were statistical 
outliers with 12 (3.1%) having an interval estimate below the national average readmission 




















3.2.5 Trend in Risk-Adjusted 30-Day Mortality and Readmission Rates 
Thirty-day all-cause mortality declined by 4.4% from 12.5% in 2010 to 8.1% in 2015, an 
average decline of -0.88% per year (Table 3.5 and Figure 3.9). The decline was observed for 
both the in hospital (-3.2%) and post-discharge (-1.6%) components of 30-day mortality. The 
decline in 30-day mortality remained statistically significant following adjustment for 
differences in patient characteristics over the same period (adjusted OR 0.991 per month from 
January 2010, 95%CI 0.990-0.992, p<0.01). Over the same period, 30-day unplanned 
readmission rate declined by 1.3% from 23.2% to 21.9%, an average decline of 0.26% per 
year (Table 3.5 and Figure 3.10). The decline in 30-day readmission rate remained 






Table 3.5: Change in overall mortality and unplanned readmission rates over the study period. 
Outcome (%) 2010 2011 2012 2013 2014 2015 Diff 2015-
2010 (%) 
Avg yearly 
Change (%) # 






30-Day Mortality 12.5 11.7 11.4 10.3 9.2 8.1 -4.4 -0.88 0.991 0.990 0.992 <0.01 
- In-Hospital Component 7.9 7.4 6.8 5.9 5.6 5.1 -2.8 -0.56 0.991 0.990 0.992 <0.01 
- Post-Discharge Component 4.6 4.3 4.6 4.3 3.6 3.0 -1.6 -0.32 0.993 0.991 0.994 <0.01 
30-day Unplanned Readmission 23.2 21.7 21.8 22.0 21.9 21.9 -1.3 -0.26 0.998 0.998 0.999 <0.01 
 
# Refers to the average annual change in outcome (expressed as a percentage) from 2010 to 2015. 
‡ Adjusted odds ratio (OR) refers to the odds of change in outcomes per month increase from January 2010 onwards, adjusting for other covariates significant in the patient-level risk model 
and clustering of patients among hospitals. 






Figure 3.9: Overall Trend in 30-day Mortality Rates During the Study Period. 
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This bi-national study of early outcomes following HF hospitalisations in Australia and New 
Zealand, found that one in ten patients died and almost a quarter experienced an unplanned 
readmission within 30 days of their hospital discharge. Additionally, a substantial decline in 
30-day all-cause mortality over the study period accompanied by modest reductions in 
readmission rates – trends that contradict the trends in HF outcomes that have been observed 
in the United States following implementation of HRRP214,379. However, the risk adjusted 30-
day mortality and readmission rates varied two to three-fold among hospitals with clear 
outlier facilities that had mortality and readmission rates statistically different from their 
peers. Such marked variation in HF outcomes implies variation in HF care practices and 
quality among hospitals and a need for coordinated clinical and policy interventions to 
standardise HF care across hospitals in Australia and New Zealand. 
 
Prior studies in the United States have reported 30-day mortality rates of 10.7% to 12.8% and 
readmission rates of 17.2% to 24.8%385-387 following HF hospitalisations although national 
studies of HF outcomes from other comparable countries are rare. The reported 30-day 
mortality (5.3% to 19.2%) and readmission (12.0%)381,382,388 rates from these countries are 
also highly heterogenous and challenging to compare due to differences in methodology and 
outcome definitions. These findings extend the existing literature by reporting 30-day 
outcomes from two comparable Economic Co-operation and Development countries, using 
similar administrative data and analytical methods used for public reporting among Medicare 
patients. The overall 30-day mortality (10.7%) and readmission (22.3%) rates that we found 
are higher than currently reported in the United States379,389 which may be a reflection of an 
older cohort (mean age ~79 years) and typically higher comorbidity burden among older 
patients. Indeed, only ~12% of patients in the study were <65 years of age, far less than 





The comparatively high rates of 30-day mortality and readmission may also reflect the limited 
application of broad clinical and policy initiatives to improve these outcomes in Australia and 
New Zealand. In the United States hospital-specific 30-day mortality and readmissions rates 
after HF hospitalisations are publicly reported with feedback of individual patient data to 
hospitals to facilitate quality improvement activities. In Australia and New Zealand, hospital-
specific HF outcomes are rarely reported either publicly or confidentially, except for the 
Australian state of New South Wales163,391, creating a critical information and quality 
measurement gap. A recent systematic review found that public reporting on mortality for a 
variety of conditions was associated with a 15% reduction in mortality392. Moreover, public 
reporting stimulates hospitals to undertake quality improvement initiatives29,393 and improve 
process of care indicators394. Our findings support public reporting of HF outcomes in 
Australia and New Zealand to inform patients and to stimulate clinicians and hospitals to 
invest in strategies to improve HF care. The methods used in this chapter are similar to that 
used in the United States12,377, providing a feasible approach for national reporting. 
 
While the overall outcome rates were elevated, a substantial temporal decline in 30-day 
mortality was observed. The decline in mortality parallels the decline in HF hospitalisations 
observed in Australia and New Zealand. The fact that in-hospital mortality declined more than 
post-discharge mortality may indicate the need for proportionately greater emphasis on 
optimising patient enrolment in post-discharge HF recovery and rehabilitation services that 
have been shown to be effective in reducing all-cause mortality and readmissions in HF 
patients.395 For many Australian patients, there is still limited access to such programs with a 
recent study showing differences in early readmission rates after hospitalisation for HF being 
primarily explained by differences in post-discharge management396. In contrast, the fact that 




are at higher risk of readmission361 and may explain the limited reduction in readmission rates 
over the study period. 
 
The relatively modest decline in the 30-day readmission rates observed is in contrast to the 
rapid decline in 30-day readmissions following HF hospitalisations observed in the United 
States following the introduction of HRRP378. The divergent trends in readmissions highlight 
the effectiveness of broad policy reforms such as HRRP in reducing readmissions. The 
Australian Government has proposed implementing similar financial penalties to reduce 
avoidable readmissions397, and such policy reform may have a similar effect in reducing 
readmissions in Australia. Nevertheless, considerable debate has centred on whether such 
financial penalties may inadvertently contribute to an increase in HF mortality with some 
studies from the United States suggesting an increase in HF mortality, although others suggest 
a decline in risk-adjusted mortality. Despite these conflicting results, it is important to note 
that no study has shown a statistical association between HRRP implementation and excess 
mortality. The British National Heart Failure Audit has also reported largely unchanged in-
hospital and 30-day mortality trend over the same period in the absence on policy intervention 
to reduce readmissions. Further studies are required to understand the divergent trends in 
mortality observed across these countries. 
 
Several limitations need consideration when interpreting these results. The use of 
administrative data, while routinely collected and readily accessible, is less granular than data 
purposely collected for research. However, validation studies have shown relatively high 
accuracy of diagnoses and procedures coding within administrative data compared to medical 
records144. Although data from the Northern Territory of Australia was unavailable, this 
region represents less than 1% of the Australian population and does not affect the 




residual confounding due to unmeasured factors that influenced outcomes independent of 
hospital care quality cannot be excluded. 
 
3.4 Conclusions 
Among patients hospitalised for HF in Australia and New Zealand, more than one in ten died 
and almost a quarter experienced an unplanned readmission within 30 days. These outcomes 
varied widely among hospitals implying differences in patient outcomes due to variation in 
HF care quality. Thirty-day mortality, nevertheless, declined substantially during the study 
period with modest reductions in 30-day readmission rates over the same period. Concerted 
clinical and policy interventions including routine public reporting of these outcomes may 







Is the LACE index a predictor of Mortality and Readmission in patients 






An estimated 55,000 Australians suffer an acute myocardial infarction (AMI) every year27 and 
reducing the number of adverse events following AMI is vital to improve patient outcomes. 
With advancement in therapies, in hospital survival following AMI has significantly 
improved, however AMI survivors discharged from hospital into the community are at risk 
for readmissions. International data demonstrates a significant problem with high readmission 
rates in the initial period following AMI163,196-202. Although national rates of AMI readmission 
are currently unknown, the New South Wales (NSW) Bureau of Health Information reports 
the 30-day all-cause risk standardised rate of readmission in NSW public hospitals is 17% 
following an index hospitalisation for AMI163. As such, 30-day readmission rates are 
attracting major attention in Australia398,399 but little is known regarding the causes of 
readmission following an AMI. 
 
The use of risk prediction models have been promoted as a valuable tool in determining the 
best treatment for Australian patients with cardiovascular disease (CVD) and thus the same 
logic is transferable in promoting optimal outcomes for these patients400. Risk prediction 
models hold a valuable place in clinical practice and research, however current risk prediction 
models have been shown to be quite poor at predicting readmission401. Notwithstanding, 
various models have been derived and validated for use in generic cohorts. One such model is 
the LACE index, developed in Canada to predict a patient’s risk of 30-day all-cause 
unplanned readmission and mortality222. Initially validated in a cohort of general medical and 
surgical patients, the LACE index was found to have good accuracy (C-statistic of 0.68)222. 
Among cardiovascular cohorts, the LACE index has been most widely assessed in those with 
heart failure (HF) as an index diagnosis. Two separate models reported a C-statistic of 0.59 in 
cohorts of Canadian HF patients235,236. In contrast, a study from the United States of patients 





Although the LACE index has been well cited in the literature, it has never been assessed in 
an AMI cohort, and more specifically among patients with an AMI undergoing angiography. 
Thus, this study primarily aims to validate the LACE index score to predict (a) 30-day all-
cause unplanned readmission and (b) the combined outcome of 30-day all-cause mortality and 
readmission in patients following an AMI undergoing angiography. The study also aims to 




This retrospective observational cohort study evaluated the 30-day outcomes of patients 
following an AMI undergoing coronary angiography enrolled in the Coronary Angiogram 
Database of South Australia (CADOSA) Registry. 
 
4.1.2 The CADOSA Registry 
The CADOSA Registry is a prospective, state-based procedural clinical registry established in 
2012 which evaluates the safety, quality and appropriateness of care received by South 
Australian patients undergoing angiography. The registry enrols consecutive patients 
undergoing coronary angiography and/or percutaneous coronary intervention (PCI) 
procedures performed in all South Australian public hospitals via opt-out consent. The 
CADOSA Registry collects baseline demographic, clinical and procedural information which 
includes all data elements corresponding to the American College of Cardiology National 
Cardiovascular Data RegistryTM (ACC-NCDRTM)402 and Cath PCI Registry403 Version 4.0. 
Registry data collection is undertaken by dedicated trained data abstractors in each 
participating facility using a standardised case report form. Regular data audits are undertaken 





4.1.3 Patient selection criteria 
Patients who had an AMI, aged ≥18 years, who were discharged alive between July 2016 and 
June 2017 from two teaching hospitals in the Central Adelaide Local Health Network were 
included in this study. Patients who were discharged to a nursing home, rehabilitation facility 
or palliative care were excluded from this study, as the process of care differs from patients in 
the community and is compliant with the exclusion criteria used in the original LACE 
study222. Non-South Australian residents were also excluded from this study, as follow-up for 
interstate and overseas patients could not be attained from South Australian administrative 
datasets. 
 
4.1.4 Ethical Approval 
The study cohort was derived from patients enrolled in the CADOSA Registry and the 
protocol for this study, which did not require informed consent, was approved by the Central 
Adelaide Local Health Network Human Ethics Committee (HREC reference number 
HREC/19/CALHN/17 and CALHN reference number: Q20190104). 
 
4.1.5 Study Protocol 
Clinical variables were extracted from the CADOSA Registry and additional variables that 
were not collected by the Registry (explicitly diabetes (with or without complications), liver 
or renal disease, tumours/cancers, dementia, connective tissue diseases AIDS and emergency 
department (ED) encounters in the past 12 months) were retrospectively obtained from 
electronic medical records. Similarly, the 30-day outcomes of patients were sourced via 





4.1.6 The LACE index 
The LACE index is comprised of four main questions that can be answered retrospectively 
from case notes222. The four component scores correspond to the index length of stay, whether 
or not the patient arrived via emergency, the comorbidities (defined using the Charlson 
comorbidity score234) and the number of emergency encounters suffered by the patients in the 
six months prior to the index admission (Table 4.1). Scoring of the LACE index was 
compliant with the original scoring system222. Lengths of stay which were between one and 
three days were scored accordingly, lengths of stay between four and six days were scored 
four points, lengths of stay between seven and 13 days were scored five points and lengths of 
stay of ≥14 days were scored seven points. If the index hospitalisation was an admission via 
ED this was scored as three, if the patient’s hospitalisation did not begin via the ED the 
domain was scored as zero. Definitions of the Charlson comorbidities are summarised in 
Table 4.1.1. All encounters that occurred in the 12 months prior to the index hospitalisation 
were assessed for any of the Charlson comorbidities and scored as follows: prior myocardial 
infarction, cerebrovascular disease, peripheral artery disease and diabetes without 
complications were all scored one point. HF, diabetes with end organ damage, chronic 
pulmonary disease and mild liver or renal disease were all scored two points. Any tumour 
(including lymphoma or leukemia), dementia and connective tissue diseases were all scored 
three points. Patients with acquired immunodeficiency syndrome (AIDS) and moderate or 
severe liver or renal disease were scored four points. Patients who had a metastatic solid 
tumour within the past five years were scored six points. The comorbidities domain was 
calculated by the addition of comorbidities, if the score was four or greater it was entered as 
the maximum of five points. If the patient had between zero and three ED encounters in the 
six months prior to their enrolment in CADOSA, they were given zero to three points 
accordingly. If the patient had four or more ED encounters, they were scored a maximum of 




patient by the summation of the four domains. The total scores ranged from one to 19, where 




Table 4.1: Scoring the LACE index. 
LACE Attribute Score/Points 




4 – 6 









Not admitted via the Emergency Department 
Admitted via the Emergency Department  
0 
3 
Charlson comorbidity index score 
Previous myocardial infarction  
Cerebrovascular disease  
Peripheral artery disease  
Diabetes without complications  
Congestive heart failure  
Diabetes with end organ damage  
Chronic pulmonary disease  
Mild liver or renal disease  
Any tumour (including lymphoma or leukemia) 
Dementia 
Connective tissue disease  
AIDS 
Moderate or severe liver or renal disease 





























Table 4.1.1 The following table provides the definitions used to define the Charlson 
comorbidities.  
Comorbidity Definition 
Previous myocardial infarction   Any previous definite or probable myocardial 
infarction. 
Cerebrovascular disease   Any previous stroke or transient ischemic attack 
(TIA). 
Peripheral artery disease  Intermittent claudication, previous surgery or 
stenting, gangrene or acute ischemia, untreated 
abdominal or thoracic aortic aneurysm. 
Diabetes without complications  No retinopathy, nephropathy or neuropathy. 
Congestive heart failure  Any patient with symptomatic congestive heart 
failure. 
Diabetes with end organ damage  Diabetes with retinopathy, nephropathy or 
neuropathy. 
Chronic pulmonary disease  Chronic lung conditions (i.e. chronic obstructive 
pulmonary disease). 
Mild liver or renal disease  Cirrhosis but no portal hypertension (i.e., no 
varices, no ascites) OR chronic hepatitis Chronic 
Renal Disease. 
Any tumour (including lymphoma 
or leukemia) 
Solid tumours must have been treated within the 
last 5 years; includes chronic lymphocytic leukemia 
and polycythaemia vera. 
Dementia Any cognitive deficit. 
Connective tissue disease  Systemic lupus erythematosus (SLE), polymyositis, 
mixed connective tissue disease, moderate to severe 
rheumatoid arthritis, and polymyalgia rheumatica. 
AIDS AIDS-defining opportunistic infection or CD4 < 
200. 
Moderate or severe liver or renal 
disease  
Cirrhosis with portal hypertension (e.g., ascites or 
variceal bleeding), End stage Renal Disease, 
Haemodialysis or Peritoneal Dialysis. 




4.1.7 Study Outcomes 
The primary outcome of this study was all-cause unplanned readmission, defined as any 
unplanned inpatient admission to a public South Australian hospital within 30 days of 
discharge. The secondary outcome was a combined outcome of 30-day all-cause mortality 
and unplanned readmission. Additionally, a tertiary outcome reported in this study was the 
number of returns to the ED, defined as patients who were treated in the ED and discharged 
home without an inpatient admission. 
 
4.1.8 Statistical Analyses 
Descriptive statistics were used to summarise the baseline characteristics for readmitted and 
non-readmitted patients. Categorical variables were analysed using chi2 tests and presented as 
frequencies and percentages. Continuous variables were analysed using Mann-Whitney U 
tests and presented as medians with interquartile ranges. The frequency of readmissions and 
mortality were calculated as the number of events divided by the number of patients and 
expressed as a percentage. 
 
4.1.9 Goodness of Fit Metrics 
Receiver Operating Characteristic (ROC) curves were used to determine the optimal cut-point 
for the desired endpoints. The performance of the LACE score as a predictor for readmission 
was evaluated according to its discriminatory power (area under the curve (AUC)), calibration 
(Hosmer-Lemeshow goodness-of-fit test404) and overall accuracy (Brier score405). As a 
secondary outcome, the same analyses were conducted to determine the ability of the LACE 






A logistic regression model was fitted with the four components of the LACE score to 
estimate the relative performance of the LACE index components in predicting 30-day all-
cause unplanned readmission or the combined measure of 30-day unplanned readmission and 
mortality, as the outcome. 
 
A two-sided p value <0.05 was considered statistically significant. All statistical analyses 
were performed using STATA 14 (StataCorp., College Station, TX, USA). 
 
4.2 Results 
4.2.1 Patient Demographics 
Amongst the 1051 patients who met the inclusion criteria for this study, 216 patients were 
excluded for the reasons listed in Figure 4.1. Explicitly, patients were excluded for the 
following reasons: 151 were non-South Australian residents, 54 were discharged to rehab, 14 
were nursing home residents, two patients were discharged for palliative care and one patient 
was discharged for ongoing psychiatric care. Thus, the final cohort for this study consisted of 
829 patients (30.6% female, median age 63 (54-74) years), of whom 306 (36.9%) were coded 
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Figure 4.1: Patient selection consort diagram. 
Patients who have had an AMI and 
undergoing angiography between 2015-16 
(n=1051) 
Excluded (n = 222) 
Non-South Australian resident (n = 151) 
Discharged to rehab (n = 54) 
Nursing home patient (n = 14) 
Discharged to end of life care (n = 2) 






The baseline characteristics of readmitted and non-readmitted patients were similar (refer to 
Table 4.2). Relative to the non-readmitted patients, readmitted patients had a longer length of 
stay (5 (4-9) vs. 4 (3-6) days, p=0.0029) and a lower GRACE score (129 (109-155) vs. 137 
(122-165), p=0.0171). Readmitted patients were less likely to be smokers (24.4% vs. 35.6%, 
p=0.04), but more likely to have peripheral artery disease (18.4% vs. 8.8%, p=0.003), diabetes 
with end organ damage (15.3% vs. 6.8%, p=0.003), connective tissue disease (8.2% vs. 3.6%, 
p=0.03) and moderate or severe liver or renal disease (8.2% vs. 4.0%, p=0.06). The 
distribution of total LACE scores among all patients was slightly negatively skewed (Figure 












n % n % n % 
Demographics 
Age, years (median, IQR) 67.5 56-77 63 53-73 0.08 63 54-74 
Females  39 39.8 215  29.4 0.04 254 30.6 
Length of stay, days (median, IQR) 5 4-9 4 3-6 0.0029 4 3-6 
Active smoker 21 24.4 239 35.6 0.04 260 34.3 
Emergency department arrival^ 96  98.0 699  95.6 0.42 795 95.9 
Emergency department 
encounters in the past 6 months 
(median, IQR) 
0 0-1 0 0-0 0.0000 0 0-0 
Total LACE Score (median, IQR) 9 7-12 8 7-10 0.0001 8 7-11 
Cardiovascular history based on hospitalisations in the preceding year (n, %) 
Cerebrovascular disease 7  7.1 52 7.1 0.99 59  7.1 
Heart failure 6  6.1 52 7.1 0.72 58 7.0 
Dyslipidaemia 62 63.9 411 60.1 0.47 473 60.6 
Hypertension 68 71.6 457 65.6 0.25 525 66.3 
Family history of coronary artery 
disease 
18 29.0 204 39.3 0.12 222 38.2 
Prior myocardial infarction 25  25.5 166 22.7 0.54 191  23.0 
Atrial fibrillation 14 15.9 96 14.3 0.68 110 14.5 
Prior percutaneous coronary 
intervention 
11 12.9 133 19.7 0.13 144 19.0 
Prior coronary artery bypass 
graft 
11 11.8 65 9.3 0.44 76 9.6 
Peripheral artery disease 18 18.4 64 8.8 0.003 82 9.9 
Multivessel disease  56 69.1 395 65.8 0.56 451 66.2 
STEMI 32 32.7 274 37.5 0.35 306 36.9 
GRACE score (median, IQR) 129 109-155 137 122-165 0.0171 131 109-157 




Chronic lung disease 8 8.2 70  (9.6) 0.65 78 9.4 
Diabetes without complications 32 32.7 187 25.6 0.14 219 26.4 
Diabetes with end organ damage 15 15.3 50 6.8 0.003 65 7.8 
Mild liver or renal disease 8 8.2 35 4.8 0.16 43 5.2 
Any tumour 8 8.2 52 7.1 0.71 60 7.2 
Dementia^ 0 0 6 0.8 1.00 6 0.7 
Connective tissue disease 8 8.2 26 3.6 0.03 34 4.1 
AIDS 0 0 0 0 - 0 0 
Moderate or severe liver or renal 
disease 
8 8.2 29 4.0 0.06 37 4.5 
Metastatic solid tumour^ 2  2.0 13  1.8 0.695 15 1.8 




PCI without CABG 
CABG  































^denotes a Fischer’s exact test was performed. 
p value corresponds to t-test or chi2 test. 
Multivessel disease is defined as: (1 MVD) vs. (2-VD + 3-VD). Abbreviations for the 
recommended therapies: Medical therapy (includes counselling). CABG (coronary artery 
bypass graft) includes planned hybrid CABG or PCI (percutaneous coronary intervention). 




















4.2.2 Study Outcomes 
Of the 829 patients, 98 (11.8%) suffered a 30-day all-cause unplanned readmission. Of the 98 
readmissions, the primary diagnosis of 55 (56%) patients was cardiovascular-related. The 
timing of these readmissions ranged from same day to 28 days post-discharge. These 
readmissions generally occurred within the first 15 days post-discharge (Figure 4.3). Nine 
patients (1.1%) were readmitted with HF and another nine patients (1.1%) were readmitted 
for reinfarction. 
 
Six patients (0.72% of the total cohort) died within 30 days of discharge, three of these deaths 
occurred in hospital. Additionally, 99 (11.9%) patients reached the combined endpoint of 
unplanned readmission and or mortality. 
 
It was noted that 32 (3.86%) patients presented to an ED within 30 days of discharge. These 
patients were treated and released back home without being admitted to hospital. Of these 32 
ED presentations, nine (28%) had a cardiac related principal diagnosis. 
 
4.2.3 Model Performance 
The model had optimal balance between sensitivity and specificity for predicting 30-day all-
cause unplanned readmission when the LACE score was ≥10. This threshold (cut-off point) 
yielded a sensitivity of 47.96% and specificity of 67.03%. It was preferable to compromise 
the sensitivity of the model over the specificity to allow for the inclusion of all potential 
unplanned readmissions. The model was satisfactory, with a Brier score of 0.1016, a non-
significant Hosmer-Lemeshow test (χ2=3.62, p=0.73), and an AUC of 0.62 (95% CI 0.56-




Table 4.3: Validity of LACE index models for 30-day all-cause readmission. The ROC AUC 
(or C-statistic) was 0.6192 (95%CI 0.56-0.68). 
 
LACE Cut-point Sensitivity (%) Specificity (%) Correctly classified (%) 
≥2 100.00 0.00 11.82 
≥3 100.00 0.27 12.06 
≥4 100.00 0.55 12.30 
≥5 100.00 0.82 12.55 
≥6 96.94 5.61 16.41 
≥7 92.86 17.92 26.78 
≥8 73.47 39.26 43.31 
≥9 58.16 55.95 56.21 
≥10 47.96 67.03 64.78 
≥11 40.82 75.79 71.65 
≥12 36.73 82.08 76.72 
≥13 24.49 89.74 82.03 
≥14 13.27 95.49 85.77 
≥15 10.20 96.99 86.73 
≥16 7.14 98.36 87.58 
≥17 2.04 99.04 87.58 
≥18 0.00 99.86 88.06 








Figure 4.4: ROC curves for the LACE index models predicting 30-day all-cause unplanned 
readmission. 
 
Similarly, there was optimal balance between sensitivity and specificity of the model for 
predicting a combined outcome of mortality and/or readmission at 30 days, when the LACE 
score was ≥10. This threshold had a sensitivity of 49.51% and specificity of  67.36%. It was 
preferable to compromise the sensitivity of the model over the specificity to allow for the 
inclusion of all potentially unplanned readmissions. The model for the composite outcome 
was also satisfactory, with a Brier score of 0.1017, a non-significant Hosmer-Lemeshow test 





Table 4.4 Combined 30-day all-cause mortality and readmission. The ROC AUC (or C-
statistic) was 0.6301 (95%CI 0.57-0.69). 
 
LACE Cut-point Sensitivity (%) Specificity (%) Correctly classified (%) 
≥2 100.00 0.00 12.42 
≥3 100.00 0.28 12.67 
≥4 100.00 0.55 12.91 
≥5 100.00 0.83 13.15 
≥6 97.09 5.65 17.01 
≥7 93.20 18.04 27.38 
≥8 74.76 39.53 43.91 
≥9 59.22 56.20 56.57 
≥10 49.51 67.36 65.14 
≥11 42.72 76.17 72.01 
≥12 37.86 82.37 76.84 
≥13 25.24 89.94 81.91 
≥14 13.59 95.59 85.40 
≥15 9.71 96.97 86.13 
≥16 6.80 98.35 86.97 
≥17 1.94 99.04 86.97 
≥18 0.00 99.86 87.45 








Figure 4.5: ROC curves for the LACE index models for the combined outcome of 30-day all-




The logistic regression identified that the two LACE index variables with the highest 
statistical significance were length of stay and the number of ED encounters in the prior six 
months (refer to Table 4.5). 
 
Table 4.5: Performance assessment of the logistic regression model for 30-day all-cause 
unplanned readmission and the composite outcome of 30-day all-cause unplanned 
readmission and mortality. 
Variable p value Odds Ratio (95%CI) 
30-day all-cause unplanned readmission 
Length of stay 0.002 1.05 (1.01-1.08) 
Admitted via the emergency department 0.251 1.33 (0.82-2.18) 
Charlson comorbidity score 0.656 1.03 (0.91-1.16) 
ED visits in the prior 6 months  0.000 1.51 (1.21-1.88) 
Composite outcome of 30-day all-cause unplanned readmission and mortality 
Length of stay 0.002 1.05 (1.02-1.08) 
Admitted via the emergency department 0.432 1.18 (0.78-1.78) 
Charlson comorbidity score 0.419 1.05 (0.93-1.18) 







This is the first study to explore the predictive power of the LACE index in a cohort of 
patients with AMI undergoing angiography in Australia. In this study cohort, a LACE score 
of ≥10 showed moderate discriminatory capacity to predict 30-day all-cause unplanned 
readmissions and the combined outcome of 30-day all-cause unplanned readmission and 
mortality. Akin to the findings of the LACE index study222, this study found that the optimal 
score at which readmission was predicted was a score of ≥10, despite having a more refined 
cohort. When predicting readmission, the model yielded a sensitivity (true positives) of 
47.96% and specificity (true negatives) of 67.03%. A higher cut-off score compromised the 
sensitivity of the model by substantially increasing the number of patients classified as high 
risk. For example, if the cut-off score was lowered to ≥9, the high risk group would have 
increased from 26% to 37%. If the cut-off was further lowered to ≥8, 53% of the group would 
have been considered at high risk. This study found a slightly improved fit of the model 
compared to a single centre study of general medical patients (n=432) found that the LACE 
index was a poor discriminator of hospital readmission (C-statistic = 0.58 (95%CI 0.48-0.68), 
but had good overall performance (Brier score = 0.082, Hosmer–Lemeshow χ2=4.97, 
p=0.66)406. 
 
The inclusion and exclusion criteria used for this study were consistent with those used in the 
original LACE study222 which derived and validated the model in a cohort of general medical 
and surgical patients. Despite the differences in cohort, the baseline characteristics of the 
original cohort were similar to the characteristics observed in this AMI population (52.6% 
female, mean age 61.3±17.0 years). The original LACE study222 reported the most common 
index diagnosis was acute coronary syndrome (ACS) (6.4%), and the combined 30-day all-
cause unplanned readmission and mortality rate was 6.0%. Similarly, the most common index 
procedure was angioplasty or coronary artery bypass graft (CABG) surgery (4.6% prevalence) 




of 4.6%. Despite the similarity in the baseline characteristics of these patient cohorts, the 
original rates are much lower to the 12.5% observed in this study. The observed difference in 
rates may be attributed to the inclusion of patients who were stable enough to undergo 
angiography. Thus, this potentially healthier cohort may explain why the observed 
readmission rate is lower than those previously published in AMI cohorts163,196-202. 
 
The logistic regression analysis of the LACE index variables identified length of stay and the 
number of ED encounters in the prior six months as the key drivers of the model. These 
findings corroborate with previous literature407 that indicated that few simple factors were 
able to predict complex outcomes such as readmission among patients undergoing non-
emergent non-cardiac procedures. Moreover, this study has shown that the incorporation of 
comorbidities, in this case the Charlson Index, into predictive models may not be of 
significant value in homogenous populations. Furthermore, the Charlson comorbidity index 
score may have proven more advantageous in the original paper (more heterogenous cohort) 
where patients may have been more likely to have comorbidities such as dementia and AIDS, 
which were negligible in this study. 
 
The LACE+ index229, is an updated version of the original LACE index was not examined 
this study due to the impracticality of variables required. Similarly, the HOSPITAL score223 is 
a more complex model that incorporates laboratory test results. This model is again 
impractical for clinical use, as the required laboratory tests required to calculate the score may 
not be performed in all patients. 
 
4.3.1 Future Directions and Implications 
Currently, the are a limited number of risk prediction models in cardiac populations for 




which requires further action. For models to be successfully implemented they need to be 
actionable. The design of a predictive model needs to be dynamic, simple and quick enough 
to be used by clinicians in a hospital setting whilst balancing and incorporating factors which 
are unique to the individual patient. Moreover, an optimal tool must be derived by using 
contextual factors that are personalised to the individual patient and take into consideration 
sociodemographic factors. In practice, a combined approach which incorporates both clinical 
judgment and insights from predictive models should aid determining which patients are at 
higher risk of readmission408. Additionally, derivation and validation of these models in 
disease specific cohorts may prove more accurate and may explain why generic tools such as 
LACE, LACE+ and HOSPITAL have had little success in large scale implementation. 
 
Whilst the LACE index is a simple scoring tool, it is limited by the inclusion of length of stay 
as a predictive variable, thus it is difficult to implement this tool in practice. For a model 
implementation to be successful, it needs to be actionable and thus high risk patients must be 
quickly identified so that care pathways can be implemented to streamline individualised care 
needs. Although it would be ideal to provide all patients with optimal treatments to reduce 
readmissions, it is not practically or financially feasible. Hence, it is important to identify 
those at higher risk and to target those patients with additional support during their 
hospitalisation and post-discharge. 
 
Developing risk-based protocols, implementing the tools and evaluating their impact on care, 
outcomes and costs are an important direction for future research to drive improvements in 
health care. In addition to producing better risk prediction models for readmission, future 
studies are required to implement interventions to reduce readmissions that are appropriately 
targeted to the needs of the individual patient. These interventions may focus on improving 
the transition period from hospital discharge to home in high risk patients. This has been 




Discharged (RED) toolkit developed by the Agency for Health care Research and Quality, 
which lowered readmission rates by 30%372. These findings reiterate the importance of 
discharge planning for the patient throughout the patient’s hospitalisation409. 
 
4.3.2 Study Limitations 
The use of Registry data enabled the analysis of consecutive ‘real world’ AMI patients, 
however the analysis was limited to two registry centres due to accessibility of records to 
obtain the LACE index. Additionally, hospitalisation outcomes were restricted to public 
hospitals only. Similarly, the assessment of time and especially the cause of mortality was 
difficult to ascertain. This limitation could be improved in future by probabilistic linkage of 
the CADOSA Registry data to the National Death Index Registry data. 
 
4.4 Conclusions 
This study found that the LACE index was a satisfactory predictor of readmission in this 
South Australian cohort of patients who underwent angiography. Moreover, the two variables 
that predicted 30-day all-cause unplanned readmission (and combined readmission and 
mortality) were the length of stay and the number of ED encounters in the prior 12 months. 
Further investigations are required in larger samples to determine whether these two variables 
consistently predict readmission as they are easy to determine and would allow clinicians to 
determine which patients are at higher risk of readmission and provide additional support, 
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Hospital readmissions are an important indicator of health care safety and quality. 
Readmission within 30 days of discharge is a key quality metric reported to government 
organisations116,168,171. Up to 30% of readmissions occur within 30 days of discharge from a 
cardiovascular condition, predominantly among patients with heart failure (HF)12 and acute 
myocardial infarction (AMI)410. Defining the risk factors of readmissions is important in 
determining optimal interventions to reduce readmissions411-413 and improving patient 
outcomes. 
 
Readmission risk prediction remains a complex and poorly understood endeavour currently 
dominated by patient-level models. These models include factors such as comorbidities, basic 
demographic data and clinical variables401. Broader social, environmental, medical and 
functional factors are likely to contribute to readmission risk but have not been widely 
studied. Sleep disturbance is known to have negative physiological and psychological effects 
including altered emotions, poor memory, impaired cognitive function and reduced 
immunity282. The hospital environment is notorious for disrupting sleep312, and sleep 
disturbance has been shown to interfere with healing414. A U-shaped relationship has been 
established indicating that both short and long periods of sleep result in adverse 
cardiovascular outcomes309,277. Thus, poor quality and quantity of sleep in the hospital 
environment may be a factor contributing to readmissions. 
 
The association between sleep characteristics and readmission in cardiovascular inpatients has 
not been previously assessed. This study aims to determine if an association exists between 
sleep quantity and sleep quality with 30-day all-cause unplanned readmission among 






This prospective observational cohort pilot study recruited patients spending a minimum of 
one night in the coronary care unit of The Queen Elizabeth Hospital, South Australia between 
June 2016 and March 2018. This study was approved by Central Adelaide Local Health 
Network (CALHN) Human Research Ethics Committee. 
 
5.1.1 Study Patients 
The inclusion criteria for this study were (i) hospital admission with a cardiovascular 
diagnosis or procedure and (ii) ability to wear an ActiGraph device on the wrist. Patients were 
excluded based on discussion with nursing staff if they were (i) not residing permanently 
within South Australia, (ii) highly dependent on medical care, (iii) had a movement disorder, 
(iv) had a cognitive impairment or intellectual disability reported by a health practitioner or 
(v) were unable to provide informed consent or communicate sufficiently in English. 
 
5.1.2 Study Protocol 
Following informed consent obtained prior to the patient’s first night in hospital and the 
administration of questionnaires assessing sleep and health status. These questionnaires 
included the Pittsburgh Sleep Quality Index (PSQI)310, Euro Quality of life questionnaire – 5 
Dimensions – 3 Levels (EQ-5D-3L)415, Epworth Sleepiness Scale (ESS)314 and the STOP 
BANG416 questionnaire (a score based on patient snoring, daytime tiredness, observed 
apnea’s, high blood pressure (BP), body mass index, age, neck circumference and gender). 
Medical history was attained via patient interview and medical record review. The ActiGraph 
GT3X+ (ActiGraph, LLC, Pensacola, FL) was placed on the patient’s preferred wrist, taking 
into consideration placement of any medical devices (such as cannulas and tubing) and they 
were instructed to wear it continuously. Patients were invited to continue wearing the 




return the device. If the patient preferred to return the ActiGraph at discharge, the ActiGraph 
was collected by the researcher following discharge. 
 
30-Day All-cause Unplanned Readmission 
A readmission was defined as a return to the emergency department or an unplanned 
admission to hospital for any reason within 30 days of discharge. Readmissions were 
determined via hospital administrative databases and medical records, or via from patient self-
report at the 30-day follow-up point. 
 
Follow-up 
At 30 days post-discharge, patients were contacted via telephone, and by mail if there were 
two failed telephone attempts. Patients were asked whether they had returned to hospital since 
discharge, and both the PSQI310 and EQ-5D-3L415 questionnaires were reassessed verbally. 
 
5.1.3 Sleep Parameters Assessment 
Actigraphy 
Polysomnography (PSG) is the gold standard measure of sleep quantity, however due to the 
intrusive nature of the device304 it was not feasible for use in this cohort of patients. 
Actigraphy uses a piezoelectric transducer to measure wake and sleep states based on 
movement300. The ActiGraph GT3X+ has been validated in various cohorts against laboratory 
based PSG417-420 with 90% sensitivity, 46% specificity and 84% accuracy306. All ActiGraph 
data was extrapolated using ActiLife v6.0 software (ActiGraph LLC). 
 
The Troiano algorithm421 was used to interpret sleep measures. A wear time threshold has not 




sleep time (TST) of all patients who wore an ActiGraph. A 70% threshold was determined 
sufficient for data analysis of our cohort, refer to Appendix C for a full description. 
 
The used the Cole-Kripe Sleep algorithm422 was used to interpret the ActiGraph data into the 
endpoints defined below: 
Total sleep time (TST): The average time (minutes) a patient was asleep during a 24-
hour period. 
Number of awakenings: The average number of times the patient awoke during a 
period characterised as sleep. 
Wake After Sleep Onset (WASO): The average time (minutes) between sleep and 
wake. In healthy sleep, WASO should be <5% of TST247. 
Average time awake: The average amount of time (minutes) the patient was awake 
during a period of sleep. 
 
Pittsburgh Sleep Quality Index (PSQI)310 
The PSQI is a validated measure of a patient’s perception of their sleep and is comprised of 
19 questions and seven domains310,311. The global score is ranked from 0 to 21, where scores 
³5 are defined as poor sleep with 90% sensitivity and 87% specificity compared to PSG310. 
 
Epworth Sleepiness Scale (ESS)314 
The ESS assesses the respondent’s propensity to fall asleep during the day across a range of 
daytime activities and scenarios314. The ESS is comprised of eight questions with higher 
scores indicating increased daytime sleepiness311,314,315. The ESS has shown to have high 







The STOP BANG questionnaire416 is comprised of eight items and has been validated against 
PSG. It detects obstructive sleep apnea (OSA) for scores ³5 with 72% (CI 54.4 – 89.6) 
sensitivity and 33.3% (CI 2.5 – 64.1) specificity316. 
 
Euro Quality of life questionnaire – 5 Dimensions – 3 Levels (EQ-5D-3L)415 
The EQ-5D-3L is a well-established quality of life questionnaire415 with acceptable construct 
validity423 and excellent reproducibility424. 
 
5.1.4 Statistical Analyses 
Descriptive data for the readmitted and non-readmitted patients were analysed using t-tests 
(for continuous variables) and chi2 tests (for categorical variables). Mean TST was displayed 
as both a continuous and categorised variable into <6 hours283,425-427, 6 to 9 hours and >9 
hours as has been reported previously426-434. Effect size was measured using Cohen’s d test to 
determine whether clinically significant difference exists between the mean values. All 
statistical analyses were performed using STATA 14 (StataCorp., College Station, TX, USA). 
 
5.2 Results 
5.2.1 Patient Demographics 
Of the 222 patients screened, 112 patients consented to participate, 38 patients withdrew prior 








Patients screened (n=223) 
Consented (n=113) 
Screen Failures (n=110) 
Refused (n=52) 
Non-English speaking (n=22) 
Cognitive impairment (n=8) 
Not first night (n=7) 
Non-compliant (n=8) 
Infectious disease (n=4) 
Interstate resident (n=3) 
Transferred in (n=2) 
Pacemaker (n=1)  
Wearing telemetry (n=1) 
CPAP (n=1) 
Profoundly deaf (n=1) 
Wear time <70% (n=16) 
Withdrew consent (n=12) 
Lost ActiGraph (n=6) 
ActiGraph data was corrupted (n=2) 
Died during index hospitalisation (n=1) 
Did not wear the ActiGraph (n=1) 
Cohort (n=75) 
Completed 30-day follow-up 
questionnaires (n=49) 
100% patients reached primary endpoint  
(30-day readmission via medical records) 




The overall cohort was elderly (mean age of 66.9±13.1years) and male dominated (72%), 
with an average length of stay of 3.0±1.5 days. Baseline characteristics of readmitted and 
non-readmitted patients were similar (Table 5.1). 
 
Table 5.1: Baseline characteristics for unplanned readmitted vs. non-readmitted 
patients. 
 Readmitted Not readmitted  
P value Mean SD Mean  SD 
Demographics and Comorbidities 
n 15 - 60 - - 
Age (years) 64.5 18.7 67.5  11.5 0.43 
Female (%) 40 - 25 - 0.25 
Length of stay (days) 3.5 1.5 2.8 1.5 0.14 
Private insurance (%) 47 - 38 - 0.57 
Single room (%) 33 - 30 - 0.80 
Live alone (%) 47 - 28 - 0.17 
Cardiovascular risk factors and comorbidities 
AF (%) 33 - 32 - 0.90 
HF (%) 33 - 15 - 0.10 
Dyslipidaemia (%) 67 - 68 - 0.90 
Hypertension (%) 60 - 75 - 0.25 
Prior Stroke (%) 20 - 12 - 0.40 
Prior Diabetes (%) 20 - 32 - 0.38 
Prior Angina(%) 73 - 25 - 0.03 
Prior MI (%) 33 - 18 - 0.21 
Prior PCI (%) 13 - 22 - 0.47 
Prior CABG (%) 20 - 8 - 0.19 
PAD (%) 13 - 3 - 0.13 
Current smoker (%) 20 - 23 - 0.95 




COPD (%) 20 - 13 - 0.51 
Arthritis (%) 13 - 22 - 0.47 
Depression (%) 20 - 10 - 0.29 
Anxiety (%) 7 - 5 - 0.81 
No OSA (%) 
OSA with CPAP (%) 














Asthma (%) 20 - 12 - 0.40 
GORD (%) 13 - 30 - 0.19 
Procedures and medications 
Angiography (%) 27 - 47 - 0.15 
Aspirin (%) 33 - 48 - 0.30 
Statin (%) 40 - 50 - 0.49 
ARB / ACE inhibitor (%) 40 - 42 - 0.91 
GTN (%) 33 - 13 - 0.07 
 
Abbreviations: AF = atrial fibrillation; HF = heart failure; PCI= Percutaneous Coronary Intervention; CABG = 
coronary artery bypass graft; AAA = Abdominal aortic aneurysm; MI = Myocardial infarction; OSA = 
obstructive sleep apnea; CPAP = continuous positive air pressure; GORD = gastro-oesophageal reflux disease; 
PAD = peripheral artery disease; COPD = chronic obstructive pulmonary disease; ARB = angiotensin II receptor 
blocker; ACE = angiotensin converting enzyme; GTN = glyceryl trinitrate.  





Comorbidities were similar, although a significantly greater number of readmitted patients 
presented with a history of prior angina (73% vs. 25%, p=0.03). Patient medications on 
admission were similar among all patients, although readmitted patients were more likely to 
be prescribed glyceryl trinitrate (GTN), consistent with their significant history of angina 
(33% vs. 13%, p=0.07). The most common reason for the index admission was an elective 
procedure (33%) followed by ACS (27%) (Table 5.2). 
 
Table 5.2: Primary Diagnoses of the Cohort 
Diagnosis Category n % 
Elective procedures 22 33 
Acute coronary syndromes 18 27 
Arrhythmias 8 12 
Heart failure 7 11 
Other 11 17 
Note: All patients who came in with chest pain were listed under ‘other’. 
 
5.2.2 Readmission Timing and Causes 
The 30-day follow-up rate for telephone calls was 65% (49 patients), however readmission 
status was available via medical records for all 75 patients. The 30-day all-cause unplanned 
readmission rate was 20%. Time to readmission varied from one to 27 days post-discharge, 
with an average time of 11.9±7.6 days. Patients wore an ActiGraph for an average of 2.8±1.8 
(range: 0 to 8) nights in hospital. Of the 37 patients who continued to wear the ActiGraph 
post-discharge, the average wear time was 10.0±5.1 (range: 1 to 20) days. The most common 
cause of 30-day readmission were cardiac-related (nine of the 15 patients). A complete list of 





Table 5.3: The causes of readmission of the 15 patients who returned to hospital. Nine of the 
15 were readmissions for something cardiovascular-related. 
 
Cardiovascular-related readmission  Non-cardiovascular-related readmission 
ST-elevated myocardial infarction. Return to Emergency Department for unknown  
reason (x2). 
Exacerbation of heart failure. Gynaecological pain. 
Coronary spasm. Haematoma on the arm. 
Chest pain (x3). Itchy skin rash. 










5.2.3 Objective sleep measures 
In-hospital TST recordings showed no difference between readmitted and non-readmitted 
patients (6.9±1.3 hours vs. 6.8±2.9 hours, p=0.96). A higher proportion of readmitted patients 
had a longer TST (6-9 hours vs. <6 hours, p=0.07) (Table 5.4). The post-discharge TST of 
non-readmitted patients was longer on average than readmitted patients however not 





Table 5.4: In-hospital and post-discharge ActiGraph data. 
 Readmitted Not Readmitted p Cohen’s d 
(95%CI) Mean SD Mean SD 
In hospital 
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WASO from actigraphy did not differ significantly between readmitted and non-readmitted 
patients, both in-hospital and post-discharge. However, in-hospital WASO recordings 
indicated that readmitted patients had longer WASOs compared to non-readmitted patients 
(84.5±85.3 minutes vs. 61.9±51.3 minutes, p=0.14) with a medium effect size (Cohen’s 
d=0.43). Further, when categorised, 67% of readmitted patients had a mean WASO of ≥60 
minutes compared to 42% of non-readmitted patients (p=0.16, Table 5.4). Although not 
statistically significant, in-hospital awakenings were increased in readmitted patients 
(13.6±4.2 vs.11.9±5.2, p=0.25), with a small to medium effect size (Cohen’s d=0.33) for the 
number of awakenings in hospital. There were no differences in the awake times between 
readmitted and non-readmitted patients for both the in-hospital and post-discharge data (Table 
5.4). 
 
5.2.4 Subjective Measures 
No differences between the readmitted and non-readmitted patients were observed in relation 
to daytime sleepiness as measured by the ESS. The STOP BANG questionnaire scores were 
also similar between groups. However, 40% of readmitted patients (compared to 13% of non-
readmitted patients, p=0.02) reported that someone had observed them stop breathing while 
sleeping. 
 
The EQ-5D-3L was answered by all 75 patients at baseline, with readmitted patients reporting 
a lower VAS (Visual Analogue Scale) score (48.7±21.9 vs. 63.3±28.7, p=0.07) indicative of 
poorer self-rated health, with small effect size (Cohen’s d=0.10). At 30 days, the mean VAS 
scores were similar between readmitted and non-readmitted patients (74.3±15.1 vs. 
76.5±22.3, p=0.80, respectively). The mobility domain of the EQ-5D-3L was significantly 





At baseline, readmitted patients had a lower PSQI global score, indicating worse sleep 
perception (9.13±3.6 vs. 6.4±4.1, p=0.02). The average 30-day PSQI global score were 
similar between readmitted and non-readmitted patients (6.3±4.2 vs. 6.0±3.9, p=0.84). All 
subjective sleep measures, both in hospital and post-discharge are summarised in Table 5.5. 
 
Table 5.5: Sleep and quality of life questionnaires data (in-hospital and post-discharge). 
 Readmitted Not readmitted  
p 
Cohen’s d 
(95%CI) Mean SD Mean SD 
In-hospital 
n 15 - 60 - - - 
ESS Mean Score 5.9 5.3 6.3 4.6 0.73 0.09 (-0.47-0.66) 
STOP BANG 4.3 1.5 4.1 1.5 0.70 0.11 (-0.45-0.67) 
PSQI 9.13 3.6 6.4 4.1 0.02 0.70 (0.12-1.27) 
n 15 - 58 - - - 
EQ-5D VAS 48.7 21.9 63.3 28.7 0.07 0.53 (-0.04-1.11) 
Post-discharge 
n 7 - 40 - - - 
EQ-5D VAS 74.3 15.1 76.5 22.3 0.80 0.10 (-0.70-0.91) 
n 8 - 41 - - - 
PSQI 6.3 4.2 6.0 3.9 0.84 0.08 (-0.68-0.83) 
**p values were taken from t-test or chi2 test, as appropriate. 
 
5.3 Discussion 
This is the first study to report sleep quality and quantity of cardiovascular inpatients, in 
relation to readmission. In line with previously published data410, this study supports a 
significant rate of readmission in the first 30-days with one in five patients returning to 
hospital. In relation to sleep, all patients slept for almost seven hours on average in hospital, 




(6 to <9 hours). On average, readmitted patients had a 20 minute longer WASO in hospital, 
implying greater disruption during sleep. While a moderate effect size was observed, 
statistical significance was not reached, suggesting a need to further examine periods of 
wakefulness during hospital stays in a larger sample size. Similarly, readmitted patients had 
two more awakenings on average, but spent less time awake during those awakenings. 
Evaluation of the ESS found higher than normal daytime sleepiness among all patients. The 
total scores for the STOP BANG questionnaire found that all patients had an intermediate to 
high risk of OSA. PSQI scores in all patients were greater than five at baseline and 30 days, 
thus patients’ perceptions of their sleep quality was poor regardless of whether they were in or 
out of hospital. Importantly, the readmitted patients had a higher PSQI score at baseline 
indicating that their recent sleep quality was noticeably poorer prior to their index 
hospitalisation, compared to non-readmitted patients. Furthermore, readmitted patients had 
significantly more issues with mobility at baseline and at 30 days. This suggests that routinely 
unhealthy sleep may be associated with poorer quality of life and may be a contributor to 
higher risk of readmission in patients with cardiac-related conditions or diseases. 
 
5.3.1 Sleep in the Inpatient Environment 
Sleep disruption during hospitalisation is a significant concern for inpatients. The negative 
consequences on patient health have been well described as resulting from a number of 
factors intrinsic to the patient, the external environment and the care process435. A systematic 
review of multiple interventions to limit the impact of sleep disturbance in hospitalised 
patients identified the potential to make improvements in the quality of patient sleep436. An 
example of a modifiable factor is noise levels in hospital, which can be improved through the 
provision of earplugs and eye masks. Changing the sound and light and even aroma in the 
environment has been shown to positively improve sleep in hospital437. Nursing care activities 




demonstrated to improve sleep conditions438. 
 
5.3.2 Sleep and Readmissions 
Management of hospitalised patients is focused on the acute illness that led to the admission 
and there is often little focus on managing stressors during hospitalisation that may contribute 
to the vulnerabilities and possible triggers that may lead to readmission. Changes to sleep, 
physical inactivity, social isolation, dietary changes, modifications in ambient brightness and 
temperature during hospitalisation produce observed responses such as delirium, 
immunosuppression and depression. 
 
The consequence of the myriad of potential contributors have been expressed in the literature 
as ‘post hospital syndrome’239. Post hospital syndrome hypothesises that the index 
hospitalisation increases a patient’s generalised risk and vulnerability for readmission239. As 
the index illness begins to heal and the patient is discharged, post hospital syndrome 
manifests and leads to readmission. The exact aetiology of post hospital syndrome is not well 
understood however allostasis overload during the index hospitalisation has been 
postulated439, whereby the increased level of chronic stress can lead to cognitive, 
cardiovascular, immune and functional deterioration. These mechanisms are depicted in 
Figure 5.2440. Sleep disturbance during the index admission may be one of several factors 
contributing to a patient’s vulnerability to readmission239 and it is well established that acute 
sleep deprivation in particular causes disruptions to the circadian rhythm441. The long term 
impacts of disturbed sleep during hospitalisation include lower physical functioning, 
increased mortality and delirium436, however there is little to no data specifically assessing 

















Figure 5.2: Possible mechanisms behind post hospital syndrome that result in patient readmission, adapted from Mesquita et al. 2015440. Sleep is a stressor that is partly physical, 
partly ambient and partly psycho-emotive. These in-hospital stressors result in physiological responses.  In addition to pre-existing comorbidities, the cognitive, cardiovascular, 















• Social isolation. 
• Loss of autonomy. 
Stressors 
Physiological responses. 
Delirium, immunosuppression, depression and changes to circadian rhythm.  
Pre-existing conditions/comorbidities. 
‘Post Hospital Syndrome’ 













Our current understanding of sleep in patients with cardiovascular disease is focused on OSA 
with observational evidence showing that OSA is associated with both coronary and 
cerebrovascular morbidity and mortality442,443. Our study showed eight (11%) patients from 
the overall cohort had been previously diagnosed with OSA (Table 5.1). However, 14 patients 
(19%) of the overall cohort indicated that someone had observed them stop breathing while 
sleeping, suggesting a potential under diagnosis of OSA among patients with cardiovascular 
disease. A study in the United States, of general medicine patients reported OSA as a risk 
factor for readmission (11.4% vs. 7.6%, p<0.01)444. Thus, OSA may be important novel 
modifiable risk factor for cardiovascular readmissions.  
 
A meta-analysis of sleep duration (assessed by various methods) in cardiovascular cohorts 
demonstrated that less than five hours and over nine hours of sleep was associated with poorer 
outcomes, specifically mortality and morbidity. However, none of the studies in the meta-
analysis assessed readmission275. Few studies have compared sleep in-hospital to at home, 
moreover no data has been reported in a cardiovascular cohort. A large Dutch cross-sectional 
observational study445 of 2000 general medicine and surgical inpatients, assessed quantity and 
quality of sleep and found that patients slept for 83 minutes less in hospital, on average. This 
study also found more nocturnal awakenings in hospital than at home, similar to the current 
study. An Australian study assessing the perceived duration of sleep in generally hospitalised 
patients also found that patients slept less in hospital than at home446. Both studies assessed 
sleep using subjective measures and thus we present the first objective measurement of sleep 






The major limitation of this study was the small sample size, illustrated well by reasonable 
effect sizes between readmitted and non-readmitted patients but results which did not achieve 
statistical significance. Importantly, we have demonstrated the feasibility of using wearable 
devices for hospitalised patients although post-discharge use may require more monitoring for 
compliance. The small sample size also limited our ability to adjust for potential confounders 
related to readmissions. This study was limited due to the lack of a sleep diary, which has 
been previously shown to corroborate the findings of actigraphy particularly for non-
compliant wear and when a patient is motionless but still awake447. The pilot study enrolled 
patients with any cardiovascular diagnosis, and to improve generalisability, future studies 
may be limited to patients with a specific cardiovascular condition such as AMI or HF. 
 
5.4 Conclusions 
This study did not find a statistically significant relationship between sleep quantity (as 
measured by actigraphy) and 30-day all-cause unplanned readmissions of cardiology 
inpatients. However poor perceived sleep quality (measured by the PSQI310) was associated 
with increased 30-day all-cause unplanned readmissions. Whilst the actigraphy data was not 
associated with readmissions, some aspects of sleep in the readmitted patients including the 
WASO and in-hospital awakenings suggest further exploration is warranted in larger studies. 
This may have implications for inpatient management if disturbance of sleep is linked to 
readmissions. If so, future research involving risk prediction models for hospital readmissions 
may be improved by wearable device technology to monitor and collect sleep data. Finally, it 
is important to characterise how changes in sleep pattern during hospitalisation correlate with 











Improving the health outcomes of patients with cardiovascular disease (CVD) via the 
reduction of readmissions has evolved in recent years. The improvement of health outcomes 
via a holistic and compassionate approach is not a novel concept. From the 5th Century Before 
the Common Era Hippocrates, Greek physician and father of modern medicine wrote the 
original Hippocratic Oath to emphasise the holistic and compassionate approach to 
medicine448. The bioethical principles in medicine still uphold the underlying principle from 
Hippocrates’s Oath – “do no harm”. Consistent with this principle, this thesis addresses the 
concept of reducing readmissions and improving the patient’s health outcomes. It further 
emphasises the value of measuring, reporting and reducing readmissions in an Australian 
context. Additionally, this thesis has explored various methods to better understand which 
study designs could best enable researchers to answer specific questions. The major findings 
of the thesis are summarised below. 
 
Chapter II employed a scoping review approach to explore the knowledge gap surrounding 
the prevalence and causes of readmission in Australian patients with CVD. This chapter 
concluded that readmission rates in the Australian context (1) were comparable to those 
observed overseas, (2) showed heterogeneity in the design, definition and measurement and 
(3) the need for future studies to test and implement interventions to reduce these rates and 
thus improve the health outcomes of patients with CVD. 
 
The scope of this thesis then focused from the broader CVDs into heart failure (HF) and acute 
myocardial infarction (AMI) specifically, as these two conditions have been shown 
internationally to have the highest rates of readmission. Chapter III utilised linked 
administrative data from Australian and New Zealand patients with a primary discharge 
diagnosis of HF. This chapter concluded that (1) the 30-day all-cause mortality rate was 
10.7% and (2) the 30-day all-cause unplanned readmission was 22.3%, which are comparable 
to previously reported rates. Moreover, this chapter found variability in the readmission rates 
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and a decline in both mortality and readmission rates between 2010 and 2015. Once again, 
Chapter III emphasised the need to standardise care provided to HF patients in Australia to 
reduce readmission and thus improve patient outcomes. 
 
Chapter IV of this thesis assessed a risk prediction model (the LACE index) in a local cohort 
of patients with AMI undergoing angiography who were derived from registry data between 
2016 and 2017, to determine which patients were most vulnerable for 30-day all-cause 
unplanned readmission and mortality. Chapter IV concluded that the LACE index (1) had 
moderate discriminatory capacity to predict readmission and mortality and (2) highlighted the 
need for more robust models to facilitate clinicians in determining which patients are at higher 
risk of readmission, allowing clinicians to adapt care to best suit the individual patient. 
 
From the findings in previous chapters it was apparent that the notion of post hospital 
syndrome may be contributing to the observed rates of readmission in patients with CVD. 
Chapter V utilised a clinical pilot study to analyse, at the patient level, whether the quality 
and quantity of sleep in hospital could be a contributing factor to the observed readmission 
rates. Chapter V (1) did not conclusively find an association between sleep quantity and 
readmission, (2) found that patients who perceived their sleep quality as being poorer were 
more likely to be readmitted within 30 days and (3) highlighted the importance of improving 
sleep both in and out of hospital, to improve patient outcomes such as reducing readmissions 
in cardiology inpatients. 
 
In summary, the data from this thesis advances the knowledge-based concerning readmissions 
in Australian patients with CVD demonstrating (1) the lack of contemporary resources 
available in Australia (2) readmissions following index admissions for HF and AMI are 
similar to international counterparts, (3) variation of readmission and mortality rates exist 
within Australia, (4) acknowledging the importance of risk prediction models in helping to 
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identify patients at higher risk and (5) the exploration of poor sleep both in (and potentially 
out of hospital) as a possible contributor to the readmissions. 
 
Thus, readmission following an index hospitalisation for a CVD is a global problem, with the 
exact underlying mechanisms remaining unclear and a limited impact of current approaches. 
These include targeting, accommodating and personalising therapy or treatment for the 
individual patient, as opposed to a hospital-level solution. By grasping the concerns and needs 
of the individual patient and tailoring therapy to accommodate the individuals needs and 
unique situation, the clinician can improve the outcomes of that patient. Furthermore, despite 
best efforts to make changes to policy, such as the Hospital Readmission Reduction Program 
(HRRP) in the United States, the rates of readmission and mortality do not appear to be 
drastically reducing. This further emphasises the need for the clinician to work together with 
the patient to determine what is best for them and not the health care system. Only when we 
change the fundamental practice of clinicians will we reap the rewards of improving patient 
centred care and optimising the outcomes, such as reducing readmission, for all patients. 
 
Future approaches to improve our understanding of the underlying causes of these 
readmissions include big data, personalised medicine and shared decision making. Big data 
analysis and the use of electronic health records have made positive change to the role of 
patients, in allowing them to work with their physician to make shared decisions. There has 
also been much controversy concerning the ethical considerations which must be maintained 
to uphold the confidentiality and autonomy of patients. Although it is beyond the scope of this 
thesis, health applications are now becoming a popular way to encourage patients to improve 
their own health. In such large datasets, the p-values <0.05 becomes irrelevant and there has 




In addition to highlighting these findings regarding readmissions, this thesis has also explored 
the capability of using different sources of data to best utilise this data to improve patient 
outcomes. With such large datasets, the capability for such amounts of information to be 
produced and analysed in rapid succession, compromises the autonomy of medicine. The use 
of patient level data analysis and observational cohort study designs are still vital in medicine 
(and cardiology) today. The critical thinking and decision making are unique human 
capabilities and although artificial intelligence and big data techniques may improve current 
practice, some skills are best left to trained clinicians who have the ability to determine when 
exceptions to the “algorithm” are necessary. There is no “typical patient”, each patient is 
unique, and this is why the guidelines may lack value in medicine today. A clinician has the 
expertise to weigh the risks and benefits and the capability to work with the patient to 
determine the optimal treatment for him or her. 
 
In such a fast-paced evolving world, the use of machine learning and artificial intelligence are 
currently a hot topic in the literature in all aspects of medicine450. However, through the 
exploration of big data techniques in Chapter III of this thesis, it is noted that the technology 
has limitations. Therefore, although this technology is important and in the future may be 
beneficial in clinical practice, at present it needs to be refined and may in fact be detrimental 
to practice at present. The use of administrative data is continuing to prove useful for 
appraisal and improvement of health care policies125,151. 
 
Such large datasets are useful to grasp the generalised overview of what is happening in a 
population. Through infrastructure such as linkage between data sets, the sharing of 





However, what is most important (and what clinicians strive to achieve everyday) is to 
improve the quality of life of individual patients. Thus, the use of “big data”, “machine 
learning” and automatic techniques will never replace the decision-making that a human is 
capable of formulating. Although, the use of such personalised medicine and advances in 
technology have allowed for the creation of applications or tools such as ePRISM, that 
provide the clinician with a real time, personalised tools to provide patients with the best 
possible therapy. 
 
Future interventions that may reduce hospital readmissions in Australia may involve (a) 
health system policy changes – financial penalties for readmissions and (b) further exploring 
the concept of post hospital syndrome, and intervening in this pathological process, (c) 
continuing patient education to allow for patient self-help and (d) home-based intiatives as 
have been described earlier in chapter II of this thesis, in reference to the work by Stewart et 
al362,451 in cohorts of patients with HF. It is anticipated that data linkage and personalised 
treatment for patients will provide optimal outcomes for patients. As was depicted in a recent 
study by Hammill and colleagues134.This study of patients with HF, found that by using both 
administrative and registry data, compared to using administrative data alone, resulted in 
improved accuracy of a model to predict 30-day outcomes. This emphasises the importance of 
linking both sources of data, with an emphasis on outcomes data, and personalising and 
delivering the information to the patients in real-time. Additionally, the models used in this 
study had better accuracy for predicting 30-day readmission as opposed to 30-day mortality. 
This speaks to the enigma surrounding readmissions that thesis has begun to explore in an 
Australian context. Finally, this thesis has highlighted the importance and supports the need 
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Abstract
Objective. International studies suggest high rates of readmissions after cardiovascular hospitalisations, but the
burden in Australia is uncertain. We summarised the characteristics, frequency, risk factors of readmissions and
interventions to reduce readmissions following cardiovascular hospitalisation in Australia.
Methods. A scoping review of the published literature from 2000–2016 was performed using Medline, EMBASE
and Cumulative Index to Nursing and Allied Health Literature (CINAHL) databases and relevant grey literature.
Results. We identi!ed 35 studies (25 observational, 10 reporting outcomes of interventions). Observational studies
were typically single-centre (11/25) and reported readmissions following hospitalisations for heart failure (HF; 10/25),
acute coronary syndrome (7/25) and stroke (6/25), with other conditions infrequently reported. The de!nition of a
readmission was heterogeneous and was assessed using diverse methods. Readmission rate, most commonly reported at
1 month (14/25), varied from 6.3% to 27%, with readmission rates of 10.1–27% for HF, 6.5–11% for stroke and 12.7–17%
for acute myocardial infarction, with a high degree of heterogeneity among studies. Of the 10 studies of interventions
to reduce readmissions, most (n = 8) evaluated HF management programs and three reported a signi!cant reduction in
readmissions. We identi!ed a lack of national studies of readmissions and those assessing the cost and resource impact of
readmissions on the healthcare system as well as a paucity of successful interventions to lower readmissions.
Conclusions. High rates of readmissions are reported for cardiovascular conditions, although substantial method-
ological heterogeneity exists among studies. Nationally standardised de!nitions are required to accurately measure
readmissions and further studies are needed to address knowledge gaps and test interventions to lower readmissions
in Australia.
What is known about the topic? International studies suggest readmissions are common following cardiovascular
hospitalisations and are costly to the health system, yet little is known about the burden of readmission in the Australian
setting or the effectiveness of intervention to reduce readmissions.
What does this paper add? We found relatively high rates of readmissions following common cardiovascular
conditions although studies differed in their methodology making it dif!cult to accurately gauge the readmission rate.
We also found several knowledge gaps including lack of national studies, studies assessing the impact on the health
system and few interventions proven to reduce readmissions in the Australian setting.








Whatare the implications forpractitioners? Practitioners shouldbe cautiouswhen interpreting studies of readmissions
due theheterogeneity inde!nitions andmethodsused inAustralian literature. Further studies areneeded to test interventions
to reduce readmissions in the Australians setting.
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Introduction
Cardiovascular disorders are among the most common cause
of hospitalisation in the Australian health system, with more
than 500 000 hospitalisations occurring annually.1 This care is
expensive, consuming 40% of the total national healthcare
expenditure on cardiovascular disease.2 International studies
have suggested that many of these hospitalisations are due to
readmissions. Selected US populations have found that one
in four patients with heart failure (HF) are readmitted within
30 days,3 increasing to one in two at 6 months.4 Similarly, 15%
of stroke patients are readmitted by 30 days,5 increasing to
20–40% by 1 year.6 High rates of readmission are also reported
in selected US populations for common conditions and proce-
dures, such as acute myocardial infarction (AMI; 19% by
30 days), percutaneous coronary intervention (PCI; 15% by
30 days)7 and peripheral artery revascularisation (17.6%
by 30 days).8 A proportion of these readmissions is inevitably
due to the underlying condition. Nevertheless, a large
proportion may be avoidable. Readmissions occurring due
to preventable reasons, such as hospital acquired infection,
thromboembolism and medication errors, are frequent, with
a systematic review suggesting that at least one-quarter of
all readmissions are preventable.9 Thus, reducing hospital
readmissions is highly desirable to improve patient care and
minimise avoidable healthcare expenditure.
Driven by the international !ndings, clinicians and policy
makers in Australia are also increasingly focusing on reducing
readmissions, with cardiovascular conditions frequently touted
as a priority condition. For example, the New South Wales
(NSW) government plans to reduce the rates of unplanned
readmissions by 2021.10 However, readmissions may be driven
by contextual factors and international data may have limited
relevance to the Australian setting. For example, Australia’s
universal healthcare system allows equal access to healthcare
services, compared with the fee-for-service model implemented
in countries such as the US. More affordable and accessible
health care in Australia may result in lower rates of readmission.
Thus, efforts to reduce readmissions through clinical or policy
intervention requires an understanding of readmissions in the
Australian setting, including the frequency of readmissions,
potential contributing factors and the effects of readmissions
on the health system.
Accordingly, we conducted a scoping review of the Austra-
lian literature to identify and synthesise available evidence
regarding readmissions following a hospitalisation for cardio-
vascular conditions. The primary objective of the study was to
systematically evaluate the Australian literature with the inten-
tion of determining the frequency of readmission. Secondary
objectives included: (1) identifying patient, hospital and social
factors that contribute to the risk of readmissions; (2) detailing
the potential effects of readmissions on the health system; and
(3) describing interventions that have been assessed in the
Australian setting to reduce readmissions.
Methods
Search strategy
We searched the Medline, EMBASE and Cumulative Index to
Nursing and Allied Health Literature (CINAHL) bibliographic
databases, restricting the search to English language human
clinical research articles published between 1 January 2000 and
11March 2016 to review contemporary cardiovascular practice.
The search was conducted using Medical Subject Heading
(MeSH) terms including patient readmission, cardiovascular
disease, coronary disease, cardiac surgical procedures and
Australia. The full search strategy is provided in Appendices
S1–S3, available as Supplementary Material to this paper.
We also searched the grey (not academically peer reviewed)
literature by examining the reference lists of retrieved papers
andconducting aGoogle search to identify anyadditional articles
and other policy documents. This included an exhaustive search
of Australian government and non-government stakeholder
websites for publications on the topic of readmission following
cardiovascular hospitalisations. A complete list of the grey
literature identi!ed is available in Appendix S4.
Study selection
Observational studies of cardiovascular readmissions were
included, as were studies reporting outcomes of interventions
to reduce cardiovascular readmissions. Articles relating to
cardiovascular readmissions were de!ned as articles in which:
(1) the primary or secondary objective related to readmissions;
or (2) hospital readmission was the primary outcome or a
substantive secondary outcome. Included studies were required
to recruit at least 100 adult (age !18 years) cardiovascular
patients from Australia and measure readmissions following
an in-patient admission for a cardiovascular condition. The
following types of publications were excluded: (1) review
articles without original data; (2) studies that included read-
missions as a composite end-point but failed to report readmis-
sion data separately; (3) multinational studies that included
data fromAustraliawithout reportingAustralian data separately;
and (4) studies that reported more than 50% of the data collected
before 2000.
Assessment of methodological quality
Abstracts were independently screened by two investigators
(CL, IR). All potentially relevant articles were extracted and
reviewed in full by the same two researchers for methodological
validity before inclusion in the review using standardised
critical appraisal instruments from the Joanna Briggs Institute
Meta-Analysis of Statistics Assessment and Review Instrument





(JBI-MAStARI; Appendix S5). Disagreement on article selec-
tion was resolved by discussion between reviewers.
Data extraction and synthesis
Relevant data were extracted from each article and entered into a
standardised database. Data extracted from all articles included
sample size, study design, study period (years), number of
centres, state(s), study aim, study hypothesis, primary outcome,
time of readmission measurement, type of rehospitalisation (in-
patient readmissions, emergency or both), factors affecting
readmission, !ndings, strengths and weakness. Data heteroge-
neity was investigated by evaluating study design, methodology
and reporting. A statistical test of heterogeneity was performed,
where appropriate, using the I2 test.11 Findings are reported using
the PreferredReporting Items for SystematicReviews andMeta-
Analysis (PRISMA) guidelines.12
Results
The search yielded 794 articles and two government reports, of
which 729 remained following exclusion of duplicates. Based on
abstracts, 657 articles were removed, with 72 full-texts articles
remaining. Twenty-!ve observational studies were identi!ed
that reported readmissions as anoutcome (Table1).Furthermore,
10 studies were identi!ed that described the outcomes of inter-
ventions to reduce readmissions (Table 2). The PRISMA "ow
chart of article selection is given in Fig. 1. Because studies of
interventions typically included highly selected populations, we
report our !ndings for observational studies and studies of
interventions separately.
Characteristics of observational studies of readmissions
Of the 25 included articles and reports,most (n= 11)were single-
centre studies.13–22 Less frequently, they were multicentre
(n= 7)23–29 or state-wide (n = 5)30–34 studies, with two stud-
ies35,36 failing to report the number of centres. The sample sizes
of these studies varied from 133 to 29 961 participants, with
a median value of 1660. Fourteen study designs involved
retrospective cohorts,15,18,20,23,26–28,30–35,37 with the majority
limited to Victoria (n= 9)15,18,21,24,26,29,33,34,36 and NSW
(n= 8).16,17,19,20,25,27,28,31
Most studies reported readmissions following a hospitalisa-
tion forHF (n= 10),13,14,23–26,28,30,31,36 acute coronary syndrome
(ACS; n = 7)14,18–20,28,33,35 and stroke (n= 6),15,16,27,29,32 with
three studies14,26,28 reporting readmission rates for more than
one condition. In addition, four publications reported readmis-
sion rates following procedures: PCI (n= 1)26 and coronary
arterybypass surgery (n= 3).21,22,34Readmission rates following
hospitalisation for other cardiovascular conditions and proce-
dures were infrequently reported.
When the primary objective of studies was considered,
most (n= 14) focused on determining the frequency of
readmission,13–15,17,20,23,26,28,29,32,33,36,38 whereas several (n=8)
evaluated one or more factors associated with readmissions,
including the development of a readmission risk mod-
el.16,18,19,21,22,25,30,34 Two studies evaluated the burden (de!ned
as bed days and costs) of readmissions on the healthcare sys-
tem,31,37 and a single study compared Australian readmission
rates to other nations.35
De!nition of readmissions and methods for
data collection
The de!nition of readmission was highly variable between
publications. All-cause readmission was reported in 16
studies,13,15,17,23,24,26–30,33–36 eight studies14,16,19,22,24,25,32,37
chose to report only patients returning to hospital for the same
cardiovascular diagnosis as their index hospitalisation and one
study21 did not report the type of readmission measured.
Approximately half the studies (n= 13) fully captured
readmissions by counting readmissions to any hospital in
the same state,6,15,21–24,26,28–31,33,34,37 whereas the remainder
(n = 12) only counted readmissions to the same
hospital.13,16–18,20,25–28,32,35,36 The time interval following
discharge ranged from 7 days to 5 years, with most studies
reporting readmission rates at 30 days after discharge.
Methods used to collect readmission data varied greatly.
Telephone follow-up (n= 3),13,21,29 hospital medical records
(n = 3),18,27,32 linked hospital administrative data
(n = 10)14,15,23,26,28,30,31,33,34,37 or a combination of more than
one of these methods16,17,19,20,22 was used to determine the
readmission status of patients, and four studies24,25,35,36 did not
report a method. The completeness of follow-up was not
reported formost studies.14,15,17,18,20,22,24,25,27,30–35,37,39Among
those that did report complete follow-up of all participants
enrolled in the study, only three13,23,36 reported complete fol-
low-up, with the remaining reporting loss to follow-up rates
ranging from 0.2% to 52%of the study population.16,19,21,26,28,29
Frequency of readmissions
All studies reported the frequency of readmissions at various
time points (Table 1), with readmission rates generally
(and expectedly) increasing with time. Eleven
studies13,15,17,20,23,26–29,33,36 reported all-cause readmissions
and as expected, these studies reported higher rates of readmis-
sion compared with studies reporting readmissions for the
same diagnosis as the index hospitalisation (Fig. 2).
Of the studies that reported readmissions as a proportion of
all patients discharged, readmissions were most commonly
reported at or within 30 days of the index hospitalisation
(n = 14).14,15,18,21,23–28,30,31,34,35 The all-cause readmission rate
among these studies was highly variable, ranging from 6.3% to
27%, with a median value of 13%. When individual conditions
for initial hospitalisation were assessed, 30-day all-cause read-
mission following HF (n= 8 studies) ranged from 10.1% to 27%
(median 18.9%), that following stroke (n= 3 studies) ranged
from 6.5% to 11% (median 11%) and that following AMI (n= 3
studies) ranged from 12.7% to 17% (median 12.9%).
Extractable 30-day data were available in 11 studies
(n = 123 874, Fig. 3). However, we could not pool the results of
the individual studies to provide a summary frequency of read-
missions due to high heterogeneity among studies (Q-test,
c2 = 2395.9, P < 0.001; I2 = 99.5). Signi!cant heterogeneity
persisted when individual conditions were evaluated, prohibit-
ing pooling of results by condition (HF (n= 6
studies),13,23,26,28,30,31 c2 = 177.27, P < 0.001, I2 = 97.2%; AMI
(n = 3 studies),18,28,35 c2 = 21.65, P < 0.001, I2 = 90.8%; stroke
(n = 3 studies),15,27,28 c2 = 54.71, P < 0.001, I2 = 96.3%).


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Of the studies that reported 30-day readmission rates, one
study assessed variation in readmission rates among hospitals for
AMI, HF and stroke, with the results indicating marked institu-
tional variation in the risk-standardised readmission ratio at
30 days, although the range among hospitals was not reported.28
Of the studies that reported readmission rates beyond30days, the
highest number of readmissions was reported among patients
withHF (76.9%of patientswere readmitted for a cardiovascular-
related diagnosis during a median follow-up of 5.3 years).14
Risk factors associated with readmissions
A risk model to predict readmission or evaluate speci!c patient
factors associated with an increased risk of readmission was
developed in eight studies.16,18,19,21,22,25,30,34 These studies used
data from single16,18,19,21,22,30 and multiple25,34 centres, and
evaluated readmissions following initial hospitalisation for
HF,25,30 ACS,18,19 coronary artery bypass graft surgery21,22,34
and ischaemic stroke.16 Appendix S6 provides a list of all patient
factors tested in risk prediction models.
Patient factors that were signi!cant inmodels were varied but
included length of stay30 and living alone,21,30 prior emergency
department attendance,18,34 prior cardiac diagnosis and proce-
dures,18 renal impairment,18 electrolyte disturbance,18 sedentary
lifestyle,28 older age28 and a higher score on the Charlson
comorbidity index.25,34 Two studies19,22 evaluated whether psy-
chiatric comorbidities increased the risk of readmission. A study
of ACS patients found readmissions to be more prominent in
patients who had pre-existing depression or developed depres-
sion after their ACS, compared with patients without a history
of depression (c2 = 8.84, d.f. = 2, P= 0.01).19 Similarly, patients
with increased stress, anxiety and depression before coronary
artery bypass surgery had increased rates of 6-month readmis-
sion.22 Finally, only one study32 from the Northern Territory
evaluated whether Indigenous status increased the risk of read-
missions following a stroke. That study concluded that the risk
of readmission for stroke was almost doubled in Indigenous
patients compared with the Caucasian population (hazard ratio
1.82; 95% con!dence interval 1.32–2.51).32
Studies that reported the burden of readmissions
The burden of readmissions can be measured in various ways,
including cost, beddays and from the perspective of the patient or
healthcare system. Two studies estimated the burden of read-
missions in Australia.31,37 A single-centre study from Western
Australia foundpatientswhowere readmitted following an index
hospitalisation for atherothrombotic disease cost the healthcare
system A$101million over 2 years, representing approximately
42% of the total cost of care over this period.37 A study of 29 161
HF patients followed for 5 years using linked data from NSW
measured theburdenplacedon thehealthcare systembycounting
the number of bed days31 and showed that there were 954 888
hospital bed-days used over the study period as a result of all-
cause readmissions.
Studies of interventions to reduce readmissions
Interventions testing the reduction of readmissions as a key
outcome were reported in 10 studies,40–49 including !ve rando-

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































interventions (n= 8 studies) targeted HF41–47,49 and consisted of
a health professional conducting a structured intervention at
either the patient’s home (e.g. home visits by a nurse, pharmacist
or other healthcare professional) or at a medical facility, usually
within a few weeks after discharge (for a description of all
interventions, see Appendix S7).
Similar to the observational studies, the de!nition of a
readmission varied. Readmissions were measured at <30 days,46
6months,42,45 12months41,44,48 and >12months.40,43,47,49 Read-
missionswere counted using linked data by one study,44whereas
another studyused a telephone call to the patient;43 the remaining
studies used hospital records.
A statistically signi!cant decline in readmissions in favour
of the intervention was observed in four studies, although only
one was a randomised trial. Davidson et al.41 evaluated an
individualised 12-week nurse-coordinated multidisciplinary
rehabilitation program for HF patients in a randomised trial.
Patients in the intervention group had a lower 12-month all-
cause readmission rate than the control group (44% vs 69%;
P= 0.01). Driscoll et al.42 examined the effect of chronic HF
management programs across 27 centres (a mixture of hospital
and home-based programs). However, that study did not
evaluate the outcome of the HF management programs against
a control group. Instead, each program was ranked using a
quality improvement tool (intervention score) based on their
level of evidence, and the results indicated that those with a high
intervention score had a lower readmission rate (14% vs 25%;
P= 0.005).42 Roughead et al.44 evaluated whether a home med-
ication review by both a general practitioner and a pharmacist
among veterans diagnosed with HF reduced readmissions in an
observational cohort. observing a 45% reduction in readmissions
for patients who received the home medication review. Finally,
Scott et al.46 tested hospital performance feedback and a mul-
tifaceted quality improvement intervention using a before–after
study design. A signi!cant reduction in same-cause readmission
was observed with the intervention in patients with HF (7.2% vs
2.4%; P= 0.02) but not in patients with an ACS.46
Discussion
This scoping review was performed to summarise the contem-
porary Australian literature on readmissions following hospita-
lisation for cardiovascular disease. We found 25 studies
evaluating hospital readmissions over the past 16 years. We
Additional records identified
through other sources (n = 2)
Records identified through
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composite endpoint (n = 20)
readmissions not core focus
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Fig. 1. Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) "ow chart of article search and selection for
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Fig. 2. (a) All-cause readmission rates reported from all observational studies classi!ed by type of disease or procedure and
(b) readmission rates of all observational studies that reported readmissions for the same cause as the initial hospitalisation. Studies
have been classi!ed into the disease or procedure reported at the patient’s initial hospitalisation. ACS, acute coronary syndrome;
AF, atrial!brillation;ATD, atherothrombotic disease; CABG, coronary artery bypass graft surgery;HF, heart failure;MI,myocardial
infarction; PCI, percutaneous coronary intervention.





observed a median 30-day readmission rate of 13% (range
6.3–27%), with reported readmission rates of 10.1–27% for HF,
6.5–11% for stroke and 12.7–17% for AMI. These !ndings
parallel the high readmission rates observed in the international
literature. However, these !gures should be interpreted with
caution because we could not pool readmissions data due to the
substantial heterogeneity among studies. Notably, there were
considerable variations in time point at which readmissionswere
measured, whether disease-speci!c or all-cause readmissions
were counted and the method and accuracy of ascertaining
the readmissions status. Furthermore, we found only a few
interventions that successfully reduced readmissions, highlight-
ing the need for clinical trials to !nd more effective strategies
to reduce readmissions.
This review also identi!ed several knowledge gaps in the
Australian literature. Although readmission after HF, stroke and
AMIwas reported, other commonand important conditions, such
as atrial !brillation and peripheral arterial disease, were rarely
studied and readmission rates for these common conditions are
unknown. Similarly, the risk of readmission among disadvan-
taged populations relevant to the Australian setting, such as
those in regional and remote areas and Indigenous populations,
is uncertain. Moreover, only one Australian study evaluated
hospital variation in early readmission rates despite early read-
missions being correlated with quality of hospital care.50 The
substantial variation in the readmission rates among hospitals
reported in this study suggests concerning variation in care
quality, although whether such variation extends to other
Australian regions is uncertain. Finally, we found a paucity of
studies assessing the effects of hospital readmissions on the
healthcare system. This information is crucial for developing
effective clinical and policy strategies to reduce readmissions
because costs and resource considerations are a major driver of
decision making for health. Taken as a whole, this research
indicates the need for Australia-wide studies of readmissions for
common cardiovascular conditions to determine the frequency,
as well as the extent of variation among Australian hospitals
and regions.
This review also highlights the need to develop and test
clinical interventions to reduce readmissions. Interventions to
reduce readmissions that have been trialled in Australia have
focused almost exclusively on home- or hospital-based manage-
ment of HF. These long-term disease management programs
focus on reducing disease-speci!c (HF) readmissions, even
thoughmost readmittedpatients return tohospitalwith diagnoses
that differ from their index hospitalisation.51,52 Thus, interven-
tions that solely target the initial condition may be inadequate to
reduce all-cause readmissions, which may explain, in part, the
limited effectiveness of interventions observed in this review.
Although some readmissions inevitably occur due to disease
progression, the quality of care transition from hospital to
community also contributes to early readmission.53,54 Although
none of the existing interventions reviewed speci!cally targeted
care transition practices, comprehensive care transition inter-
ventions have been shown to be effective in the international
literature. For example, the Re-Engineered Discharge project in
Kociol et al.35 – AMI
Rana et al.18 – AMI
BHI28 – AMI
Slamowicz et al.34 – CABG
Paul et al.13 – HF
Robertson et al.31 – HF
Saito et al.23 – HF
Huynh et al.30 – HF
BHI28 – HF
Lefkovits et al.26 – HF
Lefkovits et al.26 – PCI
Kilkenny et al.27 – Stroke
BHI28 – Stroke





















Fig. 3. Forest plot of 30-day all-cause readmissions. Note, some studies reported data for more than one cohort. AMI, acute
myocardial infarction; CABG, coronary artery bypass graft surgery; CI, con!dence interval; HF, heart failure; PCI, percutaneous
coronary intervention.





the US, consisting of seven strategies to improve the transition
from hospital to community, reported a 30% reduction in
30-day readmissions and lowered hospital costs by US$416 per
patient.55 However, discharge and follow-up care processes are
highly contextual and, due to differences in health systems,
interventions tested internationally may not be effective in the
Australian setting. Thus, it is essential that such interventions
are customised and tested in the local setting to determine their
effectiveness in reducing readmissions.
This review also highlights the need for standardisedmethods
to measure and report readmissions in Australia. Standardised
methods are necessary for sustained quality improvement
efforts. For example, the USGovernment’s Centre for Medicare
andMedicaid Services and the American College of Cardiology
publicly report readmission rates for AMI,56 stroke57 HF3
and PCI58 among US hospitals using nationally standardised
methods. These efforts have stimulated clinical and policy
interventions, such as the American Heart Association’s Target
HF program (http://www.heart.org/en/professional/quality-im-
provement/target-heart-failure, accessed 20 January 2018) and
the American College of Cardiology’s Hospital to Home initia-
tive (https://cvquality.acc.org/initiatives/hospital-to-home/about-
h2h, accessed 20 January 2018), as well as policy initiatives by
the US Government, such as the Hospital Readmission Reduc-
tion Program,59 and is thought to contribute to the declining
readmission rates in the US Medicare population.60 Developing
standardisedmethods to report and compare readmission rates in
Australia may act as a catalyst for similar large-scale clinical and
policy efforts to reduce readmissions.
This review has important limitations. We chose to focus
solely on readmissions following hospitalisation for cardiovas-
cular disease and the !ndings may not be generalisable to
other conditions. In addition, grey literature was included; even
though grey literature has not been academically peer reviewed,
it makes an important contribution to this study because we
can present a more in-depth evaluation of readmissions in the
Australian setting.
Conclusions
Relatively high rates of readmissions are reported for cardio-
vascular conditions in Australia, paralleling the high rates of
readmissions reported in the international literature, although
the Australian literature should be interpreted with caution due
to the substantial methodological heterogeneity among studies.
Furthermore, several knowledge gaps exist, most notably a
paucity of studies assessing the effects of hospital readmissions
on the healthcare system. Moreover, only a few interventions
have been shown to successfully reduce readmissions. Further
research is required to fully determine the burden of readmis-
sions, develop standardised measures to report readmissions
and to test interventions to reduce readmissions in theAustralians
setting.
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Appendix S1: Search terms for OVID Medline 
Date searched – 11 March 2016 
Patient Readmission OR re-presentation.mp. OR Patient Admission OR representation.mp. OR hospitalisation.mp. 
OR Hospitalization OR Treatment Outcome OR revisit$.tw. OR readmission$.tw. OR rehospitali$.tw. OR 
rehospitaliz$.tw. OR represent$.tw. OR rehospitali$.tw. OR unplanned.tw. OR return.tw. AND exp Australia OR 
western australia.tw. OR new south wales.tw. OR south australia.tw. OR victoria.tw. OR queensland.tw. OR 
northern territory.tw. OR australian capital territory.tw. OR tasmania.tw. OR   australia.tw. OR perth.tw. OR 
sydney.tw. OR adelaide.tw. OR melbourne.tw. OR brisbane.tw. OR darwin.tw. OR canberra.tw. OR hobart.tw. AND  
*Cardiovascular Diseases OR Adult OR *Heart Failure OR *Stroke OR  *Peripheral Arterial Disease OR  
*Peripheral Vascular Diseases OR *Atrial Fibrillation OR  *Heart Valves OR   *Aortic Valve OR *Heart Valve 
Diseases OR *Atherosclerosis OR *Myocardial Infarction *Coronary Disease/ or *Acute Coronary Syndrome or 
*Angina, Unstable or *Myocardial Ischemia or *Coronary Artery Disease OR *Cardiovascular Diseases OR 
*Cardiac Surgical Procedures OR *Angiography/ or *Coronary Angiography/ OR *Chest Pain OR *Coronary Artery 
Bypass OR *Cardiopulmonary Bypass/ OR  *Cardiac Catheterization/ 
 







Appendix S2: Search Terms for EMBASE  
Date searched – 28 July 2016 
 
're presentation' OR hospitalisation OR revisit OR revisit* OR readmi* OR rehospitali* OR unplanned AND 
('australia'/exp OR australia OR  'western australia' OR 'new south wales' OR  'south australia' OR 'victoria' OR 
'queensland' OR 'northern territory' OR 'australian capital territory' OR tasmania OR perth OR sydney OR  adelaide 
OR melbourne OR brisbane OR darwin OR canberra OR hobart) AND ('cardiovascular disease*' OR 'heart failure' 
OR stroke OR 'peripheral artery disease' OR 'peripheral vascular disease' OR 'atrial fibrillation' OR 'heart valves' OR 
atherosclerosis OR 'myocardial infarction' OR 'coronary disease' OR 'chest pain' OR 'coronary artery bypass' OR 
'cardiopulmonary bypass' OR 'cardiac catheteri*ation') AND ([adult]/lim OR [middle aged]/lim OR [aged]/lim) 









Appendix S3: Search terms for CINHAL 
Date searched - 21 September 2016 
coronary disease OR acute coronary syndrome OR angina OR myocardial ischemia OR coronary artery disease OR 
Cardiac Surgical Procedures OR angiography OR Chest Pain OR coronary artery bypass* OR Cardiopulmonary 
Bypass OR cardiac catheterization) AND (australia OR western australia OR new south wales OR south australia 
OR victoria OR queensland OR northern territory OR australian capital territory OR tasmania OR perth OR sydney 
OR adelaide  OR melbourne OR brisbane OR darwin OR canberra OR hobart )) AND (cardiovascular disease OR 
adult OR heart failure OR stroke OR peripheral artery disease OR peripheral vascular disease OR atrial fibrillation 
OR heart valve* OR aortic valve* OR heart valve disease OR atherosclerosis OR myocardial infarction OR coronary 
disease OR acute coronary syndrome OR angina OR myocardial ischemia OR coronary artery disease OR Cardiac 
Surgical Procedures OR angiography OR Chest Pain OR coronary artery bypass* OR Cardiopulmonary Bypass OR 
cardiac catheterization )) AND (Patient Readmission OR re-present* OR Patient Admission OR represent* OR 
hospitalisation OR hospitalization OR treatment outcomes OR revisit* OR readmission* OR rehospitali* OR 
unplanned   AND coronary disease OR acute coronary syndrome OR angina OR myocardial ischemia OR coronary 
artery disease OR Cardiac Surgical Procedures OR angiography OR Chest Pain OR coronary artery bypass* OR 
Cardiopulmonary Bypass OR cardiac catheterization AND coronary disease OR acute coronary syndrome OR 
angina OR myocardial ischemia OR coronary artery disease OR Cardiac Surgical Procedures OR angiography OR 
Chest Pain OR coronary artery bypass* OR Cardiopulmonary Bypass OR cardiac catheterization 
 
Limiters - Published Date: 200000101-20160831; English Language; Research Article; Human; Journal Subset: 






Appendix S4: Search terms for grey literature  
A Google search was conducted on Sunday 11 Sep 2016 using the terms ‘Australia hospital readmissions 
cardiovascular’. The first 20 pages of about 149,000 results were analysed. There were 10 links per page so first 200 
websites were searched.  
The Australian and New Zealand clinical trial registry was searched on 1 October 2016 with search terms 
cardiovascular readmission and gave 14 results.  
 
Moreover, the Australian clinical trials website was also searched on 1 October 2016 with the search parameters 
readmission cardiovascular and gave 16 results.  
 
All federal and state government health websites, the Australian Institute of Health and Welfare, the Australian 
Bureau of Statistics, the Australian Heart Foundation, the Australian Commission on Safety and Quality in Health 






















Appendix S6: Predictors of readmissions 
Paper Time Condition Significant 
Variables 
Insignificant Variables C-Stat 
Murphy et al 
(2008)1 









Country of birth 





Family history of CVD 
Diabetes 
Previous MI 
Length of time on 
waiting list  
Length of hospital stay 
NHYA class  
HADS (depression) on 
admission  
Not given 




















Nil given AUC for 3 
models 
HOSPITAL 

































Ischemic stroke Depression (but 
not after 
adjustment) 
Anxiety Not in the 
paper 


































































Presence of life 
threatening 
arrhythmia 


























Past admission for heart 
condition 
Current smo0ker 




















Years since HF 
diagnosis 
Tully et al 
(2008)7 





CCS class III/IV  
hypertension 















Not in the 
paper 
*Models for 7 days and 6-month models not present. 
HADS = hospital anxiety and depression scale 
CABG = coronary artery bypass graft 
CVD = cardiovascular disease 
ACS = acute coronary syndrome 
IHD = ischemic heart disease  
MI = myocardial infarction 
NYHA = New York Heart Association classification 
LOS = length of stay 






Appendix S7: Description of the interventions  
Study  Intervention Description 
Davidson et al 
(2010) 9 
 
12-week multidisciplinary weekly cardiac rehab program. Patients were counselled to 
undertake home-based exercise program tailored to their needs, promote self-
management and treatment. Nursing, pharmacy, physiotherapy occupational therapy and 
dieticians involved. Compared to usual care. 
Driscoll et al 
(2013)10 
A survey was mailed to 48 program coordinators asking them to identify specific 
interventions implemented in their program. Examined the effect of chronic heart failure 
management programs from 27 centres (mixture of hospital and home-based programs). 
Each program was given an intervention score 
Stewart et al 
(2012)11 
The nurse led clinic-based intervention group received ongoing management via 
specialist, multidisciplinary clinic without home visits. Home intervention was 
predominantly managed via out-reach program of home visits by a specialist heart 
failure nurse with close liaison with the patient’s family physician and referral to other 
health care services as required. 
Roughead et al 
(2009)12 
The exposed group were veterans who had received Home Medicine Review (HMR) and 
had all health services fully subsidised by the Department of Veteran Affairs (DVA), 
were dispensed beta blocker subsidised for heart failure in the 6 months before the HMR 
and aged 65 years and older at time of review. The unexposed group were veterans who 
had all health services fully subsidised by the DVA and aged 65 years and older who had 
been dispensed a beta blocker but had NOT had an HMR. 
Barker et al 
(2012)13 
A pharmacist visited patients within 96 hours of discharge and a 6-month follow-up. 
Usual care discussion was generic about how they were feeling, no pharmacy advice was 
given unless patient asked. The intervention group had a discussion about medication 
regime to ensure medication use was as prescribed and followed evidence based 
guidelines, follow-up appointment and expired medications and disposed of them. 
Scott et al 
(2004)14 
Provision of comparative baseline feedback at a facilitative workshop combined with 
hospital-specific quality-improvement interventions supported by onsite quality officers 
and a central program management group.  
Mudge et al 
(2010)15 
Education and performance feedback for hospital and primary care practitioners, clinical 
decision support tools, individualised guideline-based treatment plans, patient education 
and self-management support and improved hospital community integration.  
Stewart et al 
(1999)16 
Both arms of the study were essentially nurse-led (two teams at each site) with tertiary 
qualified nurses with post-graduate qualifications in cardiac care and experience in heart 
failure management. The key point of differentiation was the mode of delivery, the 




disciplinary clinic and no home visits were applied. Alternatively, the home intervention 
group was predominantly managed via an out-reach program of home visits by a 
specialist heart failure nurse with close liaison with the patient's family physician and 
referral to other health care services as required. This approach did not preclude home-
based intervention patients attending a cardiology outpatient clinic. 
Stewart et al 
(2015)17 
Face-to-face home visits with additional telephone support Communications with other 
health professionals delivered via automated reporting systems based on standardised 
and structured assessments 
Martin et al 
(2016)18 
A single and simultaneous page to the cardiology team to facilitate rapid access to the 
cardiac catheterisation laboratory, this was called the ‘Cath Lab Code’. In addition, the 
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Appendix S1: Search terms for OVID Medline 
Date searched – 11 March 2016 
Patient Readmission OR re-presentation.mp. OR Patient Admission OR representation.mp. 
OR hospitalisation.mp. OR Hospitalization OR Treatment Outcome OR revisit$.tw. OR 
readmission$.tw. OR rehospitali$.tw. OR rehospitaliz$.tw. OR represent$.tw. OR 
rehospitali$.tw. OR unplanned.tw. OR return.tw. AND exp Australia OR western australia.tw. 
OR new south wales.tw. OR south australia.tw. OR victoria.tw. OR queensland.tw. OR 
northern territory.tw. OR australian capital territory.tw. OR tasmania.tw. OR   australia.tw. 
OR perth.tw. OR sydney.tw. OR adelaide.tw. OR melbourne.tw. OR brisbane.tw. OR 
darwin.tw. OR canberra.tw. OR hobart.tw. AND  *Cardiovascular Diseases OR Adult OR 
*Heart Failure OR *Stroke OR  *Peripheral Arterial Disease OR  *Peripheral Vascular 
Diseases OR *Atrial Fibrillation OR  *Heart Valves OR   *Aortic Valve OR *Heart Valve 
Diseases OR *Atherosclerosis OR *Myocardial Infarction *Coronary Disease/ or *Acute 
Coronary Syndrome or *Angina, Unstable or *Myocardial Ischaemia or *Coronary Artery 
Disease OR *Cardiovascular Diseases OR *Cardiac Surgical Procedures OR *Angiography/ 
or *Coronary Angiography/ OR *Chest Pain OR *Coronary Artery Bypass OR 
*Cardiopulmonary Bypass/ OR  *Cardiac Catheterization/ 
 
Limited to English language and humans and yr="2000 -Current" and "all adult (19 plus 




Appendix S2: Search Terms for EMBASE  
Date searched – 28 July 2016 
 
're presentation' OR hospitalisation OR revisit OR revisit* OR readmi* OR rehospitali* OR 
unplanned AND ('australia'/exp OR australia OR  'western australia' OR 'new south wales' OR  
'south australia' OR 'victoria' OR 'queensland' OR 'northern territory' OR 'australian capital 
territory' OR tasmania OR perth OR sydney OR  adelaide OR melbourne OR brisbane OR 
darwin OR canberra OR hobart) AND ('cardiovascular disease*' OR 'heart failure' OR stroke 
OR 'peripheral artery disease' OR 'peripheral vascular disease' OR 'atrial fibrillation' OR 'heart 
valves' OR atherosclerosis OR 'myocardial infarction' OR 'coronary disease' OR 'chest pain' 
OR 'coronary artery bypass' OR 'cardiopulmonary bypass' OR 'cardiac catheteri*ation') AND 






Appendix S3: Search terms for CINHAL 
Date searched - 21 September 2016 
coronary disease OR acute coronary syndrome OR angina OR myocardial ischaemia OR 
coronary artery disease OR Cardiac Surgical Procedures OR angiography OR Chest Pain OR 
coronary artery bypass* OR Cardiopulmonary Bypass OR cardiac catheterization) AND 
(australia OR western australia OR new south wales OR south australia OR victoria OR 
queensland OR northern territory OR australian capital territory OR tasmania OR perth OR 
sydney OR adelaide  OR melbourne OR brisbane OR darwin OR canberra OR hobart )) AND 
(cardiovascular disease OR adult OR heart failure OR stroke OR peripheral artery disease OR 
peripheral vascular disease OR atrial fibrillation OR heart valve* OR aortic valve* OR heart 
valve disease OR atherosclerosis OR myocardial infarction OR coronary disease OR acute 
coronary syndrome OR angina OR myocardial ischaemia OR coronary artery disease OR 
Cardiac Surgical Procedures OR angiography OR Chest Pain OR coronary artery bypass* OR 
Cardiopulmonary Bypass OR cardiac catheterization )) AND (Patient Readmission OR re-
present* OR Patient Admission OR represent* OR hospitalisation OR hospitalization OR 
treatment outcomes OR revisit* OR readmission* OR rehospitali* OR unplanned   AND 
coronary disease OR acute coronary syndrome OR angina OR myocardial ischaemia OR 
coronary artery disease OR Cardiac Surgical Procedures OR angiography OR Chest Pain OR 
coronary artery bypass* OR Cardiopulmonary Bypass OR cardiac catheterization AND 
coronary disease OR acute coronary syndrome OR angina OR myocardial ischaemia OR 
coronary artery disease OR Cardiac Surgical Procedures OR angiography OR Chest Pain OR 
coronary artery bypass* OR Cardiopulmonary Bypass OR cardiac catheterization 
 
Limiters - Published Date: 200000101-20160831; English Language; Research Article; 
Human; Journal Subset: Australia & New Zealand; Publication Type: Journal Article; 
Language: English   
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Appendix S4: Search terms for grey literature  
A Google search was conducted on Sunday 11 Sep 2016 using the terms ‘Australia hospital 
readmissions cardiovascular’. The first 20 pages of about 149,000 results were analysed. 
There were 10 links per page so first 200 websites were searched.  
The Australian and New Zealand clinical trial registry was searched on 1 October 2016 with 
search terms cardiovascular readmission and gave 14 results.  
 
Moreover, the Australian clinical trials website was also searched on 1 October 2016 with the 
search parameters readmission cardiovascular and gave 16 results.  
 
All federal and state government health websites, the Australian Institute of Health and 
Welfare (AIHW), the Australian Bureau of Statistics (ABS), the Australian Heart Foundation, 
the Australian Commission on Safety and Quality in Health Care and the Bureau of Health 

















Appendix S6: Predictors of readmissions 
Paper Time Condition Significant Variables Insignificant Variables C-Stat 





History of hypertension  
Higher HADS (anxiety) on 
admission 
Sex 
Country of birth 
School leaving age 
Manual occupation 
High cholesterol Smoking status 
BMI 
Family history of CVD 
Diabetes 
Previous MI 
Length of time on waiting list  
Length of hospital stay NHYA class  
HADS (depression) on admission  
Not given 




MI Total time in emergency 
Number of emergencies 
Number of emergency-to-ward 
transfers 
Nil given AUC for 3 models 
HOSPITAL score = 0.60 
Comorbidities =0.53 









Acute kidney failure 
Urinary tract infection 
Long-term use of anticoagulants 
Disorders of magnesium 
metabolism  
Left ventricular failure 
Presence of cardiac device 
Invasive coronary investigation 
undertaken in past year 
Debridement of skin and 
subcutaneous tissue 






Depression (but not after 
adjustment) 
Anxiety Not in the paper 
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Length of stay 
Living alone 
Age 
Discharge during winter 
Remoteness index categories 
Number of coded diagnoses at 
discharge 
Male 





HF NYHA classification 






Presence of life-threatening 
arrhythmia 
Presence of abnormal troponin 

















Presence of abnormal troponin 
Remoteness index 
Discharge during winter 
Presence of life threatening 
arrhythmia 
 
0.82 for death 
 
0.69 for readmission 





CABG on admission 
Diabetes history 
LVEF <35% 
Past history of CVA/TIA 
New depression onset post 
baseline 
Female sex 
Past admission for heart condition 
Current smo0ker 














Years since HF diagnosis 
0.8 
Tully et al (2008)352 6 month CABG 
surgery 
Peripheral vascular disease 
 
Depression  
Aged ≥ 71 
CCS class III/IV  
hypertension 
Not in the paper 











Not in the paper 
*Models for 7 days and 6 month models not present. 
HADS = hospital anxiety and depression scale, CABG = coronary artery bypass graft, CVD = cardiovascular disease, ACS = acute coronary syndrome, IHD 
= ischaemic heart disease , MI = myocardial infarction, NYHA = New York Heart Association classification, LOS = length of stay, CCS = Canadian 




Appendix S7: Description of the interventions  
Study  Intervention Description 
Davidson et al 
(2010)355 
 
12-week multidisciplinary weekly cardiac rehab program. Patients 
were counselled to undertake home-based exercise program tailored 
to their needs, promote self-management and treatment. Nursing, 
pharmacy, physiotherapy occupational therapy and dieticians 
involved. Compared to usual care. 
Driscoll et al 
(2013)356 
A survey was mailed to 48 program coordinators asking them to 
identify specific interventions implemented in their program. 
Examined the effect of chronic heart failure management programs 
from 27 centres (mixture of hospital and home-based programs). Each 
program was given an intervention score 
Stewart et al 
(2012)362 
The nurse led clinic-based intervention group received ongoing 
management via specialist, multidisciplinary clinic without home 
visits. Home intervention was predominantly managed via out-reach 
program of home visits by a specialist heart failure nurse with close 
liaison with the patient’s family physician and referral to other health 
care services as required. 
Roughead et al 
(2009)358 
The exposed group were veterans who had received Home Medicine 
Review (HMR) and had all health services fully subsidised by the 
Department of Veteran Affairs (DVA), were dispensed beta blocker 
subsidised for heart failure in the 6 months before the HMR and aged 
65 years and older at time of review. The unexposed group were 
veterans who had all health services fully subsidised by the DVA and 
aged 65 years and older who had been dispensed a beta blocker but 
had NOT had an HMR. 
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Barker et al 
(2012)359 
A pharmacist visited patients within 96 hours of discharge and a 6-
month follow-up. Usual care discussion was generic about how they 
were feeling, no pharmacy advice was given unless patient asked. The 
intervention group had a discussion about medication regime to 
ensure medication use was as prescribed and followed evidence based 
guidelines, follow-up appointment and expired medications and 
disposed of them. 
Scott et al 
(2004)360 
Provision of comparative baseline feedback at a facilitative workshop 
combined with hospital-specific quality-improvement interventions 
supported by onsite quality officers and a central program 
management group.  
Mudge et al 
(2010)361 
Education and performance feedback for hospital and primary care 
practitioners, clinical decision support tools, individualised guideline-
based treatment plans, patient education and self-management support 
and improved hospital community integration.  
Stewart et al 
(1999)451 
Both arms of the study were essentially nurse-led (two teams at each 
site) with tertiary qualified nurses with post-graduate qualifications in 
cardiac care and experience in heart failure management. The key 
point of differentiation was the mode of delivery, the clinic-based 
intervention group received ongoing management via a specialist, 
multi-disciplinary clinic and no home visits were applied. 
Alternatively, the home intervention group was predominantly 
managed via an out-reach program of home visits by a specialist heart 
failure nurse with close liaison with the patient's family physician and 
referral to other health care services as required. This approach did 




Stewart et al 
(2015)363 
Face-to-face home visits with additional telephone support 
Communications with other health professionals delivered via 
automated reporting systems based on standardised and structured 
assessments. 
Martin et al 
(2016)364 
A single and simultaneous page to the cardiology team to facilitate 
rapid access to the cardiac catheterisation laboratory, this was called 
the ‘Cath Lab Code’. In addition, the Cath Lab Code with a pre-
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The tables in this Appendix C depict the validity of ActiGraph wear time. 
 
Table 1: For all patients who wore an ActiGraph (n=92), regardless of the wear time. 
Average time worn (%) Number of patients  % of patients 
0 1 1.09 
4.4 1 1.09 
41.1 1 1.09 
42.8 1 1.09 
44 1 1.09 
44.7 1 1.09 
44.9 1 1.09 
46.3 1 1.09 
51.8 1 1.09 
59.5 1 1.09 
67 3 3.26 
67.8 1 1.09 
70.3 1 1.09 
74 2 2.17 
74.3 1 1.09 
74.4 1 1.09 
75 1 1.09 
75.5 1 1.09 
77 1 1.09 
77.4 1 1.09 
78.4 1 1.09 
78.8 1 1.09 
79.3 1 1.09 
80 2 2.17 
80.4 1 1.09 
81.6 1 1.09 
82 2 2.17 
83.5 1 1.09 
84.3 1 1.09 
84.3 1 1.09 
84.5 1 1.09 
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84.7 1 1.09 
85.4 1 1.09 
85.5 1 1.09 
86 1 1.09 
86.5 1 1.09 
86.6 1 1.09 
87 1 1.09 
87.4 1 1.09 
88.3 1 1.09 
88.7 1 1.09 
88.8 1 1.09 
89 1 1.09 
89.5 1 1.09 
90 1 1.09 
91.3 1 1.09 
91.4 1 1.09 
91.6 1 1.09 
91.9 1 1.09 
92 4 4.35 
93.2 1 1.09 
94.6 1 1.09 
94.8 1 1.09 
96.3 1 1.09 
96.5 1 1.09 
96.8 1 1.09 
97.4 1 1.09 
97.7 1 1.09 
97.9 1 1.09 
98 1 1.09 
98.6 1 1.09 
98.8 1 1.09 
98.95 1 1.09 
NA 3 3.26 
100 18 19.6 
Total 92  
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Three patients who had NA as a wear time, this was because the data did not have useable or 
interpretable data.  
 
So, there were 89 patients with ActiGraph data that were recorded with wear times wearing 
from 0 to 100% wear time.  
 
From this data we lowered the average wear time being >= to 80% (there were 63 patients), 
shown in Table 2a and 2b. 
 
Table 2a: Patients who had a wear time ≥ 80% (n=63). 
Average time worn (%) Number of patients % of patients 
80 2 2.2 
80.4 1 1.1 
81.6 1 1.1 
82 2 2.2 
83.5 1 1.1 
84.3 1 1.1 
84.3 1 1.1 
84.5 1 1.1 
84.7 1 1.1 
85.4 1 1.1 
85.5 1 1.1 
86 1 1.1 
86.5 1 1.1 
86.6 1 1.1 
87 1 1.1 
87.4 1 1.1 
88.3 1 1.1 
88.7 1 1.1 
88.8 1 1.1 
89 1 1.1 
89.5 1 1.1 
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90 1 1.1 
91.3 1 1.1 
91.4 1 1.1 
91.6 1 1.1 
91.9 1 1.1 
92 4 4.4 
93.2 1 1.1 
94.6 1 1.09 
94.8 1 1.09 
96.3 1 1.09 
96.5 1 1.09 
96.8 1 1.09 
97.4 1 1.09 
97.7 1 1.09 
97.9 1 1.09 
98 1 1.09 
98.6 1 1.09 
98.8 1 1.09 
98.95 1 1.09 
100 18 19.6 




Table 2b: Differences between patients with ≥80% wear time and <80% wear time. Simple t-
test and chi2 tests were performed to determine a P value.  
 
 Weartime (%)  
 <80% (n=29) ≥80% (n=63) P value 
Age 71±12.1 66.5±13.3 0.1246 
Female 11/29 =  15/63 = 0.162 
ESS baseline 6.7±4.2 6.1±4.7 0.5964 
EQ5D baseline 58.8±26.5 58.9±28.4 0.9789 
PSQI baseline 5.2±3.1 7.1±4.2 0.0371 
STOP BANG baseline 4.1±1.4 4.1±1.5 0.9415 
Body Mass Index 28.1±5.6 30.1±5.4 0.1138 
Neck circumference 39.4±2.5 39.2±4.1 0.8496 





Table 3a: Patients who had a wear time ≥ 75% (n=70). 
Average time worn (%) Number of patients  % of patients 
75 1 1.09 
75.5 1 1.09 
77 1 1.09 
77.4 1 1.09 
78.4 1 1.09 
78.8 1 1.09 
79.3 1 1.09 
80 2 2.17 
80.4 1 1.09 
81.6 1 1.09 
82 2 2.17 
83.5 1 1.09 
84.3 1 1.09 
84.3 1 1.09 
84.5 1 1.09 
84.7 1 1.09 
85.4 1 1.09 
85.5 1 1.09 
86 1 1.09 
86.5 1 1.09 
86.6 1 1.09 
87 1 1.09 
87.4 1 1.09 
88.3 1 1.09 
88.7 1 1.09 
88.8 1 1.09 
89 1 1.09 
89.5 1 1.09 
90 1 1.09 
91.3 1 1.09 
91.4 1 1.09 
91.6 1 1.09 
91.9 1 1.09 
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92 4 4.35 
93.2 1 1.09 
94.6 1 1.09 
94.8 1 1.09 
96.3 1 1.09 
96.5 1 1.09 
96.8 1 1.09 
97.4 1 1.09 
97.7 1 1.09 
97.9 1 1.09 
98 1 1.09 
98.6 1 1.09 
98.8 1 1.09 
98.95 1 1.09 
100 18 19.6 





Table 3b: Differences between patients with ≥75% wear time and <75% wear time. Simple t-
test and chi2 tests were performed to determine a p value.  
 Wear time (%)  
 <75% (n=22) ≥75% (n=70) P value 
Age 71.3±13.3 66.8±12.9 0.1620 
Female 10 16 0.0400 
ESS baseline 6.5±4.2 6.2±4.7 0.8401 
EQ-5D-3L baseline 55.2±29.1 60.0±27.3 0.4955 
PSQI baseline 4.6±2.7 7.1±4.2 0.0101 
STOP BANG baseline 3.9±1.4 4.1±1.5 0.5125 
Body Mass Index 28.8±6.1 29.7±5.3 0.4895 
Neck circumference 39.5±2.8 39.2±3.9 0.7898 




Table 4a: Patients who had a wear time ≥ 70% (n=75).   
Average time worn (%) Number of patients % of patients 
70.3 1 1.09 
74 2 2.17 
74.3 1 1.09 
74.4 1 1.09 
75 1 1.09 
75.5 1 1.09 
77 1 1.09 
77.4 1 1.09 
78.4 1 1.09 
78.8 1 1.09 
79.3 1 1.09 
80 2 2.17 
80.4 1 1.09 
81.6 1 1.09 
82 2 2.17 
83.5 1 1.09 
84.3 1 1.09 
84.3 1 1.09 
84.5 1 1.09 
84.7 1 1.09 
85.4 1 1.09 
85.5 1 1.09 
86 1 1.09 
86.5 1 1.09 
86.6 1 1.09 
87 1 1.09 
87.4 1 1.09 
88.3 1 1.09 
88.7 1 1.09 
88.8 1 1.09 
89 1 1.09 
89.5 1 1.09 
90 1 1.09 
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91.3 1 1.09 
91.4 1 1.09 
91.6 1 1.09 
91.9 1 1.09 
92 4 4.35 
93.2 1 1.09 
94.6 1 1.09 
94.8 1 1.09 
96.3 1 1.09 
96.5 1 1.09 
96.8 1 1.09 
97.4 1 1.09 
97.7 1 1.09 
97.9 1 1.09 
98 1 1.09 
98.6 1 1.09 
98.8 1 1.09 
98.95 1 1.09 
100 18 19.6 





Table 4b: Differences between patients with ≥70% wear time and <70% wear time. Simple t-
test and chi2 tests were performed to determine a p value.  
 Wear time (%)  
 <70% (n=17) ≥70% (n=75) p value 
Age 71.8±13.5 67.0±12.9 0.1727 
Female 8 18 0.057 
ESS baseline 6.1±4.2 6.3±4.7 0.8694 
EQ-5D-3L baseline 49.1±28.6 61.1±27.1 0.1069 
PSQI baseline 3.9±2.0 7.1±4.0 0.0031 
STOP BANG baseline 3.7±1.4 4.2±1.5 0.2321 
Body Mass Index 28.3±6.7 29.8±5.2 0.3420 
Neck circumference 38.9±2.8 39.3±3.8 0.6807 
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